var title_f30_47_31472="Minoxidil: Pediatric drug information";
var content_f30_47_31472=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"11\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Minoxidil: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block inc\" id=\"F12618227\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F12645352\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/55/21364?source=see_link\">",
"       Minoxidil (systemic): Pediatric drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12615 Version 27.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-67CE5B8581-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_47_31472=[""].join("\n");
var outline_f30_47_31472=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/55/21364?source=related_link\">",
"      Minoxidil (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_47_31473="Patient information: Methicillin-resistant Staphylococcus aureus (MRSA) (The Basics)";
var content_f30_47_31473=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?19/1/19474\">",
"         Patient information: Hospital-acquired pneumonia (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?22/4/22595\">",
"         Patient information: Methicillin-resistant Staphylococcus aureus (MRSA) (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Methicillin-resistant Staphylococcus aureus (MRSA) (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/methicillin-resistant-staphylococcus-aureus-mrsa-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H482789289\">",
"      <span class=\"h1\">",
"       What is methicillin-resistant Staphylococcus aureus (MRSA)?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Methicillin-resistant Staphylococcus aureus is an infection that is hard to cure. Doctors and nurses sometimes call it MRSA or \"Mursa\" for short.",
"     </p>",
"     <p>",
"      People normally carry all sorts of germs inside their body and on their skin. The body usually controls these germs, so they do no harm. About 1 in 3 people have a germ on their skin called &ldquo;staph.&rdquo; In these people, staph usually causes no problems. But if they get a cut or a scrape, the germ can cause an infection.",
"     </p>",
"     <p>",
"      A staph infection can be mild, and affect only the skin. But if the infection goes deeper into the body, it can be very serious. These more serious infections tend to happen in young children, older adults, and people who cannot fight infection well.",
"     </p>",
"     <p>",
"      One especially dangerous form of staph infection is the antibiotic resistant form. This form is difficult to treat and get rid of. It involves germs that have learned to outsmart the drugs normally used to kill them.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H482789296\">",
"      <span class=\"h1\">",
"       How do you catch MRSA?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Many people carry MRSA on their skin without knowing it. You can pick up the germ by:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Touching a person who has MRSA on his or her skin",
"       </li>",
"       <li>",
"        Being nearby when a person with MRSA breathes, coughs, or sneezes",
"       </li>",
"       <li>",
"        Touching a table, handle or other surface that has the germ on it",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If the germ is on your skin and you cut yourself or have another injury, you can get infected.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H482789303\">",
"      <span class=\"h1\">",
"       How do I know if I have a MRSA infection?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you get a MRSA infection, you will probably have some skin problems. You may have a red tender lump, and it might ooze pus. &nbsp;Or you may have a cluster of bumps that look like pimples or insect bites. If the infection gets into the blood, it can give you a fever or make you feel tired.",
"     </p>",
"     <p>",
"      If your doctor thinks you have MRSA, he or she can take a swab from your skin and check it for germs. In some cases, blood tests, X-rays, and other tests may be needed.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H482789310\">",
"      <span class=\"h1\">",
"       Can MRSA be treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Your doctor can give you special antibiotics &mdash; germ-killing medicines &mdash; to treat your infection. If you get treated with medicines to take at home, it is very important that you follow the directions exactly. Take",
"      <strong>",
"       ALL",
"      </strong>",
"      the pills you are given, even if you feel better before you finish the pills. If you do not take them all, the germ could come back even stronger.",
"     </p>",
"     <p>",
"      If you do not get better with the medicines that come in pill form, or if you are very sick, your doctor may put you in the hospital. There he or she can give you stronger medicines through a tube in one of your veins (IV).",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H482789317\">",
"      <span class=\"h1\">",
"       Is there any way to prevent MRSA?",
"      </span>",
"      &nbsp;&mdash;&nbsp;People everywhere should wash their hands often with soap and water. But it is especially important for people who are in the hospital or a nursing home. Washing your hands is the best way to prevent most infections.",
"     </p>",
"     <p>",
"      If you are a patient in a hospital, you should also make sure your doctors and nurses wash",
"      <strong>",
"       their",
"      </strong>",
"      hands before they touch you. If there is no sink, they can use an alcohol-based hand gel to clean up.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H482789324\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?19/1/19474?source=see_link\">",
"       Patient information: Hospital-acquired pneumonia (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?22/4/22595?source=see_link\">",
"       Patient information: Methicillin-resistant Staphylococcus aureus (MRSA) (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?30/47/31473?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15481 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-C006335B05-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_47_31473=[""].join("\n");
var outline_f30_47_31473=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H482789289\">",
"      What is methicillin-resistant Staphylococcus aureus (MRSA)?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H482789296\">",
"      How do you catch MRSA?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H482789303\">",
"      How do I know if I have a MRSA infection?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H482789310\">",
"      Can MRSA be treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H482789317\">",
"      Is there any way to prevent MRSA?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H482789324\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?19/1/19474?source=related_link\">",
"      Patient information: Hospital-acquired pneumonia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?22/4/22595?source=related_link\">",
"      Patient information: Methicillin-resistant Staphylococcus aureus (MRSA) (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_47_31474="Hurthle cell lesion";
var content_f30_47_31474=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F80758&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F80758&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hurthle cell lesion: Appearance on fine needle aspirate of a thyroid nodule",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 290px; height: 470px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Fine-needle aspiration biopsy specimen showing mostly eosinophillic oxyphillic cells with abundant cytoplasm and round oval nuclei with prominent nucleoli.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Stephanie L. Lee.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_47_31474=[""].join("\n");
var outline_f30_47_31474=null;
var title_f30_47_31475="Molluscum dermatitis";
var content_f30_47_31475=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F86487&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F86487&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Molluscum dermatitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 405px; height: 540px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Eczematous plaques surround lesions of molluscum contagiosum.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_47_31475=[""].join("\n");
var outline_f30_47_31475=null;
var title_f30_47_31476="Auranofin: Drug information";
var content_f30_47_31476=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Auranofin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?9/27/9653?source=see_link\">",
"    see \"Auranofin: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?18/28/18884?source=see_link\">",
"    see \"Auranofin: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708624\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F138065\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Ridaura&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F138066\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Ridaura&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F138102\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Gold Compound",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F138068\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Rheumatoid arthritis:",
"     </b>",
"     Oral: Initial: 6 mg/day in 1-2 divided doses; after 6 months may be increased to 9 mg/day in 3 divided doses; discontinue therapy if no response after 3 months at 9 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Signs of clinical improvement may not be evident until after 3 months of therapy.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F138069\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F138070\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no dosage adjustments provided in the manufacturer&rsquo;s labeling. The following guidelines have been used by some clinicians (Aronoff, 2007):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     50-80 mL/minute: Administer 50% of dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;50 mL/minute: Avoid use.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15673231\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F138047\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ridaura&reg;: 3 mg [gold 29%]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F138031\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F138049\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of active stage classic or definite rheumatoid arthritis in patients who do not respond to or tolerate other agents",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F138109\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Ridaura&reg; may be confused with Cardura&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F138100\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (24%), pruritus (17%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea/loose stools (47%), abdominal pain (14%), stomatitis (13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Alopecia (1% to 3%), urticaria (1% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (10%), vomiting (10%), anorexia (3% to 9%), dyspepsia (3% to 9%), flatulence (3% to 9%), constipation (1% to 3%), dysgeusia (1% to 3%), glossitis (1% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Anemia (1% to 3%), eosinophilia (1% to 3%), leukopenia (1% to 3%), thrombocytopenia (1% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Transaminases increased (1% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Conjunctivitis (3% to 9%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Proteinuria (3% to 9%), hematuria (1% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Agranulocytosis, aplastic anemia, angioedema, corneal deposits, dysphagia, enterocolitis (ulcerative), fever, GI hemorrhage, gingivitis, gold bronchitis, hepatotoxicity, interstitial pneumonitis, jaundice, metallic taste, melena, neutropenia, pancytopenia, peripheral neuropathy, pure red cell aplasia.",
"     <b>",
"      Note:",
"     </b>",
"     Exfoliative dermatitis has been reported with other gold compounds.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F138052\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     History of severe toxicity to gold compounds including anaphylaxis, bone marrow aplasia, severe hematologic disorders, exfoliative dermatitis, necrotizing enterocolitis, or pulmonary fibrosis.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F138035\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dermatologic reactions: Dermatitis and lesions of the mucous membranes are common and may be serious; pruritus may precede the early development of a skin reaction. Consider alternative therapy in patients with dermatitis (urticaria or eczema; relative contraindication); may increase risk and/or symptoms of gold toxicity may be more difficult to detect.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastrointestinal effects: Signs of toxicity include persistent diarrhea, stomatitis, and enterocolitis; avoid use in patients with prior inflammatory bowel disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hematologic effects: Signs of toxicity include hematologic depression (depressed hemoglobin, leukocytes, granulocytes, or platelets). Avoid use in patients with a history of blood dyscrasias (anemia, agranulocytosis), hemorrhagic diathesis, or drug induced granulocytopenia. Symptoms of gold toxicity may be difficult to detect in patients with prior abnormalities; consider alternative therapy. Therapy should be discontinued if platelet count falls to &lt;100,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     , WBC &lt;4000/mm",
"     <sup>",
"      3",
"     </sup>",
"     , granulocytes &lt;1500/mm",
"     <sup>",
"      3",
"     </sup>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic effects: May be associated with the development of cholestatic jaundice. Consider alternative therapy in patients with hepatic impairment (relative contraindication); may increase risk and/or symptoms of gold toxicity may be more difficult to detect.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pulmonary toxicity: May be associated with interstitial fibrosis; monitor closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal effects: Renal toxicity ranges from mild proteinuria to nephrotic syndrome. Consider alternative therapy in patients with renal impairment; may increase risk and/or symptoms of gold toxicity may be more difficult to detect.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; ACE inhibitors: Concurrent use of gold products with ACE inhibitors may increase the risk of nitritoid reactions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Monitoring: Laboratory monitoring should be completed prior to each new prescription. Frequent monitoring of patients for signs and symptoms of toxicity will prevent serious adverse reactions.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298799\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6218148\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F138043\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13273270\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in animal reproduction studies.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F138071\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F13273271\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Injectable gold salts have been detected in breast milk.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F138054\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Ridaura Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3 mg (60): $1223.92",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F138045\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Patients should have baseline CBC with differential, platelet count, renal function tests, liver function tests, and urinalysis; CBC with differential, platelet count and urinalysis should also be monitored monthly during therapy. Skin and oral mucosa should be inspected for skin rash, bruising or oral ulceration/stomatitis. Specific questioning for symptoms such as pruritus, rash, stomatitis or metallic taste should be included. Dosing should be withheld in patients with significant gastrointestinal, renal, dermatologic, or hematologic effects (platelet count falls to &lt;100,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     , WBC &lt;4000, granulocytes &lt;1500/mm",
"     <sup>",
"      3",
"     </sup>",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F138048\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Gold: Normal: 0-0.1 mcg/mL (SI: 0-0.0064 micromole/L); Therapeutic: 1-3 mcg/mL (SI: 0.06-0.18 micromole/L); Urine: &lt;0.1 mcg/24 hours",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038534\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Aktil (TH);",
"     </li>",
"     <li>",
"      Auropan (HN, HR, HU, RU);",
"     </li>",
"     <li>",
"      Crytion (UY);",
"     </li>",
"     <li>",
"      Goldar (IN);",
"     </li>",
"     <li>",
"      Ridaura (AE, AR, AT, AU, BE, BF, BG, BH, BJ, BR, CH, CI, CL, CY, CZ, DE, DK, EE, EG, ES, ET, FI, GB, GH, GM, GN, GR, IE, IL, IQ, IR, IT, JO, JP, KE, KP, KW, LB, LR, LU, LY, MA, ML, MR, MT, MU, MW, NE, NG, NL, NO, NZ, OM, PT, QA, RU, SA, SC, SD, SE, SK, SL, SN, SY, TN, TR, TW, TZ, UG, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Ridaura Tiltab (AE, BH, CY, EG, HK, IL, IQ, IR, JO, KW, LB, LY, MY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Ridauran (FR)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F138034\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The exact mechanism of action of gold is unknown; gold is taken up by macrophages which results in inhibition of phagocytosis and lysosomal membrane stabilization; other actions observed are decreased serum rheumatoid factor and alterations in immunoglobulins. Additionally, complement activation is decreased, prostaglandin synthesis is inhibited, and lysosomal enzyme activity is decreased.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F138051\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Delayed; therapeutic response may require as long as 3-4 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Prolonged",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: ~25% gold in dose is absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 60%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination (single or multiple dose dependent): 21-31 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: ~2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (~60% of absorbed gold); remainder in feces",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Aronoff GR, Bennett WM, Berns JS, et al,",
"      <i>",
"       Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children",
"      </i>",
"      , 5th ed. Philadelphia, PA: American College of Physicians; 2007, p 97, 170.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cook NJ, Owen ET, and Donlon JB, &ldquo;A Further Possible Cause of Diarrhoea Caused by Oral Gold,&rdquo;",
"      <i>",
"       Br J Rheumatol",
"      </i>",
"      , 1995, 34(4):395-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?30/47/31476/abstract-text/7788162/pubmed\" id=\"7788162\" target=\"_blank\">",
"        7788162",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fernandez-Herlihy L, &ldquo;Requiem for Gold?&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 1991, 114(11):993-4.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Parez MC, Gomez C, Mataix R, et al, &ldquo;Bone Marrow Splasia and Gold Salts. Report of Two Cases and Review of the Literature,&rdquo;",
"      <i>",
"       Rev Clin Esp",
"      </i>",
"      , 1995, 194:540-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?30/47/31476/abstract-text/7938822/pubmed\" id=\"7938822\" target=\"_blank\">",
"        7938822",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ulmeanu V, Toma M, Eugah B, et al, &ldquo;Severe Thrombocytopenia Following Treatment With Gold Salts,&rdquo;",
"      <i>",
"       Clin Exp Rheumatol",
"      </i>",
"      , 12(Suppl 11):112.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8999 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-122.72.76.133-B1A854215F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_47_31476=[""].join("\n");
var outline_f30_47_31476=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708624\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138065\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138066\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138102\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138068\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138069\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138070\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15673231\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138047\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138031\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138049\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138109\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138100\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138052\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138035\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298799\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6218148\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138043\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13273270\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138071\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13273271\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138054\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138045\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138048\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038534\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138034\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138051\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8999\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8999|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?9/27/9653?source=related_link\">",
"      Auranofin: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?18/28/18884?source=related_link\">",
"      Auranofin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_47_31477="Med bronchogen cyst CXR I";
var content_f30_47_31477=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F74804%7EPULM%2F51294&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F74804%7EPULM%2F51294&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mediastinal subcarinal bronchogenic cyst",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A chest radiograph shows a subtle subcarinal mass.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mediastinal subcarinal bronchogenic cyst",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 250px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A CT scan proves the cystic nature of the subcarinal mass that bulges to the right into azygoesophageal recess.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_47_31477=[""].join("\n");
var outline_f30_47_31477=null;
var title_f30_47_31478="Cabazitaxel: Drug information";
var content_f30_47_31478=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Cabazitaxel: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?33/41/34453?source=see_link\">",
"    see \"Cabazitaxel: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F10412108\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F10327446\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Jevtana&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F13210063\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Jevtana&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F10412153\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antineoplastic Agent, Antimicrotubular;",
"     </li>",
"     <li>",
"      Antineoplastic Agent, Taxane Derivative",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F10412137\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Premedicate at least 30 minutes prior to each dose of cabazitaxel with an antihistamine (eg, diphenhydramine I.V. 25 mg or equivalent), a corticosteroid (eg, dexamethasone 8 mg I.V. or equivalent), and an H",
"     <sub>",
"      2",
"     </sub>",
"     antagonist  (eg, ranitidine 50 mg I.V. or equivalent). Antiemetic prophylaxis is also recommended. Details concerning dosing in combination regimens should also be consulted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Prostate cancer:",
"     </b>",
"     I.V.: 25 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose once every 3 weeks (in combination with prednisone)",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F10412138\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Severe renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute) or end-stage renal disease: Use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F10412139\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hepatic impairment (total bilirubin &ge;ULN or AST and/or ALT &ge;1.5 times ULN): Use is not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block dot drugH1Div\" id=\"F10412140\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adjustment for Toxicity",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <i>",
"      Hematologic toxicity:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Neutropenia &ge; grade 3 for &gt; 1 week despite WBC growth factors: Delay treatment until ANC &gt;1500/mm",
"     <sup>",
"      3",
"     </sup>",
"     and then reduce dose to 20 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     with continued WBC growth factor secondary prophylaxis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Neutropenic fever: Delay treatment until improvement/resolution and ANC &gt;1500/mm",
"     <sup>",
"      3",
"     </sup>",
"     and then reduce dose to 20 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     with continued WBC growth factor secondary prophylaxis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Persistent hematologic toxicity (despite dosage reduction): Discontinue treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <i>",
"      Nonhematologic toxicity:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Severe hypersensitivity: Discontinue immediately.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Diarrhea &ge;grade 3 or persistent despite appropriate medication, fluids, and electrolyte replacement: Delay treatment until improves or resolves and then reduce dose to 20 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Persistent diarrhea (despite dosage reduction): Discontinue treatment.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F10412147\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Jevtana&reg;: 40 mg/mL (1.5 mL) [contains ethanol 13% (in diluent), polysorbate 80; supplied with diluent]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F10412150\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F10412143\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.V.: Infuse over 1 hour using a 0.22 micron inline filter. Do not use polyurethane-containing infusion sets for administration. Allow to reach room temperature prior to infusion. Premedicate with an antihistamine, a corticosteroid, and an H",
"     <sub>",
"      2",
"     </sub>",
"     antagonist at least 30 minutes prior to infusion. Observe closely during infusion (for hypersensitivity). Antiemetic prophylaxis (oral or I.V.) is also recommended.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (meets NIOSH, 2012 criteria)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F10412126\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F10327706\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of hormone-refractory metastatic prostate cancer (in patients previously treated with a docetaxel-containing regimen)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F10409423\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Cabazitaxel may be confused with DOCEtaxel, PACLitaxel",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Jevtana&reg; may be confused with Xgeva&reg;, Xtandi&reg;, Zometa&reg;, Zytiga&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the  Institute for Safe Medication Practices (ISMP) includes among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Administration issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Cabazitaxel requires a two-step dilution process prior to administration.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F10412117\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Adverse reactions reported for combination therapy with prednisone.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Fatigue (37%), fever (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Diarrhea (47%; grades 3/4: 6%), nausea (34%), vomiting (22%), constipation (20%), abdominal pain (17%), anorexia (16%), taste alteration (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hematologic: Anemia (98%; grades 3/4: 11%), leukopenia (96%; grades 3/4: 69%), neutropenia (94%; grades 3/4: 82%; nadir: 12 days [range: 4-17 days]), thrombocytopenia (48%; grades 3/4: 4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Weakness (20%), back pain (16%), peripheral neuropathy (13%; grades 3/4: &lt;1%), arthralgia (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Renal: Hematuria (17%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Dyspnea (12%), cough (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Peripheral edema (9%), arrhythmia (5%), hypotension (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Dizziness (8%), headache (8%), pain (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Alopecia (10%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: Dehydration (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Dyspepsia (10%), weight loss (9%), mucosal inflammation (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Genitourinary: Urinary tract infection (8%), dysuria (7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hematologic: Neutropenic fever (grades 3/4: 7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hepatic: ALT increased (grades 3/4: &le;1%), AST increased (grades 3/4: &le;1%), bilirubin increased (grades 3/4: &le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Muscle spasm (7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Hypersensitivity (eg, rash, erythema, hypotension, bronchospasm), electrolyte imbalance, renal failure, sepsis, septic shock",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F10412113\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to cabazitaxel, polysorbate 80, or any component of the formulation; neutrophil count &le;1500/mm",
"     <sup>",
"      3",
"     </sup>",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F10412114\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bone marrow suppression:",
"     <b>",
"      [U.S. Boxed Warning]: Deaths due to neutropenia have been reported. Do not administer in patients with neutrophil count &le;1500/mm",
"      <sup>",
"       3",
"      </sup>",
"      . Monitor blood counts frequently.",
"     </b>",
"     Dose reductions are recommended following neutropenic fever or prolonged neutropenia. Administration of WBC growth factors may reduce the risk of complications due to neutropenia. Consider primary WBC growth factor prophylaxis in high-risk patients (eg, &gt;65 years of age, poor performance status, history of neutropenic fever, extensive prior radiation, poor nutrition status, or other serious comorbidities); secondary prophylaxis and therapeutic WBC growth factors should be considered in all patients with increased risk for neutropenic complications.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastrointestinal toxicity: Nausea, vomiting and diarrhea may occur. Diarrhea may be severe and may result in dehydration and electrolyte imbalance. Antiemetics, antidiarrhea medication, and fluid and electrolyte replacement may be necessary. Diarrhea &ge; grade 3 may require treatment delay and or dosage reduction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions:",
"     <b>",
"      [U.S. Boxed Warning]: Severe hypersensitivity reactions, including generalized rash, erythema, hypotension, and bronchospasm may occur. May require immediate discontinuation if hypersensitivity is severe. Premedicate with an I.V. antihistamine, corticosteroid and H",
"      <sub>",
"       2",
"      </sub>",
"      antagonist prior to infusion. Use in patients with history of severe hypersensitivity to cabazitaxel or polysorbate 80 is contraindicated.",
"     </b>",
"     Observe closely during infusion, especially during the first and second infusions; reaction may occur within minutes. Do not rechallenge after severe hypersensitivity reactions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal failure: Renal failure has been reported from clinical trials; generally associated with dehydration, sepsis, or obstructive uropathy. Use with caution in patients with severe renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute) and end-stage renal disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use is not recommended in patients with hepatic impairment (total bilirubin &ge;ULN or AST and/or ALT &ge;1.5 times ULN). Due to extensive hepatic metabolism, cabazitaxel exposure is increased in patients with hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CYP3A4 inducers/inhibitors: Avoid concomitant use of strong CYP3A4 inducers and inhibitors; use moderate CYP3A4 inhibitors with caution. Strong CYP3A4 inducers (eg, carbamazepine, phenobarbital, phenytoin, rifabutin rifampin, rifapentine) may decrease the levels/effects of cabazitaxel. Strong CYP3A4 inhibitors (eg, atazanavir, clarithromycin, indinavir, itraconazole,  ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconazole) may increase the levels/effects of cabazitaxel.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Patients &ge;65 years of age are more likely to experience certain adverse reactions, including neutropenia and neutropenic fever.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (meets NIOSH, 2012 criteria)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298920\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2C8 (minor), CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F10449303\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antineoplastic Agents (Anthracycline, Systemic): Taxane Derivatives may enhance the adverse/toxic effect of Antineoplastic Agents (Anthracycline, Systemic). Taxane Derivatives may increase the serum concentration of Antineoplastic Agents (Anthracycline, Systemic). Taxane Derivatives may also increase the formation of toxic anthracycline metabolites in heart tissue.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Antineoplastic Agents may decrease the absorption of Cardiac Glycosides. This may only affect digoxin tablets.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Digitoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     DOXOrubicin: Taxane Derivatives may decrease the metabolism of DOXOrubicin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Platinum Derivatives: May enhance the myelosuppressive effect of Taxane Derivatives. Administer Taxane derivative before Platinum derivative when given as sequential infusions to limit toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Antineoplastic Agents may enhance the anticoagulant effect of Vitamin K Antagonists. Antineoplastic Agents may diminish the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F10412121\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Food: Avoid grapefruit juice (may increase the levels/effects of cabazitaxel).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herb/Nutraceutical: Avoid St John's wort (may increase metabolism and decrease cabazitaxel concentrations).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F10412109\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F10412110\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal studies have demonstrated adverse effects (embryotoxicity, fetotoxicity and fetal loss) at doses significantly lower than human doses. There are no adequate and well-controlled studies in pregnant women. May cause fetal harm if administered during pregnancy. Pregnant women should avoid exposure to cabazitaxel.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F10412111\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F10412112\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Due to the potential for serious adverse reactions in the nursing infant, breast-feeding is not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F10412142\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid grapefruit juice.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322856\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Jevtana Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     60 mg/1.5 mL (1.5 mL): $10089.70",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F10412145\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential and platelets (weekly during first cycle, then prior to each treatment cycle); monitor for hypersensitivity",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F12992818\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Jevtana (AR, AU, BR, CH, CR, CZ, DO, EE, FR, GB, GT, HK, HN, IE, IL, MY, NI, PA, SE, SG, SV)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F10412127\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cabazitaxel is a taxane derivative which is a microtubule inhibitor; it binds to tubulin promoting assembly into microtubules and inhibiting disassembly which stabilizes microtubules.  This inhibits microtubule depolymerization and cell division, arresting the cell cycle and inhibiting tumor proliferation. Unlike other taxanes, cabazitaxel has a poor affinity for multidrug resistance (MDR) proteins, therefore conferring activity in resistant tumors.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F10412129\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: V",
"     <sub>",
"      dss",
"     </sub>",
"     : 4864 L; has greater CNS penetration than other taxanes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: 89% to 92%; primarily to serum albumin and lipoproteins",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Extensively hepatic; primarily via CYP3A4 and 3A5; also via CYP2C8 (minor)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: Terminal: 95 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Feces (76% as metabolites); Urine (~4%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      De Bono JS, Oudard S, Ozguroglu M, et al, &ldquo;Cabazitaxel or Mitoxantrone With Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel: Final Results of a Multinational Phase III Trial (TROPIC),&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2010, 28(7s):4508 [abstract 4508 from 2010 ASCO Annual Meeting]",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mita AC, Denis LJ, Rowinsky Ek, et al, &ldquo;Phase I and Pharmacokinetic Study of XRP6258 (RPR 116258A), a Novel Taxane, Administered as a 1-Hour Infusion Every 3 Weeks in Patients With Advanced Solid Tumors,",
"      <i>",
"       Clin Cancer Res",
"      </i>",
"      , 2009, 15(2):723-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?30/47/31478/abstract-text/19147780 /pubmed\" id=\"19147780 \" target=\"_blank\">",
"        19147780",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Comprehensive Cancer Network&reg; (NCCN), &ldquo;Clinical Practice Guidelines in Oncology&trade;: Prostate Cancer,&rdquo; Version 1.2011. Available at file://www.nccn.org/professionals/physician_gls/PDF/prostate.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sartor AO, Oudard S, Ozguroglu M, et al, &ldquo;Cabazitaxel or Mitoxantrone With Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel: Final Results of a Multinational Phase III Trial (TROPIC),&rdquo; 2010:9 [abstract 9 from 2010 ASCO Genitourinary Cancers Symposium]",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15577 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-217.117.136.88-94DAD92080-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_47_31478=[""].join("\n");
var outline_f30_47_31478=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10412108\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10327446\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13210063\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10412153\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10412137\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10412138\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10412139\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10412140\">",
"      Dosing: Adjustment for Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10412147\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10412150\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10412143\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10412126\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10327706\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10409423\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10412117\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10412113\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10412114\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298920\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10449303\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10412121\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10412109\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10412110\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10412111\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10412112\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10412142\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322856\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10412145\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12992818\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10412127\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10412129\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/15577\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/15577|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?33/41/34453?source=related_link\">",
"      Cabazitaxel: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_47_31479="Mediastinal seminoma I Low";
var content_f30_47_31479=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F66422&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F66422&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mediastinal seminoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 230px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Photomicrograph shows discohesive cells with abundant cytoplasm, vesicular nuclei, and prominent nucleoli surrounded by numerous lymphocytes. (Hematoxylin and eosin, magnification 50x).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William Travis, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_47_31479=[""].join("\n");
var outline_f30_47_31479=null;
var title_f30_47_31480="Levothyroxine: Pediatric drug information";
var content_f30_47_31480=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Levothyroxine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?40/43/41656?source=see_link\">",
"    see \"Levothyroxine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?13/20/13638?source=see_link\">",
"    see \"Levothyroxine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709010\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F188360\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Levothroid&reg;;",
"     </li>",
"     <li>",
"      Levoxyl&reg;;",
"     </li>",
"     <li>",
"      Synthroid&reg;;",
"     </li>",
"     <li>",
"      Tirosint&reg;;",
"     </li>",
"     <li>",
"      Unithroid&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F188361\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Eltroxin&reg;;",
"     </li>",
"     <li>",
"      Euthyrox;",
"     </li>",
"     <li>",
"      Levothyroxine Sodium;",
"     </li>",
"     <li>",
"      Synthroid&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1059804\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Thyroid Product",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11443808\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Doses should be adjusted based on clinical response and laboratory parameters; on a weight basis, dosing is higher in neonates, infants, and children than adults due to the higher metabolic clearance.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Congenital hypothyroidism:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: 10-15 mcg/kg once daily; titrate as rapidly as possible (&lt;2 weeks after initiation of therapy) to achieve target serum T",
"     <sub>",
"      4",
"     </sub>",
"     concentration (&gt;10 mcg/dL); in full-size, term infants, some have suggested an initial dose of 50 mcg/day. If patient at risk for development of cardiac failure, begin with a lower dose (25 mcg/day). In severe cases of hypothyroidism (serum T",
"     <sub>",
"      4",
"     </sub>",
"     &lt;5 mcg/dL), begin treatment at a higher dosage of ~50 mcg/day (12-17 mcg/kg/dose) (AAP, 2006; Selva, 2002).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V., I.M.: 50% to 75% of the oral dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Organ donor management in brain-dead patients (hormone replacement therapy):",
"     </b>",
"     I.V.: Initial:  5 mcg/kg bolus dose, followed by 1.4 mcg/kg/",
"     <b>",
"      hour",
"     </b>",
"     infusion (Zuppa, 2004)",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1059796\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?40/43/41656?source=see_link\">",
"      see \"Levothyroxine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Doses should be adjusted based on clinical response and laboratory parameters; on a weight basis, dosing is higher in infants and children than adults due to the higher metabolic clearance.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infants, Children, and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Hypothyroidism (acquired or congenital): Note:",
"     </b>",
"     Hyperactivity in older children may be minimized by starting at one-quarter (25%) of the recommended dose and increasing each week by that amount until the full dose is achieved (4 weeks). Children with severe or chronic hypothyroidism should be started at 25 mcg/day; adjust dose by 25 mcg every 2-4 weeks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Manufacturer labeling:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     1-3 months: 10-15 mcg/kg once daily; if the infant is at risk for development of cardiac failure, use a lower starting dose of ~25 mcg/day; if the initial serum T",
"     <sub>",
"      4",
"     </sub>",
"     is very low (&lt;5 mcg/dL), begin treatment at a higher dosage of ~50 mcg/day (12-17 mcg/kg/day) (AAP, 2006; Selva, 2002)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     3-6 months: 8-10 mcg/kg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     6-12 months: 6-8 mcg/kg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     1-5 years: 5-6 mcg/kg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     6-12 years: 4-5 mcg/kg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     &gt;12 years with incomplete growth and puberty: 2-3 mcg/kg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Adolescents with growth and puberty complete: 1.7 mcg/kg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Alternate dosing: Fixed dosages:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     3-6 months: 25-50 mcg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     6-12 months: 50-75 mcg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     1-5 years: 75-100 mcg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     6-12 years: 100-125 mcg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     &gt;12 years with incomplete growth and puberty: &ge;150 mcg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.V., I.M.: 50% to 75% of the oral dose; alternatively, some clinicians administer up to 80% of the oral dose in adults patients.",
"     <b>",
"      Note:",
"     </b>",
"     Bioavailability of the oral formulation is highly variable, but absorption has been measured to be ~80%, when the oral tablet formulation was administered in the recommended fasting state (Dickerson, 2010; Fish, 1987).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Organ donor management in brain-dead patients (hormone replacement therapy)",
"     </b>",
"     (Nakagawa, 2008; Zuppa, 2004): I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Infants &lt;6 months: Initial: 5 mcg/kg bolus dose, followed by 1.4 mcg/kg/",
"     <b>",
"      hour",
"     </b>",
"     infusion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Infants 6-12 months: Initial: 4 mcg/kg bolus dose, followed by 1.3 mcg/kg/",
"     <b>",
"      hour",
"     </b>",
"     infusion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children 1-5 years: Initial: 3 mcg/kg bolus dose, followed by 1.2 mcg/kg/",
"     <b>",
"      hour",
"     </b>",
"     infusion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children 6-12 years: Initial: 2.5 mcg/kg bolus dose, followed by 1 mcg/kg/",
"     <b>",
"      hour",
"     </b>",
"     infusion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children &ge;12 years and Adolescents &le;16 years: Initial: 1.5 mcg/kg bolus dose, followed by 0.8 mcg/kg/",
"     <b>",
"      hour",
"     </b>",
"     infusion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adolescents &gt;16 years: Initial: 0.8 mcg/kg bolus dose, followed by 0.8 mcg/kg/",
"     <b>",
"      hour",
"     </b>",
"     infusion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Hypothyroidism:",
"     </b>",
"     Adults &lt;50 years of age and older adults who have been recently treated for hyperthyroidism or who have been hypothyroid for only a few months:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: ~1.7 mcg/kg/day usual doses are &le;200 mcg/day [range: 100-125 mcg/day (70 kg adult)]; doses &ge;300 mcg/day are rare (consider poor compliance, malabsorption, and/or drug interactions). Titrate dose every 6 weeks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Patients with combined hypothyroidism and cardiac disease should be monitored carefully for changes in stability.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V., I.M.: 50% of the oral dose; alternatively, some clinicians administer up to 80% of the oral dose.",
"     <b>",
"      Note:",
"     </b>",
"     Bioavailability of the oral formulation is highly variable, but absorption has been measured to be ~80%, when the oral tablet formulation was administered in the recommended fasting state (Dickerson, 2010; Fish, 1987).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Severe hypothyroidism:",
"     </b>",
"     Oral: Initial: 12.5-25 mcg/day; adjust dose by 25 mcg/day every 2-4 weeks as appropriate",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Subclinical hypothyroidism (if treated):",
"     </b>",
"     Oral: 1 mcg/kg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Myxedema coma or stupor:",
"     </b>",
"     I.V.: 200-500 mcg one time, then 100-300 mcg the next day if necessary; smaller doses should be considered in patients with cardiovascular disease",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      TSH suppression:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Well-differentiated thyroid cancer: Highly individualized; doses &gt;2 mcg/kg/day may be needed to suppress TSH to &lt;0.1 mIU/L in intermediate- to high-risk tumors. Low-risk tumors may be maintained at or slightly below the lower limit of normal (0.1-0.5 mIU/L) (Cooper, 2009).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Benign nodules and nontoxic multinodular goiter: Routine use of T",
"     <sub>",
"      4",
"     </sub>",
"     for TSH suppression is not recommended in patients with benign thyroid nodules. In patients deemed appropriate candidates, treatment should never be fully suppressive (TSH &lt;0.1 mIU/L) (Cooper, 2009; Gharib, 2010). Avoid use if TSH is already suppressed.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F188330\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, soft gelatin, oral, as sodium:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tirosint&reg;: 13 mcg, 25 mcg, 50 mcg, 75 mcg, 88 mcg, 100 mcg, 112 mcg, 125 mcg, 137 mcg, 150 mcg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution, as sodium: 100 mcg, 200 mcg [DSC], 500 mcg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as sodium: 25 mcg, 50 mcg, 75 mcg, 88 mcg, 100 mcg, 112 mcg, 125 mcg, 137 mcg, 150 mcg, 175 mcg, 200 mcg, 300 mcg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Levothroid&reg;: 25 mcg, 75 mcg, 88 mcg, 100 mcg, 112 mcg, 125 mcg, 137 mcg, 150 mcg, 175 mcg, 200 mcg, 300 mcg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Levothroid&reg;: 50 mcg [scored; dye free]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Levoxyl&reg;: 25 mcg, 75 mcg, 88 mcg, 100 mcg, 112 mcg, 125 mcg, 137 mcg, 150 mcg, 175 mcg, 200 mcg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Levoxyl&reg;: 50 mcg [scored; dye free]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Synthroid&reg;: 25 mcg, 75 mcg, 88 mcg, 100 mcg, 112 mcg, 125 mcg, 137 mcg, 150 mcg, 175 mcg, 200 mcg, 300 mcg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Synthroid&reg;: 50 mcg [scored; dye free]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Unithroid&reg;: 25 mcg, 75 mcg, 88 mcg, 100 mcg, 112 mcg, 125 mcg, 150 mcg, 175 mcg, 200 mcg, 300 mcg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Unithroid&reg;: 50 mcg [scored; dye free]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F188314\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes capsule",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1059808\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Capsules: Must be swallowed whole; do not cut, crush, or attempt to dissolve capsules in water to prepare a suspension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tablets: Administer on an empty stomach 30-60 minutes prior to breakfast with a full glass of water to prevent gagging. If administration on an empty stomach poses a challenge, particularly in infants and small children, it may be administered with food to improve adherence and consistency of administration. For infants, crush tablet and mix with breast-milk, non-soy-based formula, or water and use immediately (Zeitler, 2010).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Parenteral: Reconstitute vial with 5 mL NS, final concentration dependent upon vial size; administer I.V. over 2- to 3-minute period; may administer I.M.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F188389\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not mix I.V. solution with other I.V. infusion solutions.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1059800\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Synthroid&reg;, Levotroid&reg;, Tirosint&reg;: Store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Protect from light and moisture.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Unithroid&reg;, Levoxyl&reg;: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Protect from light and moisture.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Parenteral: Store intact vial at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); protect from light; manufacturer recommends use immediately after preparation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Stability  in polypropylene syringes (100 mcg/mL in NS) at 5&deg;C &plusmn; 1&deg;C is 7 days (Gupta, 2000).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Stability in latex-free, PVC minibags stored at 25&deg;C is dependent upon concentration and light exposure: 0.4 mcg/mL in NS is stable for 18 hours protected from light and ~17 hours when exposed to light; 2 mcg/mL in NS is stable for 12 hours protected from light and 6.5 hours when exposed to light",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1059807\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Tablets: Replacement or supplemental therapy in congenital or acquired hypothyroidism of any etiology (FDA approved in all ages); pituitary TSH suppressant for the treatment or prevention of various types of euthyroid goiter, thyroid nodules, thyroiditis, multinodular goiter, and thyroid cancer (FDA approved in adults);",
"     <b>",
"      Note:",
"     </b>",
"     Not indicated for treatment of  transient hypothyroidism associated with subacute thyroiditis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Capsules (Tirosint&reg;): Replacement or supplemental therapy in congenital or acquired hypothyroidism of any etiology (FDA approved in older children and adults); pituitary TSH suppressant for the treatment or prevention of various types of euthyroid goiter, thyroid nodules, thyroiditis, multinodular goiter, and thyroid cancer (FDA approved in adults);",
"     <b>",
"      Note:",
"     </b>",
"     Not indicated for treatment of  transient hypothyroidism associated with subacute thyroiditis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Parenteral: Treatment of myxedema coma (FDA approved in adults); has also been used for organ donor management",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F188391\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Levothyroxine may be confused with lamoTRIgine, Lanoxin&reg;, levofloxacin, liothyronine",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Levoxyl&reg; may be confused with Lanoxin&reg;, Levaquin&reg;, Luvox&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Synthroid&reg; may be confused with Symmetrel&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Administration issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Significant differences exist between oral and I.V. dosing. Use caution when converting from one route of administration to another.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       To avoid errors due to misinterpretation of a decimal point, always express dosage in mcg (",
"       <b>",
"        not",
"       </b>",
"       mg).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F188388\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Angina, arrhythmia, cardiac arrest, flushing, heart failure, hypertension, MI, palpitation, pulse increased, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Anxiety, emotional lability, fatigue, fever, headache, hyperactivity, insomnia, irritability, nervousness, pseudotumor cerebri (children), seizure (rare)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Alopecia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Fertility impaired, menstrual irregularities",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal cramps, diarrhea, increased appetite, vomiting, weight loss",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Increased liver function tests",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Decreased bone mineral density, muscle weakness, slipped capital femoral epiphysis (children), tremor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Dyspnea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis, heat intolerance, hypersensitivity (to inactive ingredients, symptoms include angioedema, arthralgia, fever, flushing, GI symptoms, pruritus, rash, serum sickness, urticaria, wheezing)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Levoxyl&reg;: Choking, dysphagia, gagging",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1059813\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to levothyroxine sodium or any component;",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Additionally:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Oral formulations (tablets and capsules): Acute MI; thyrotoxicosis of any etiology; uncorrected adrenal insufficiency",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Capsules (Tirosint&reg;): Inability to swallow capsule whole (eg, infants, small children)",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1059795\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with extreme caution in patients with adrenal insufficiency; symptoms may be exaggerated or aggravated. Use with caution and reduce dosage in patients with angina pectoris and other cardiovascular disease; chronic hypothyroidism predisposes patients to coronary artery disease. Use with caution in patients with diabetes mellitus and insipidus; symptoms may be exaggerated or aggravated. Use with caution in patients with myxedema; symptoms may be exaggerated or aggravated.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Routine use of T",
"     <sub>",
"      4",
"     </sub>",
"     for TSH suppression is not recommended in patients with benign thyroid nodules and should never be fully suppressive (TSH &lt;0.1 mIU/mL) (Cooper, 2009; Gharib, 2010). Use of T",
"     <sub>",
"      4",
"     </sub>",
"     for TSH suppression is often physician-dependent; may be considered in select patients, including patients who reside in iodine-deficient areas, young patients with small thyroid nodules, and patients with nonfunctioning nodular goiters (Gharib, 2010). Use of T",
"     <sub>",
"      4",
"     </sub>",
"     for TSH suppression should be avoided in postmenopausal women; men &gt;60 years of age; patients with cardiovascular disease, osteoporosis, or systemic illness; and patients with large thyroid nodules, long-standing goiters, or low-normal TSH levels (Gharib, 2010).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Long-term therapy can decrease bone mineral density; postmenopausal women and women using suppressive doses should receive the lowest dose necessary for clinical response.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     In neonates and infants, cardiac overload, arrhythmias, and aspiration from avid suckling may occur during initiation of therapy (eg, first 2 weeks); monitor closely.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1059794\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not for use in the treatment of obesity or for weight loss",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; in euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction; larger doses may produce serious or even life-threatening toxic effects particularly when used with some anorectic drugs (sympathomimetic amines). Should not be used for treatment of infertility without unrelated hypothyroidism.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Overtreatment may result in craniosynostosis in infants and premature closure of epiphyses in children; monitor use closely.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Levoxyl&reg; oral tablets may rapidly swell and disintegrate, causing choking or gagging (should be administered with a full glass of water); use caution in patients with dysphagia or other swallowing disorders.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299600\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F188323\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aluminum Hydroxide: May decrease the serum concentration of Levothyroxine. Management: Separate administration of oral levothyroxine and aluminum hydroxide by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the serum concentration of Thyroid Products. Management: Administer oral thyroid products at least 4 h prior to colesevelam, and at least 1 h before or 4-6 h after cholestyramine.  Specific recommendations for colestipol are not available. Monitor for decreased concentrations/effects of the thyroid product.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Polystyrene Sulfonate: May decrease the serum concentration of Thyroid Products. Management: To minimize risk of interaction, separate dosing of oral calcium polystyrene sulfonate and thyroid products (eg, levothyroxine) or administer calcium polystyrene sulfonate rectally. Monitor for signs/symptoms of hypothyroidism with concomitant use (oral).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Salts: May diminish the therapeutic effect of Thyroid Products. Management: Separate the doses of the thyroid product and the oral calcium supplement by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May decrease the serum concentration of Thyroid Products.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Estrogen Derivatives: May diminish the therapeutic effect of Thyroid Products.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May decrease the serum concentration of Thyroid Products. Phenytoin may also displace thyroid hormones from protein binding sites.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iron Salts: May decrease the serum concentration of Levothyroxine. Management: Separate oral administration of iron salts and levothyroxine by at least 4 hours.  Separation of doses is not required with parenterally administered iron salts or levothyroxine.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ferumoxytol; Iron Dextran Complex; Iron Sucrose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lanthanum: May decrease the serum concentration of Thyroid Products. Management: Administer oral thyroid products at least two hours before or after lanthanum.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of Levothyroxine. Management: Separate oral administration of iron-containing multivitamins and levothyroxine by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Orlistat: May decrease the serum concentration of Levothyroxine. Management: Separate administration of oral levothyroxine and orlistat  by a least 4 hours. Monitor patients closely for signs and symptoms of hypothyroidism.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May decrease the serum concentration of Thyroid Products. Phenytoin may also displace thyroid hormones from protein binding sites.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Raloxifene: May decrease the absorption of Levothyroxine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifampin: May decrease the serum concentration of Thyroid Products.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sevelamer: May decrease the serum concentration of Levothyroxine. Management: Consider separating administration of sevelamer and levothyroxine by at least several hours whenever possible in order to decrease the risk of a significant interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Iodide I131: Thyroid Products may diminish the therapeutic effect of Sodium Iodide I131.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Polystyrene Sulfonate: May decrease the serum concentration of Thyroid Products. Management: To minimize risk of interaction, separate dosing of oral sodium polystyrene sulfonate and thyroid products (e.g., levothyroxine) or administer sodium polystyrene sulfonate rectally. Monitor for signs/symptoms of hypothyroidism with concomitant use (oral).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sucralfate: May decrease the serum concentration of Levothyroxine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Thyroid Products may increase the metabolism of Theophylline Derivatives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dyphylline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Thyroid Products may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1059815\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Limit intake of goitrogenic foods (eg, asparagus, cabbage, peas, turnip greens, broccoli, spinach, brussel sprouts, lettuce, soybeans); absorption may be decreased with soy-based infant formulas, cottonseed meal, walnuts, and dietary fiber",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F188326\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F188341\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Endogenous thyroid hormones minimally cross the placenta; the fetal thyroid becomes active around the end of the first trimester. Levothyroxine has not been shown to increase the risk of congenital abnormalities.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Uncontrolled maternal hypothyroidism may result in adverse neonatal outcomes (eg, premature birth, low birth weight, and respiratory distress) and adverse maternal outcomes (eg, spontaneous abortion, pre-eclampsia, stillbirth, and premature delivery). To prevent adverse events, normal maternal thyroid function should be maintained prior to conception and throughout pregnancy. Levothyroxine is considered the treatment of choice for the control of hypothyroidism during pregnancy. Due to alterations of endogenous maternal thyroid hormones, the levothyroxine dose may need to be increased during pregnancy and the dose usually needs to be decreased after delivery.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1059803\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     T",
"     <sub>",
"      4",
"     </sub>",
"     , TSH, heart rate, blood pressure, clinical signs of hypo- and hyperthyroidism; growth, bone development (children); TSH is the most reliable guide for evaluating adequacy of thyroid replacement dosage. TSH may be elevated during the first few months of thyroid replacement despite patients being clinically euthyroid. In cases where T",
"     <sub>",
"      4",
"     </sub>",
"     remains low and TSH is within normal limits, an evaluation of \"free\" (unbound) T",
"     <sub>",
"      4",
"     </sub>",
"     is needed to evaluate further increase in dosage.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     In congenital hypothyroidism, adequacy of replacement should be determined using both TSH and total- or free-T",
"     <sub>",
"      4",
"     </sub>",
"     . During the first 3 years of life, total- or free-T",
"     <sub>",
"      4",
"     </sub>",
"     should be maintained in the upper",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     of the normal range; this should result in normalization of the TSH. In some patients, TSH may not normalize due to a resetting of the pituitary-thyroid feedback as a result of",
"     <i>",
"      in utero",
"     </i>",
"     hypothyroidism. Monitor closely for cardiac overload, arrhythmias, and aspiration from avid suckling.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Pediatric patients: Monitor closely for under/overtreatment. Undertreatment may decrease intellectual development and linear growth and lead to poor school performance due to impaired concentration and slowed mentation. Overtreatment may adversely affect brain maturation and accelerate bone age (leading to premature closure of the epiphyses and reduced adult height); craniosynostosis has been reported in infants. Perform routine clinical examinations at regular intervals (to assess mental and physical growth and development). Monitor TSH and total or free T",
"     <sub>",
"      4",
"     </sub>",
"     at 2 and 4 weeks after starting treatment, every 1-2 months during the first year of life, every 2-3 months between ages 1-3 years, and every 3-12 months thereafter until growth is completed; repeat tests two weeks after any change in dosage.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Adults: Monitor TSH every 6-8 weeks until normalized, 8-12 weeks after dosage changes, and every 6-12 months throughout therapy.",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F1059806\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption style=\"text-align:center;\">",
"      Thyroid Function Tests",
"     </caption>",
"     <col align=\"left\" width=\"200\">",
"     </col>",
"     <col align=\"center\" width=\"100\">",
"     </col>",
"     <col align=\"center\" width=\"200\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Lab Parameter",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Age",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"       </th>",
"      </tr>",
"     </thead>",
"     <tbody valign=\"middle\">",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         T",
"         <sub>",
"          4",
"         </sub>",
"         (thyroxine) serum concentration",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1-7 days",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         10.1-20.9 mcg/dL",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         8-14 days",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         9.8-16.6 mcg/dL",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1 month to 1 year",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         5.5-16.0 mcg/dL",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &gt;1 year",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         4.0-12.0 mcg/dL",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Free thyroxine index (FTI)",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1-3 days",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         9.3-26.6",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1-4 weeks",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         7.6-20.8",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1-4 months",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         7.4-17.9",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         4-12 months",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         5.1-14.5",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1-6 years",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         5.7-13.3",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &gt;6 years",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         4.8-14.0",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         T",
"         <sub>",
"          3",
"         </sub>",
"         serum concentration",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Newborns",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         100-470 ng/dL",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1-5 years",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         100-260 ng/dL",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         5-10 years",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         90-240 ng/dL",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         10 years to Adult",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         70-210 ng/dL",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         T",
"         <sub>",
"          3",
"         </sub>",
"         uptake",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         35% to 45%",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         TSH serum concentration",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Cord",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         3-22 micro international units/mL",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1-3 days",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &lt;40 micro international units/mL",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         3-7 days",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &lt;25 micro international units/mL",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &gt;7 days",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0-10 micro international units/mL",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1059793\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Primary active compound is T",
"     <sub>",
"      3",
"     </sub>",
"     (triiodothyronine), which may be converted from T",
"     <sub>",
"      4",
"     </sub>",
"     (thyroxine) by deiodination in liver and peripheral tissues; exact mechanism of action is unknown; however, it is believed the thyroid hormone exerts its many metabolic effects through control of DNA transcription and protein synthesis; involved in normal metabolism, growth, and development; promotes gluconeogenesis, increases utilization and mobilization of glycogen stores, and stimulates protein synthesis, increases basal metabolic rate",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1059811\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Therapeutic:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: 3-5 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: Within 6-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Maximum effect: 4-6 weeks",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1059812\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Erratic (40% to 80%, per manufacturer); decreases with age",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Oral tablets: 64% (nonfasting state) to 79% to 81% (fasting state) (Dickerson, 2010; Fish, 1987)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: &gt;99%; bound to plasma proteins, including thyroxine-binding globulin, thyroxine-binding prealbumin, and albumin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic to triiodothyronine (T",
"     <sub>",
"      3",
"     </sub>",
"     ; active); ~80% T",
"     <sub>",
"      4",
"     </sub>",
"     deiodinated in kidney and periphery; glucuronidation/conjugation also occurs; undergoes enterohepatic recirculation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: Euthyroid: 6-7 days; Hypothyroid: 9-10 days; Hyperthyroid: 3-4 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: 2-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Urine (major route of elimination; decreases with age); feces (~20%)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1059802\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?13/20/13638?source=see_link\">",
"      see \"Levothyroxine: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not change brands without physician's knowledge; report immediately to physician any chest pain, increased pulse, palpitations, heat intolerances, excessive sweating; do not discontinue without notifying physician. Take in the morning at least 30 minutes prior to breakfast. Do not take antacids, calcium, or iron supplements within 4 hours of thyroid medication.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1059814\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Equivalent doses: The following statement on relative potency of thyroid products is included in a joint statement by American Thyroid Association (ATA), American Association of Clinical Endocrinologists (AACE) and The Endocrine Society (TES): For purposes of conversion, levothyroxine sodium (T",
"     <sub>",
"      4",
"     </sub>",
"     ) 100 mcg is usually considered equivalent to desiccated thyroid 60 mg, thyroglobulin 60 mg, or liothyronine sodium (T",
"     <sub>",
"      3",
"     </sub>",
"     ) 25 mcg. However, these are rough guidelines only and do not obviate the careful re-evaluation of a patient when switching thyroid hormone preparations, including a change from one brand of levothyroxine to another. Joint position statement is available at file://www.thyroid.org/professionals/advocacy/04_12_08_thyroxine.html.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Several medications have effects on thyroid production or conversion. The impact in thyroid replacement has not been specifically evaluated, but patient response should be monitored:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Methimazole: Decreases thyroid hormone secretion, while propylthiouracil decrease thyroid hormone secretion and decreases conversion of T",
"     <sub>",
"      4",
"     </sub>",
"     to T",
"     <sub>",
"      3",
"     </sub>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Beta-adrenergic antagonists: Decrease conversion of T",
"     <sub>",
"      4",
"     </sub>",
"     to T",
"     <sub>",
"      3",
"     </sub>",
"     (dose related, propranolol &ge;160 mg/day); patients may be clinically euthyroid.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Iodide, iodine-containing radiographic contrast agents may decrease thyroid hormone secretion; may also increase thyroid hormone secretion, especially in patients with Graves' disease.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Other agents reported to impact on thyroid production/conversion include aminoglutethimide, amiodarone, chloral hydrate, diazepam, ethionamide, interferon-alpha, interleukin-2, lithium, lovastatin (case report), glucocorticoids (dose-related), mercaptopurine, sulfonamides, thiazide diuretics, and tolbutamide.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     In addition, a number of medications have been noted to cause transient depression in TSH secretion, which may complicate interpretation of monitoring tests for levothyroxine, including corticosteroids, octreotide, and dopamine. Metoclopramide may increase TSH secretion",
"    </p>",
"   </div>",
"   <div class=\"block exp drugH1Div\" id=\"F11417459\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Extemporaneous Preparations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A 25 mcg/mL oral suspension may be made with tablets and 40 mL glycerol. Crush twenty-five 0.1 mg levothyroxine tablets in a mortar and reduce to a fine powder. Add small portions of glycerol and mix to a uniform suspension. Transfer to a calibrated 100 mL amber bottle; rinse the mortar with about 10 mL of glycerol and pour into the bottle; repeat until all 40 mL of glycerol is used. Add quantity of water sufficient to make 100 mL. Label \"shake well\" and \"refrigerate\". Stable for 8 days refrigerated.",
"    </p>",
"    <div class=\"reference\">",
"     Boulton DW, Fawcett JP, and Woods DJ, \"Stability of an Extemporaneously Compounded Levothyroxine Sodium Oral Liquid,\"",
"     <i>",
"      Am J Health Syst Pharm",
"     </i>",
"     , 1996, 53(10):1157-61.",
"     <span class=\"pubmed-id\">",
"      8734676",
"     </span>",
"    </div>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics, Rose SR, Section on Endocrinology and Committee on Genetics, American Thyroid Association, et al, \"Update of Newborn Screening and Therapy for Congenital Hypothyroidism,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2006, 117(6):2290-303.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?30/47/31480/abstract-text/16740880/pubmed\" id=\"16740880\" target=\"_blank\">",
"        16740880",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cooper DS, Kloos RT, Mazzaferri EL, et al, \"Revised American Thyroid Association Management Guidelines for Patients With Thyroid Nodules and Differentiated Thyroid Cancer,\"",
"      <i>",
"       Thyroid",
"      </i>",
"      , 2009, 19(11):1167-214.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?30/47/31480/abstract-text/19860577/pubmed\" id=\"19860577\" target=\"_blank\">",
"        19860577",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      de Groot JW, Zonnenberg BA, Plukker JT, et al,  \"Imatinib Induces Hypothyroidism in Patients Receiving Levothyroxine,\"",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 2005, 78(4):433-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?30/47/31480/abstract-text/16198662/pubmed\" id=\"16198662\" target=\"_blank\">",
"        16198662",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dickerson DN, Maish GO 3rd, Minard G, et al, \"Clinical Relevancy of Levothyroxine &ndash; Continuous Enteral Nutrition Interaction,\"",
"      <i>",
"       Nutr Clin Pract",
"      </i>",
"      , 2010, 25(6):646-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?30/47/31480/abstract-text/21139130/pubmed\" id=\"21139130\" target=\"_blank\">",
"        21139130",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fish LH, Schwartz HL, Cavenaugh J, et al, \"Replacement Dose, Metabolism, and Bioavailability of Levothyroxine in the Treatment of Hypothyroidism,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 316(13):764-70.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?30/47/31480/abstract-text/3821822/pubmed\" id=\"3821822\" target=\"_blank\">",
"        3821822",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gharib H, Papini E, Paschke R, et al, \"American Association of Clinical Endocrinologists, Associazione Medici Endocrinologi, and European Thyroid Association Medical Guidelines for Clinical Practice for Diagnosis and Management of Thyroid Nodules,\"",
"      <i>",
"       Endocr Pract",
"      </i>",
"      , 2010, 16(Supp 1):1-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?30/47/31480/abstract-text/20497938/pubmed\" id=\"20497938\" target=\"_blank\">",
"        20497938",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gupta VD, \"Stability of Levothyroxine Sodium Injection in Polypropylene Syringes,\"",
"      <i>",
"       Int J Pharm Compound",
"      </i>",
"      , 2000, 4(6):482-3.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nakagawa TA, \"Updated Pediatric Donor Management and Dosing Guidelines,\" 2008. Available at file://www.natco1.org/prof_development/documents/FINALNATCOPedDonorManagementGuidelines_Jan08.pdf. Last accessed June 2012.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Selva KA, Mandel SH, Rien L, et al, \"Initial Treatment Dose of L-thyroxine in Congenital Hypothyroidism,\"",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 2002, 141(6):786-92.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?30/47/31480/abstract-text/12461494/pubmed\" id=\"12461494\" target=\"_blank\">",
"        12461494",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Strong DK, Decarie D, and Ensom MHH, \"Stability of Levothyroxine in Sodium Chloride for IV Administration,\"",
"      <i>",
"       Can J Hosp Pharm",
"      </i>",
"      , 2010, 63(6):437-43.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Zeitler P, Solberg P, and Pharmacy and Therapeutics Committee of the Lawson Wilkins Pediatric Endocrine Society, \"Food and Levothyroxine Administration in Infants and Children,\"",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 2010, 157(1):13-14.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?30/47/31480/abstract-text/20547262/pubmed\" id=\"20547262\" target=\"_blank\">",
"        20547262",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Zuppa AF, Nadkarni V, Davis L, et al, \"The Effect of a Thyroid Hormone Infusion on Vasopressor Support in Critically Ill Children With Cessation of Neurologic Function,\"",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2004, 32(11):2318-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?30/47/31480/abstract-text/15640648/pubmed\" id=\"15640648\" target=\"_blank\">",
"        15640648",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12550 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-198.199.123.20-28C064E6EE-14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_47_31480=[""].join("\n");
var outline_f30_47_31480=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709010\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188360\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188361\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059804\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11443808\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059796\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188330\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188314\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059808\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188389\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059800\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059807\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188391\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188388\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059813\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059795\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059794\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299600\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188323\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059815\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188326\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188341\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059803\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059806\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059793\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059811\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059812\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059802\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059814\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11417459\">",
"      Extemporaneous Preparations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12550\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12550|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?40/43/41656?source=related_link\">",
"      Levothyroxine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?13/20/13638?source=related_link\">",
"      Levothyroxine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_47_31481="Overview of Candida infections in children";
var content_f30_47_31481=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of Candida infections in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?30/47/31481/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/47/31481/contributors\">",
"     Carol A Kauffman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/47/31481/contributors\">",
"     Judith R Campbell, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?30/47/31481/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/47/31481/contributors\">",
"     Sheldon L Kaplan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?30/47/31481/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/47/31481/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?30/47/31481/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical manifestations of infection with",
"    <em>",
"     Candida",
"    </em>",
"    species range from local mucous membrane infection to widespread dissemination with multisystem organ failure.",
"    <em>",
"     Candida",
"    </em>",
"    are considered normal flora in the gastrointestinal and genitourinary tracts of humans, but invade and cause disease when there is an imbalance in their ecological niche. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/19/37176?source=see_link\">",
"     \"Biology of Candida infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic will provide an overview of",
"    <em>",
"     Candida",
"    </em>",
"    infections in children. Many of these infections are discussed in detail in other topic reviews; they are briefly summarized here. The clinical features, diagnosis, and treatment of candidemia in children and",
"    <em>",
"     Candida",
"    </em>",
"    infections in neonates are discussed separately.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/6/25703?source=see_link\">",
"       \"Clinical features and diagnosis of candidemia in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/16/3336?source=see_link\">",
"       \"Treatment of candidemia in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/30/24039?source=see_link\">",
"       \"Epidemiology and risk factors for Candida infection in neonates\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/62/31720?source=see_link\">",
"       \"Clinical manifestations and diagnosis of Candida infection in neonates\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/51/40760?source=see_link\">",
"       \"Treatment of Candida infection in neonates\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1198561\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;The immune response of the host is an important determinant of the type of infection caused by",
"    <em>",
"     Candida",
"    </em>",
"    .",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most benign infections are characterized by local overgrowth on skin or mucous membranes as a result of changes in the normal flora. More extensive",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      persistent mucous membrane infections occur in individuals with deficiencies in cell-mediated immunity.",
"     </li>",
"     <li>",
"      Candidemia results when",
"      <em>",
"       Candida",
"      </em>",
"      species gain access to the bloodstream, typically in immune compromised individuals or patients in the intensive care unit or with vascular devices. Widespread dissemination may occur in neonates, neutropenic hosts, or severely ill patients in the intensive care unit.",
"     </li>",
"     <li>",
"      Invasive focal infections, such as endocarditis, and meningitis, most often occur after hematogenous spread in patients with anatomic abnormalities or devices (eg, prosthetic heart valves, central nervous system shunts).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The different",
"    <em>",
"     Candida",
"    </em>",
"    species generally are capable of producing all of the clinical syndromes, although infection with",
"    <em>",
"     Candida albicans",
"    </em>",
"    is the most common. The major reasons to identify the infecting",
"    <em>",
"     Candida",
"    </em>",
"    species are that",
"    <em>",
"     C. glabrata",
"    </em>",
"    and",
"    <em>",
"     C. krusei",
"    </em>",
"    are less susceptible to azole antifungal agents than are other species and",
"    <em>",
"     C. lusitaniae",
"    </em>",
"    may be resistant to",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/12/201?source=see_link\">",
"     amphotericin B",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H364113269\">",
"    <span class=\"h1\">",
"     MUCOCUTANEOUS CANDIDIASIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Oropharyngeal candidiasis",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H364112468\">",
"    <span class=\"h3\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oropharyngeal candidiasis, or thrush, is common in young infants. It also may be seen in older children treated with antibiotics, inhaled glucocorticoids (for asthma or rhinitis), chemotherapy, or radiation therapy and in children with cellular immune deficiency, such as the acquired immunodeficiency syndrome (AIDS). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/60/7114?source=see_link&amp;anchor=H4#H4\">",
"     \"Major side effects of inhaled glucocorticoids\", section on 'Topical candidiasis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Oropharyngeal candidiasis can manifest in several ways. The pseudomembranous form is the most common. It appears as white plaques on the buccal mucosa, palate, tongue, or the oropharynx (",
"    <a class=\"graphic graphic_picture graphicRef69465 \" href=\"UTD.htm?9/63/10228\">",
"     picture 1",
"    </a>",
"    ). Infants with thrush may be asymptomatic or may refuse to eat due to discomfort from the infection. In older children, typical symptoms may include a cottony feeling in the mouth, loss of taste, and sometimes pain on eating and swallowing. However, many are asymptomatic.",
"   </p>",
"   <p>",
"    Other forms of oropharyngeal candidiasis include angular cheilitis (perl&egrave;che) (",
"    <a class=\"graphic graphic_picture graphicRef71723 \" href=\"UTD.htm?32/40/33410\">",
"     picture 2",
"    </a>",
"    ) and acute atrophic candidiasis (glossitis). Angular cheilitis is painful fissuring at the corners of the mouth. It can occur in individuals who habitually lick the corners of the mouth, creating an environment in which",
"    <em>",
"     Candida",
"    </em>",
"    can establish an infection but also occurs in the absence of lip-licking (eg, in immunocompromised patients) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/47/31481/abstract/1\">",
"     1",
"    </a>",
"    ]. In acute atrophic candidiasis (glossitis), alteration of the bacterial flora of the oral mucosa (eg, secondary to broad spectrum antibiotics) results in erosion of the papillae on the dorsum of the tongue [",
"    <a class=\"abstract\" href=\"UTD.htm?30/47/31481/abstract/1\">",
"     1",
"    </a>",
"    ]. The tongue is smooth, erythematous, and often painful.",
"   </p>",
"   <p>",
"    Oropharyngeal candidiasis is usually diagnosed clinically, based upon the characteristic white plaques (",
"    <a class=\"graphic graphic_picture graphicRef69465 \" href=\"UTD.htm?9/63/10228\">",
"     picture 1",
"    </a>",
"    ). If necessary, it can be confirmed by scraping the lesions with a tongue depressor and performing a Gram stain or potassium hydroxide (KOH) preparation on the scrapings. Demonstration of budding yeasts with or without pseudohyphae confirms the diagnosis (",
"    <a class=\"graphic graphic_picture graphicRef79879 \" href=\"UTD.htm?27/37/28242\">",
"     picture 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/51/31543?source=see_link&amp;anchor=H4044416#H4044416\">",
"     \"Dermatologic procedures\", section on 'Potassium hydroxide (KOH) prep'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Culture of the lesions is rarely indicated unless oral candidiasis is recalcitrant or recurrent, in which case it is probably caused by an unusual",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    azole-resistant species. Recurrent, recalcitrant, or extensive oral candidiasis also warrants evaluation of the immune system and HIV testing. In addition, evaluation for cellular immune deficiency may be warranted in children older than one year of age who develop oropharyngeal candidiasis in the absence of a predisposing factor (eg, recent antibiotics, inhaled glucocorticoids, cancer). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/58/43945?source=see_link&amp;anchor=H22451541#H22451541\">",
"     \"Laboratory evaluation of the immune system\", section on 'Overview of clinical manifestations and testing for specific components of the immune system'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/3/3130?source=see_link&amp;anchor=H18840505#H18840505\">",
"     \"Natural history and classification of pediatric HIV infection\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32199424\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most cases of oropharyngeal candidiasis are caused by",
"    <em>",
"     C. albicans",
"    </em>",
"    . Meta-analyses of randomized trials demonstrate that topical antifungal therapy is effective for oropharyngeal candidiasis in most patients, even those who are immunocompromised [",
"    <a class=\"abstract\" href=\"UTD.htm?30/47/31481/abstract/2\">",
"     2",
"    </a>",
"    ]. However, the initial management of oral candidiasis in children may vary depending on age and severity of infection. The treatment recommendations provided below are consistent with those in the 2009 Infectious Diseases Society of America (IDSA) guidelines for the management of candidiasis [",
"    <a class=\"abstract\" href=\"UTD.htm?30/47/31481/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Treatment of infants",
"      </strong>",
"      &ndash; The successful treatment of oropharyngeal candidiasis in infants involves topical antifungal agents and measures to prevent reinfection, including sterilization or decolonization of items and body sites that are placed in the infant&rsquo;s mouth [",
"      <a class=\"abstract\" href=\"UTD.htm?30/47/31481/abstract/1\">",
"       1",
"      </a>",
"      ]. Bottle nipples and pacifiers that are to be reused should be boiled after each use. The treatment of",
"      <em>",
"       Candida",
"      </em>",
"      breast colonization",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      infection in lactating women is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/15/17658?source=see_link&amp;anchor=H14#H14\">",
"       \"Common problems of breastfeeding and weaning\", section on 'Candidal infection'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      We suggest that oral candidiasis in immunocompetent infants be treated with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/23/34160?source=see_link\">",
"       nystatin",
"      </a>",
"      suspension (0 to 30 days: 100,000 units [50,000 units to each cheek] four times daily for 7 to 14 days; &ge;30 days: 200,000 units [100,000 units to each cheek] four times daily for 7 to 14 days) [",
"      <a class=\"abstract\" href=\"UTD.htm?30/47/31481/abstract/1,4\">",
"       1,4",
"      </a>",
"      ]. Nystatin suspension may be squirted into the mouth or applied with gauze or cotton swab. Treatment is continued until two to three days after resolution of lesions, which typically occurs within two weeks. Failure to improve or resolve within two weeks may be related to persistent reexposure (eg, from pacifiers or bottle nipples) or infection with an unusual species.",
"      <br/>",
"      <br/>",
"      In randomized trials, 10 to 21 days of treatment with nystatin suspension was associated with clinical cure rates of 29 to 80 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?30/47/31481/abstract/5-7\">",
"       5-7",
"      </a>",
"      ]. Oral",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/43/26297?source=see_link\">",
"       fluconazole",
"      </a>",
"      may be used as an alternative to nystatin. In a randomized trial, compared with nystatin, oral fluconazole was associated with faster clearance of lesions, increased clinical cure rates (100 percent versus 29 percent), and increased mycologic cure rates (73 versus 6 percent); the rates of side effects were similar [",
"      <a class=\"abstract\" href=\"UTD.htm?30/47/31481/abstract/6\">",
"       6",
"      </a>",
"      ]. However, given the typically benign clinical course of oropharyngeal candidiasis in immunocompetent infants, we suggest nystatin as the initial treatment.",
"      <br/>",
"      <br/>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/61/26578?source=see_link\">",
"       Gentian violet",
"      </a>",
"      (0.5% or 1%) applied to the buccal mucosa once or twice daily is also effective [",
"      <a class=\"abstract\" href=\"UTD.htm?30/47/31481/abstract/4\">",
"       4",
"      </a>",
"      ]. However, gentian violet can stain the infant&rsquo;s lips and clothing and may cause irritation and ulceration [",
"      <a class=\"abstract\" href=\"UTD.htm?30/47/31481/abstract/8-10\">",
"       8-10",
"      </a>",
"      ]. Given the availability of other effective agents, gentian violet is rarely recommended.",
"      <br/>",
"      <br/>",
"      We suggest treatment with oral fluconazole (6",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      on day 1 of therapy followed by 3",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      once daily for 14 days), for oropharyngeal candidiasis that is refractory to nystatin and appropriate decolonization measures. Culture",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      evaluation for immune deficiency may be warranted for infants with oropharyngeal candidiasis that does not respond to oral fluconazole. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/58/43945?source=see_link&amp;anchor=H22451541#H22451541\">",
"       \"Laboratory evaluation of the immune system\", section on 'Overview of clinical manifestations and testing for specific components of the immune system'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <strong>",
"       Treatment of older children",
"      </strong>",
"      &ndash; We suggest that older children with mild oral candidiasis (defined clinically as involvement of &lt;50 percent of the oral mucosa and absence of lesions that are deep and erosive) be treated with topical",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/23/34160?source=see_link\">",
"       nystatin",
"      </a>",
"      or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/58/34720?source=see_link\">",
"       clotrimazole",
"      </a>",
"      for 7 to 14 days [",
"      <a class=\"abstract\" href=\"UTD.htm?30/47/31481/abstract/3\">",
"       3",
"      </a>",
"      ]. Nystatin may be administered as suspension (400,000 to 600,000 units swished and held in the mouth as long as possible before being swallowed four times per day; or squirted into the mouth for children who cannot cooperate with the swish and swallow method); or as a lozenge (one to two lozenges [each 200,000 units] four times per day) [",
"      <a class=\"abstract\" href=\"UTD.htm?30/47/31481/abstract/1\">",
"       1",
"      </a>",
"      ]. Clotrimazole is administered as a lozenge (10 mg; five or six times per day). Nystatin and clotrimazole lozenges should not be used in children younger than four years (they are a choking hazard).",
"      <br/>",
"      <br/>",
"      Treatment of severe (defined clinically as &ge;50 percent involvement of the oral mucosa",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      lesions that are deep and erosive) or refractory oropharyngeal candidiasis, particularly in immunocompromised children, may require systemic therapy. We suggest that older children with moderate to severe oropharyngeal candidiasis be treated with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/43/26297?source=see_link\">",
"       fluconazole",
"      </a>",
"      (6",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      orally once on the first day, followed by 3",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      once per day for 7 to 14 days) [",
"      <a class=\"abstract\" href=\"UTD.htm?30/47/31481/abstract/3\">",
"       3",
"      </a>",
"      ]. An alternative antifungal agent and evaluation for fluconazole-resistant",
"      <em>",
"       Candida",
"      </em>",
"      or immune deficiency may be warranted if the child does not respond to empiric fluconazole.",
"      <br/>",
"      <br/>",
"      Neutropenic patients may require intravenous antifungal therapy (eg, fluconazole 6",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      intravenously once on the first day, followed by 3",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      once per day for at least 14 days) or another antifungal agent if a resistant",
"      <em>",
"       Candida",
"      </em>",
"      is suspected.",
"      <br/>",
"      <br/>",
"      In a randomized trial in immunocompromised children (including those with malignancy, immune disorder, HIV, and those receiving immunosuppressive therapy) with oropharyngeal candidiasis, fluconazole was more effective than nystatin in clinical and mycologic cure [",
"      <a class=\"abstract\" href=\"UTD.htm?30/47/31481/abstract/11\">",
"       11",
"      </a>",
"      ]. In a meta-analysis of 22 studies assessing treatment for oropharyngeal candidiasis in patients with HIV infection, treatment with fluconazole was superior to nystatin for clinical cure in adults [",
"      <a class=\"abstract\" href=\"UTD.htm?30/47/31481/abstract/2\">",
"       2",
"      </a>",
"      ]. Clinical cure rates were similar among patients treated with fluconazole,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/10/34976?source=see_link\">",
"       ketoconazole",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/59/6074?source=see_link\">",
"       itraconazole",
"      </a>",
"      solution, clotrimazole troches, and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/18/35112?source=see_link\">",
"       posaconazole",
"      </a>",
"      solution, but fluconazole and itraconazole solution were superior to clotrimazole troches for mycologic cure [",
"      <a class=\"abstract\" href=\"UTD.htm?30/47/31481/abstract/2\">",
"       2",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Treatment of severe oropharyngeal candidiasis that is refractory to oral or intravenous fluconazole generally is treated intravenously with amphotericin (deoxycholate or lipid formulation) or an echinocandin.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H364112951\">",
"    <span class=\"h2\">",
"     Diaper dermatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <em>",
"     Candida",
"    </em>",
"    diaper dermatitis is common in young infants. It is typically caused by",
"    <em>",
"     C. albicans",
"    </em>",
"    . The rash of",
"    <em>",
"     Candida",
"    </em>",
"    diaper dermatitis classically occurs in the inguinal region and has areas of confluent erythema with discrete erythematous papules and plaques, superficial scale, and satellite lesions (",
"    <a class=\"graphic graphic_picture graphicRef59361 graphicRef72165 \" href=\"UTD.htm?35/41/36501\">",
"     picture 4A-B",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <em>",
"     Candida",
"    </em>",
"    diaper dermatitis is usually diagnosed clinically, based upon the location and appearance of the rash. If necessary, the diagnosis can be confirmed by scraping the lesions and performing a Gram stain or potassium hydroxide (KOH) preparation on the scrapings. Budding yeasts with or without pseudohyphae establish the diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/51/31543?source=see_link&amp;anchor=H4044416#H4044416\">",
"     \"Dermatologic procedures\", section on 'Potassium hydroxide (KOH) prep'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The treatment of",
"    <em>",
"     Candida",
"    </em>",
"    diaper dermatitis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/33/37401?source=see_link&amp;anchor=H27#H27\">",
"     \"Overview of diaper dermatitis in infants and children\", section on 'Antifungal agents'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Persistent",
"    <em>",
"     Candida",
"    </em>",
"    diaper rash in young children may be a sign of type 1 diabetes mellitus, chronic mucocutaneous candidiasis, or an underlying immunodeficiency. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/59/40889?source=see_link&amp;anchor=H14#H14\">",
"     \"Epidemiology, presentation, and diagnosis of type 1 diabetes mellitus in children and adolescents\", section on 'Young children'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/1/22553?source=see_link&amp;anchor=H10714495#H10714495\">",
"     \"Chronic mucocutaneous candidiasis\", section on 'Overview'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H522962008\">",
"    <span class=\"h2\">",
"     Intertrigo",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <em>",
"     Candida",
"    </em>",
"    intertrigo refers to",
"    <em>",
"     Candida",
"    </em>",
"    infection of closely opposed skin surfaces (eg, neck folds in infants, the axillae, intergluteal folds, etc). Clinical features include erythematous, macerated plaques and erosions with peripheral scale and satellite papulopustules (",
"    <a class=\"graphic graphic_picture graphicRef62523 \" href=\"UTD.htm?27/43/28338\">",
"     picture 5",
"    </a>",
"    ). The lesions may be painful if skin breakdown accompanies the infection. The diagnosis and treatment of",
"    <em>",
"     Candida",
"    </em>",
"    intertrigo are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/59/30648?source=see_link\">",
"     \"Candidal intertrigo\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H364112958\">",
"    <span class=\"h2\">",
"     Vulvovaginitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Predisposing factors for vulvovaginal candidiasis in infants include diaper use, broad-spectrum antibiotics, and immunosuppression (including glucocorticoids and HIV infection). Additional risk factors in adolescents include certain contraceptive devices (vaginal sponges, diaphragms, intrauterine devices), estrogen therapy (including oral contraceptives), and pregnancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/1/15386?source=see_link&amp;anchor=H4#H4\">",
"     \"Candida vulvovaginitis\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The primary clinical manifestations of",
"    <em>",
"     Candida",
"    </em>",
"    vulvovaginitis are itching and discharge. Dysuria and vaginal irritation also may be present. Dyspareunia may be a complaint in sexually active adolescents. Examination shows vulvar erythema and swelling and vaginal erythema and discharge, which is classically curd-like, but may be watery. Some patients, primarily those with",
"    <em>",
"     C. glabrata",
"    </em>",
"    infection, have little discharge and often only erythema on vaginal examination [",
"    <a class=\"abstract\" href=\"UTD.htm?30/47/31481/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diagnosis of",
"    <em>",
"     Candida",
"    </em>",
"    vulvovaginitis is typically made clinically. If necessary, confirmation is easily obtained by observing budding yeast, with or without pseudohyphae, on a wet mount or KOH preparation of vaginal secretions (",
"    <a class=\"graphic graphic_picture graphicRef59030 \" href=\"UTD.htm?9/37/9809\">",
"     picture 6",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/1/15386?source=see_link&amp;anchor=H5#H5\">",
"     \"Candida vulvovaginitis\", section on 'Clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The treatment of",
"    <em>",
"     Candida",
"    </em>",
"    vulvovaginitis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/1/15386?source=see_link&amp;anchor=H12#H12\">",
"     \"Candida vulvovaginitis\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H364112986\">",
"    <span class=\"h2\">",
"     Balanitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <em>",
"     Candida",
"    </em>",
"    balanitis may occur as a component of diaper dermatitis in infants. In also may be acquired sexually in adolescents. Clinical features include white patches on the penis in association with severe burning and itching. The infection can spread to the thighs, gluteal folds, buttocks, and scrotum. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/55/33654?source=see_link&amp;anchor=H7#H7\">",
"     \"Balanoposthitis in children: Epidemiology and pathogenesis\", section on 'Fungal'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis and treatment of",
"    <em>",
"     Candida",
"    </em>",
"    balanitis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/23/24953?source=see_link\">",
"     \"Balanoposthitis in children: Clinical manifestations, diagnosis, and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Esophagitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Esophageal candidiasis occurs predominantly in individuals with hematologic malignancies and human immunodeficiency virus (HIV). In patients with HIV infection, esophageal candidiasis is an AIDS-defining illness. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/3/3130?source=see_link&amp;anchor=H18840540#H18840540\">",
"     \"Natural history and classification of pediatric HIV infection\", section on 'Candida esophagitis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The hallmark of",
"    <em>",
"     Candida",
"    </em>",
"    esophagitis is pain with swallowing (odynophagia). Patients usually localize their pain to a discrete retrosternal area. Concomitant thrush may or may not be present.",
"   </p>",
"   <p>",
"    <em>",
"     Candida",
"    </em>",
"    esophagitis usually is diagnosed endoscopically. White mucosal plaque-like lesions suggest the diagnosis. Confirmatory biopsy demonstrates yeasts and pseudohyphae invading mucosal cells. An alternative diagnostic approach in",
"    <span class=\"nowrap\">",
"     HIV/AIDS",
"    </span>",
"    patients with suggestive clinical features is to treat with systemic antifungal agents (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/43/26297?source=see_link\">",
"     fluconazole",
"    </a>",
"    loading dose of 6",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    orally on the first day followed by 3",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    orally once per day). Odynophagia due to candidiasis typically improves within several days; if symptoms do not improve within three to four days, endoscopy and biopsy should be performed [",
"    <a class=\"abstract\" href=\"UTD.htm?30/47/31481/abstract/13\">",
"     13",
"    </a>",
"    ]. If endoscopy reveals clinical features suggestive of candidiasis, treatment with an antifungal agent other than fluconazole may be warranted pending culture results. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/38/4707?source=see_link&amp;anchor=H3#H3\">",
"     \"Evaluation of the HIV-infected patient with odynophagia and dysphagia\", section on 'Diagnostic studies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Chronic mucocutaneous candidiasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic mucocutaneous candidiasis is a rare syndrome that usually has its onset in childhood. Some patients with chronic mucocutaneous candidiasis have autosomal recessive polyglandular autoimmune syndrome type I (which may be manifested by hypoparathyroidism, hypothyroidism, and adrenal insufficiency), whereas others have no associated diseases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/1/22553?source=see_link\">",
"     \"Chronic mucocutaneous candidiasis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/0/40969?source=see_link&amp;anchor=H3#H3\">",
"     \"Causes of primary adrenal insufficiency (Addison's disease)\", section on 'Polyglandular autoimmune syndrome type I'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An underlying T cell defect is thought to be responsible for the inability of these patients to eradicate",
"    <em>",
"     Candida",
"    </em>",
"    from mucous membranes and cutaneous structures [",
"    <a class=\"abstract\" href=\"UTD.htm?30/47/31481/abstract/14\">",
"     14",
"    </a>",
"    ]. The clinical manifestations are severe, recurrent thrush (",
"    <a class=\"graphic graphic_picture graphicRef59947 \" href=\"UTD.htm?2/53/2911\">",
"     picture 7",
"    </a>",
"    ), vaginitis, onychomycosis (",
"    <a class=\"graphic graphic_picture graphicRef71698 \" href=\"UTD.htm?28/24/29070\">",
"     picture 8",
"    </a>",
"    ), and chronic skin lesions. Hyperkeratotic, crusted skin lesions on the face, scalp, and hands can lead to psychosocial problems (",
"    <a class=\"graphic graphic_picture graphicRef64895 \" href=\"UTD.htm?10/1/10258\">",
"     picture 9",
"    </a>",
"    ). Visceral invasion is rare. Chronic suppressive antifungal treatment is required to achieve remission. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/1/22553?source=see_link&amp;anchor=H572076#H572076\">",
"     \"Chronic mucocutaneous candidiasis\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1200993\">",
"    <span class=\"h1\">",
"     INVASIVE CANDIDIASIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1198823\">",
"    <span class=\"h2\">",
"     Candidemia and acute disseminated candidiasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Candidemia refers to the presence of",
"    <em>",
"     Candida",
"    </em>",
"    species in the blood. Neonates, immunocompromised hosts, and children in intensive care units are most at risk for the development of candidemia. Acute disseminated candidiasis occurs when several viscera are infected as a result of hematogenous spread. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/6/25703?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical features and diagnosis of candidemia in children\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical manifestations of candidemia vary from minimal fever to a fulminant sepsis syndrome indistinguishable from severe bacterial infection. Signs of multiorgan system failure may be present. Clinical clues include characteristic eye lesions (",
"    <a class=\"graphic graphic_picture graphicRef58685 graphicRef73318 \" href=\"UTD.htm?20/15/20720\">",
"     picture 10A-B",
"    </a>",
"    ), skin lesions (",
"    <a class=\"graphic graphic_picture graphicRef55977 graphicRef75717 \" href=\"UTD.htm?32/12/32964\">",
"     picture 11A-B",
"    </a>",
"    ), and, less commonly, muscle abscesses. The clinical manifestations and treatment of candidemia are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/6/25703?source=see_link&amp;anchor=H8#H8\">",
"     \"Clinical features and diagnosis of candidemia in children\", section on 'Clinical manifestations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/16/3336?source=see_link\">",
"     \"Treatment of candidemia in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1201712\">",
"    <span class=\"h2\">",
"     Invasive focal infections",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Urinary tract infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Candiduria is common in hospitalized patients, but it is difficult to distinguish colonization from infection of the bladder [",
"    <a class=\"abstract\" href=\"UTD.htm?30/47/31481/abstract/15\">",
"     15",
"    </a>",
"    ]. Risk factors for candiduria include indwelling bladder catheter, antibiotics, diabetes, and recent surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?30/47/31481/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <em>",
"     Candida",
"    </em>",
"    pyelonephritis is rare. It can be secondary to hematogenous seeding and is typically characterized by multiple microabscesses in the setting of disseminated candidiasis. It can also occur as an ascending infection in patients with obstruction. Ascending infection usually is unilateral and develops more insidiously than hematogenous infection. Although",
"    <em>",
"     Candida",
"    </em>",
"    infection of the bladder and",
"    <em>",
"     Candida",
"    </em>",
"    pyelonephritis may coexist, it is important to distinguish them because the treatments differ. The symptoms of",
"    <em>",
"     Candida",
"    </em>",
"    pyelonephritis are similar to those of bacterial pyelonephritis: fever, chills, flank pain, and dysuria. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/49/15128?source=see_link&amp;anchor=H7#H7\">",
"     \"Candida infections of the bladder and kidneys\", section on 'Clinical characteristics'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/40/21129?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical features and diagnosis of urinary tract infections in infants and children older than one month\", section on 'Clinical presentation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with either lower or upper tract infection due to",
"    <em>",
"     Candida",
"    </em>",
"    can develop \"fungus balls\" or mycetomas that consist of masses of hyphae. Fungus balls can grow to a large size and lead to obstruction of the collecting system; surgical intervention or percutaneous drainage is required when obstruction occurs.",
"   </p>",
"   <p>",
"    The diagnosis and treatment of",
"    <em>",
"     Candida",
"    </em>",
"    infections of the bladder and kidneys are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/49/15128?source=see_link\">",
"     \"Candida infections of the bladder and kidneys\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Peritonitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <em>",
"     Candida",
"    </em>",
"    infection of the peritoneal cavity can occur as a result of postoperative wound infection, gastrointestinal perforation, or chronic peritoneal dialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?30/47/31481/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. Peritonitis associated with primary perforation or secondary to a surgical procedure is usually polymicrobial. Prominent symptoms include fever, chills, and abdominal pain. These are the same as those of bacterial peritonitis, which is often coexistent. Complications of",
"    <em>",
"     Candida",
"    </em>",
"    peritonitis include bloodstream invasion with sepsis and abscess formation requiring surgical drainage. Diagnosis is best made by aspiration of fluid under computed tomographic (CT) or ultrasound guidance or at the time of surgery. Culture of",
"    <em>",
"     Candida",
"    </em>",
"    species from an indwelling drain is NOT adequate for the diagnosis of infection since it often reflects only colonization or contamination of the drain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/27/8631?source=see_link&amp;anchor=H5#H5\">",
"     \"Fungal peritonitis in continuous peritoneal dialysis\", section on 'Laboratory findings and diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients who have indwelling Tenckhoff catheters for chronic peritoneal dialysis usually develop",
"    <em>",
"     Candida",
"    </em>",
"    peritonitis only after they have had episodes of bacterial peritonitis [",
"    <a class=\"abstract\" href=\"UTD.htm?30/47/31481/abstract/18\">",
"     18",
"    </a>",
"    ]. The symptoms may be subtle, consisting of mild abdominal pain and low-grade fever; the first signs frequently are poor flow and cloudiness of the dialysate. The diagnosis is easily made by culturing the dialysate fluid. In contrast to bacterial peritonitis in these patients, treatment with antifungal agents is rarely effective unless the catheter is removed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/11/17594?source=see_link&amp;anchor=H25#H25\">",
"     \"Microbiology and therapy of peritonitis in continuous peritoneal dialysis\", section on 'Indications for catheter removal'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Endophthalmitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <em>",
"     Candida",
"    </em>",
"    endophthalmitis can develop following trauma or eye surgery or through hematogenous seeding of the retina and choroid as a complication of candidemia. Patients with",
"    <em>",
"     Candida",
"    </em>",
"    endophthalmitis may or may not have evidence of disseminated candidiasis in other organ systems. Diagnosis requires an ophthalmologic examination.",
"    <em>",
"     Candida",
"    </em>",
"    endophthalmitis can be sight-threatening if it is not treated. Thus, the Infectious Diseases Society of America (IDSA) guidelines for the management of candidiasis recommend at least one dilated retinal examination, preferably by an ophthalmologist early in the course of therapy for all patients with candidemia [",
"    <a class=\"abstract\" href=\"UTD.htm?30/47/31481/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/33/13849?source=see_link&amp;anchor=H27883763#H27883763\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of fungal endophthalmitis\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Osteoarticular infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <em>",
"     Candida",
"    </em>",
"    species infect bones and joints as a result of hematogenous seeding or exogenous inoculation during trauma, intraarticular injection, a surgical procedure, or injection drug use.",
"    <em>",
"     Candida",
"    </em>",
"    arthritis or osteomyelitis most often develops as a sequel to candidemia. Bone or joint involvement may become evident during an episode of fungemia or may have a more subtle presentation after the fungemia has resolved [",
"    <a class=\"abstract\" href=\"UTD.htm?30/47/31481/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]. Swelling and decreased range of motion are the major symptoms (as in bacterial osteoarticular infections), but these may be mild [",
"    <a class=\"abstract\" href=\"UTD.htm?30/47/31481/abstract/22\">",
"     22",
"    </a>",
"    ]. Radiographic findings do not distinguish between bacterial and fungal infection. The etiologic diagnosis is established by obtaining synovial fluid or bone aspirate for culture. Even a single colony of",
"    <em>",
"     Candida",
"    </em>",
"    on culture of joint fluid or bone aspirate should be viewed as pathogenic, and the patient should be treated with antifungal agents. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/39/20087?source=see_link\">",
"     \"Clinical features of hematogenous osteomyelitis in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/32/33289?source=see_link\">",
"     \"Evaluation and diagnosis of hematogenous osteomyelitis in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/30/14826?source=see_link\">",
"     \"Bacterial arthritis: Clinical features and diagnosis in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <em>",
"     Candida",
"    </em>",
"    osteoarticular infections in neonates are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/62/31720?source=see_link&amp;anchor=H15#H15\">",
"     \"Clinical manifestations and diagnosis of Candida infection in neonates\", section on 'Osteoarticular infections'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Meningitis/CNS infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <em>",
"     Candida",
"    </em>",
"    species can cause acute meningitis during the course of widespread dissemination.",
"    <em>",
"     Candida",
"    </em>",
"    meningitis most often occurs in neonates with candidemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/62/31720?source=see_link&amp;anchor=H12#H12\">",
"     \"Clinical manifestations and diagnosis of Candida infection in neonates\", section on 'Central nervous system infection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <em>",
"     Candida",
"    </em>",
"    species uncommonly can cause ventriculoperitoneal shunt infections [",
"    <a class=\"abstract\" href=\"UTD.htm?30/47/31481/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1198646\">",
"    <span class=\"h3\">",
"     Endocarditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Risk factors for",
"    <em>",
"     Candida",
"    </em>",
"    endocarditis include indwelling central venous catheters, underlying congenital heart disease, a history of cardiac surgery, and prolonged candidemia [",
"    <a class=\"abstract\" href=\"UTD.htm?30/47/31481/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]. The clinical manifestations of",
"    <em>",
"     Candida",
"    </em>",
"    endocarditis are similar to those of bacterial endocarditis. They include fever, changing or new heart murmurs, and signs and symptoms of heart failure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/15/27896?source=see_link&amp;anchor=H7#H7\">",
"     \"Infective endocarditis in children\", section on 'Clinical manifestations'",
"    </a>",
"    .) Peripheral embolization is more likely with candidal than with bacterial endocarditis and affected patients can develop other complications of candidemia (eg, visual loss secondary to endophthalmitis). (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Endophthalmitis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The diagnostic criteria for",
"    <em>",
"     Candida",
"    </em>",
"    endocarditis are similar to those for bacterial endocarditis. Cultures of blood show persistent candidemia, and echocardiographic studies usually reveal large valvular vegetations. In some cases, an early manifestation of endocarditis is embolization of the large vegetation to a major vessel, such as the femoral artery. Examination of the embolus by histopathology shows yeasts and by culture yields",
"    <em>",
"     Candida",
"    </em>",
"    species. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/15/27896?source=see_link&amp;anchor=H8#H8\">",
"     \"Infective endocarditis in children\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H522957355\">",
"    <span class=\"h2\">",
"     Hepatosplenic or chronic disseminated candidiasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatosplenic candidiasis (also called chronic disseminated candidiasis) is seen almost entirely in patients with hematologic malignancies who have just recovered from an episode of neutropenia [",
"    <a class=\"abstract\" href=\"UTD.htm?30/47/31481/abstract/27\">",
"     27",
"    </a>",
"    ]. Some patients have a documented history of candidemia; in others it is assumed that the patient was candidemic during the period of neutropenia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/53/10071?source=see_link&amp;anchor=H6#H6\">",
"     \"Hepatosplenic candidiasis (chronic disseminated candidiasis)\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The classic presentation of hepatosplenic candidiasis consists of persistent fever, which is frequently high and spiking, in a patient who was recently neutropenic and whose neutrophil count has returned to normal. The fever is often accompanied by right upper quadrant discomfort or pain, nausea, vomiting, and anorexia. Laboratory testing typically reveals an elevated serum alkaline phosphatase concentration. Discrete persistent microabscesses occur in the liver, spleen, and, sometimes, kidneys.",
"   </p>",
"   <p>",
"    The diagnosis can be established by visualizing multiple characteristic lucencies in the liver, spleen, and kidneys on ultrasonography, magnetic resonance imaging, or CT scan (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef61598 \" href=\"UTD.htm?26/63/27632\">",
"     image 1",
"    </a>",
"    ). Biopsy reveals multiple granulomas (",
"    <a class=\"graphic graphic_picture graphicRef81112 \" href=\"UTD.htm?39/46/40674\">",
"     picture 12",
"    </a>",
"    ); yeasts and pseudohyphae can be seen using special stains. Blood cultures are negative, and even culture of liver obtained at biopsy frequently is also negative.",
"   </p>",
"   <p>",
"    The treatment of hepatosplenic candidiasis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/53/10071?source=see_link&amp;anchor=H11#H11\">",
"     \"Hepatosplenic candidiasis (chronic disseminated candidiasis)\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?42/49/43793?source=see_link\">",
"       \"Patient information: Diaper rash (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?26/54/27489?source=see_link\">",
"       \"Patient information: Thrush (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?43/41/44690?source=see_link\">",
"       \"Patient information: Diaper rash in infants and children (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H552172751\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The clinical manifestations of infection with",
"      <em>",
"       Candida",
"      </em>",
"      species range from local mucous membrane infection to widespread dissemination with multisystem organ failure. The immune response of the host is an important determinant of the type of infection. (See",
"      <a class=\"local\" href=\"#H1198561\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Oropharyngeal candidiasis (thrush) is common in infants (",
"      <a class=\"graphic graphic_picture graphicRef69465 \" href=\"UTD.htm?9/63/10228\">",
"       picture 1",
"      </a>",
"      ). It also may be seen in older children treated with antibiotics, inhaled glucocorticoids, chemotherapy, or radiation therapy and in children with cellular immunodeficiency. Oropharyngeal candidiasis usually is diagnosed clinically but can be confirmed with Gram stain or potassium hydroxide (KOH) preparation demonstrating budding yeast with or without pseudohyphae (",
"      <a class=\"graphic graphic_picture graphicRef79879 \" href=\"UTD.htm?27/37/28242\">",
"       picture 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Oropharyngeal candidiasis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The treatment of oropharyngeal candidiasis varies with age and severity of infection (see",
"      <a class=\"local\" href=\"#H32199424\">",
"       'Treatment'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      We suggest that oral candidiasis in immunocompetent infants be treated with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/23/34160?source=see_link\">",
"       nystatin",
"      </a>",
"      suspension (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Infants younger than 30 days are treated with 50,000 units to each cheek (100,000 units per dose) four times daily for 7 to 14 days; infants &ge;30 days are treated with 100,000 units to each cheek (200,000 units per dose) four times daily for 7 to 14 days.",
"      <br/>",
"      <br/>",
"      We suggest treatment with oral",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/43/26297?source=see_link\">",
"       fluconazole",
"      </a>",
"      (6",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      on day 1 of therapy followed by 3",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      once daily for 14 days), for oropharyngeal candidiasis that is refractory to nystatin and appropriate decolonization measures (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      We suggest that older children with mild oral candidiasis (absence of deep, erosive lesions and involvement of &lt;50 percent of the oral mucosa) be treated with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/23/34160?source=see_link\">",
"       nystatin",
"      </a>",
"      (suspension or lozenge) or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/58/34720?source=see_link\">",
"       clotrimazole",
"      </a>",
"      lozenges (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). The dosing regimens are as follows: nystatin suspension 400,000 to 600,000 units &ldquo;swish and swallow&rdquo; four times per day for 7 to 14 days; nystatin lozenges 200,000 to 400,000 units four times per day for 7 to 14 days; clotrimazole lozenge (10 mg) five or six times per day for 7 to 14 days.",
"     </li>",
"     <li>",
"      We suggest that older children with moderate to severe oropharyngeal candidiasis (deep, erosive lesions",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      involvement of &ge;50 percent of the oral mucosa) be treated with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/43/26297?source=see_link\">",
"       fluconazole",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_4?title=Grade 2A\">",
"       Grade 2A",
"      </a>",
"      ). The regimen is as follows: 6",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      orally once on the first day, followed by 3",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      orally once per day for at least 14 days. An alternative antifungal agent and evaluation for fluconazole-resistant",
"      <em>",
"       Candida",
"      </em>",
"      or immune deficiency may be warranted if the child does not respond to empiric fluconazole.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <em>",
"       Candida",
"      </em>",
"      diaper dermatitis is common in young infants. Clinical features include involvement of the inguinal folds, confluent erythema with discrete papules, plaques, satellite lesions, and superficial scale (",
"      <a class=\"graphic graphic_picture graphicRef59361 graphicRef72165 \" href=\"UTD.htm?35/41/36501\">",
"       picture 4A-B",
"      </a>",
"      ). Persistent",
"      <em>",
"       Candida",
"      </em>",
"      diaper rash may be a sign of type 1 diabetes mellitus, chronic mucocutaneous candidiasis, or an underlying immunodeficiency. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/33/37401?source=see_link&amp;anchor=H6#H6\">",
"       \"Overview of diaper dermatitis in infants and children\", section on 'Candidal dermatitis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Clinical features of",
"      <em>",
"       Candida",
"      </em>",
"      intertrigo include erythematous, macerated plaques and erosions with peripheral scale and satellite papulopustules (",
"      <a class=\"graphic graphic_picture graphicRef62523 \" href=\"UTD.htm?27/43/28338\">",
"       picture 5",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/59/30648?source=see_link\">",
"       \"Candidal intertrigo\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Predisposing factors for vulvovaginal candidiasis in infants include diaper use, broad-spectrum antibiotics, and immunosuppression (including glucocorticoids and HIV infection). Additional risk factors in adolescents include certain contraceptive devices (vaginal sponges, diaphragms, intrauterine devices), estrogen therapy (including oral contraceptives), and pregnancy. Clinical features include itching, dysuria, vaginal irritation, vulvar erythema and swelling, vaginal erythema, and vaginal discharge. The diagnosis is typically made clinically but can be confirmed with a wet mount or KOH preparation of vaginal secretions demonstrating budding yeast, with or without pseudohyphae (",
"      <a class=\"graphic graphic_picture graphicRef59030 \" href=\"UTD.htm?9/37/9809\">",
"       picture 6",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H364112958\">",
"       'Vulvovaginitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Esophageal candidiasis occurs predominantly in individuals with hematologic malignancies and human immunodeficiency virus (HIV) infection. Retrosternal pain with swallowing is the hallmark clinical feature. The diagnosis is usually made endoscopically. However, in patients with HIV infection, a trial of systemic antifungal therapy may obviate the need for endoscopy. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Esophagitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinical manifestations of chronic mucocutaneous candidiasis include severe, recurrent thrush (",
"      <a class=\"graphic graphic_picture graphicRef59947 \" href=\"UTD.htm?2/53/2911\">",
"       picture 7",
"      </a>",
"      ), vaginitis, onychomycosis (",
"      <a class=\"graphic graphic_picture graphicRef71698 \" href=\"UTD.htm?28/24/29070\">",
"       picture 8",
"      </a>",
"      ), and chronic skin lesions (",
"      <a class=\"graphic graphic_picture graphicRef64895 \" href=\"UTD.htm?10/1/10258\">",
"       picture 9",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/1/22553?source=see_link\">",
"       \"Chronic mucocutaneous candidiasis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Candidemia refers to the presence of",
"      <em>",
"       Candida",
"      </em>",
"      species in the blood. Neonates, immunocompromised hosts, and children in intensive care units are at greatest risk. The clinical manifestations vary from minimal fever to a fulminant sepsis syndrome indistinguishable from severe bacterial infection. Clinical clues to candidemia include characteristic eye lesions (",
"      <a class=\"graphic graphic_picture graphicRef58685 graphicRef73318 \" href=\"UTD.htm?20/15/20720\">",
"       picture 10A-B",
"      </a>",
"      ), skin lesions (",
"      <a class=\"graphic graphic_picture graphicRef55977 graphicRef75717 \" href=\"UTD.htm?32/12/32964\">",
"       picture 11A-B",
"      </a>",
"      ), and, less commonly, muscle abscesses. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/6/25703?source=see_link\">",
"       \"Clinical features and diagnosis of candidemia in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/16/3336?source=see_link\">",
"       \"Treatment of candidemia in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Invasive focal infections may occur after trauma, surgical procedures, or hematogenous spread in patients with anatomic abnormalities or prosthetic devices. (See",
"      <a class=\"local\" href=\"#H1201712\">",
"       'Invasive focal infections'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Knapp KM, Flynn PM. Candidiasis. In: Textbook of Pediatric Infectious Diseases, 6th ed, Feigin RD, Cherry JD, Demmler-Harrison GJ, Kaplan SL.  (Eds), Saunders Elsevier, Philadelphia 2009. p.2741.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/47/31481/abstract/2\">",
"      Pienaar ED, Young T, Holmes H. Interventions for the prevention and management of oropharyngeal candidiasis associated with HIV infection in adults and children. Cochrane Database Syst Rev 2010; :CD003940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/47/31481/abstract/3\">",
"      Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/47/31481/abstract/4\">",
"      Su CW, Gaskie S, Jamieson B, Triezenberg D. Clinical inquiries. What is the best treatment for oral thrush in healthy infants? J Fam Pract 2008; 57:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/47/31481/abstract/5\">",
"      Hoppe JE. Treatment of oropharyngeal candidiasis in immunocompetent infants: a randomized multicenter study of miconazole gel vs. nystatin suspension. The Antifungals Study Group. Pediatr Infect Dis J 1997; 16:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/47/31481/abstract/6\">",
"      Goins RA, Ascher D, Waecker N, et al. Comparison of fluconazole and nystatin oral suspensions for treatment of oral candidiasis in infants. Pediatr Infect Dis J 2002; 21:1165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/47/31481/abstract/7\">",
"      Boon JM, Lafeber HN, Mannetje AH, et al. Comparison of ketoconazole suspension and nystatin in the treatment of newborns and infants with oral candidosis. Mycoses 1989; 32:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/47/31481/abstract/8\">",
"      Horsfield P, Logan FA, Newey JA. Letter: Oral irritation with gentian violet. Br Med J 1976; 2:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/47/31481/abstract/9\">",
"      Leung AK. Gentian violet in the treatment of oral candidiasis. Pediatr Infect Dis J 1988; 7:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/47/31481/abstract/10\">",
"      John RW. Necrosis of oral mucosa after local application of crystal violet. Br Med J 1968; 1:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/47/31481/abstract/11\">",
"      Flynn PM, Cunningham CK, Kerkering T, et al. Oropharyngeal candidiasis in immunocompromised children: a randomized, multicenter study of orally administered fluconazole suspension versus nystatin. The Multicenter Fluconazole Study Group. J Pediatr 1995; 127:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/47/31481/abstract/12\">",
"      Sobel JD, Chaim W. Treatment of Torulopsis glabrata vaginitis: retrospective review of boric acid therapy. Clin Infect Dis 1997; 24:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/47/31481/abstract/13\">",
"      Darouiche RO. Oropharyngeal and esophageal candidiasis in immunocompromised patients: treatment issues. Clin Infect Dis 1998; 26:259.",
"     </a>",
"    </li>",
"    <li>",
"     Kirkpatrick CH. Chronic mucocutaneous candidiasis. In: Candidiasis pathogenesis, diagnosis, and treatment, Bodey, GP (Eds), Raven Press, New York 1993. p.167.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/47/31481/abstract/15\">",
"      Fisher JF, Sobel JD, Kauffman CA, Newman CA. Candida urinary tract infections--treatment. Clin Infect Dis 2011; 52 Suppl 6:S457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/47/31481/abstract/16\">",
"      Kauffman CA, Vazquez JA, Sobel JD, et al. Prospective multicenter surveillance study of funguria in hospitalized patients. The National Institute for Allergy and Infectious Diseases (NIAID) Mycoses Study Group. Clin Infect Dis 2000; 30:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/47/31481/abstract/17\">",
"      Calandra T, Bille J, Schneider R, et al. Clinical significance of Candida isolated from peritoneum in surgical patients. Lancet 1989; 2:1437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/47/31481/abstract/18\">",
"      Cheng IK, Fang GX, Chan TM, et al. Fungal peritonitis complicating peritoneal dialysis: report of 27 cases and review of treatment. Q J Med 1989; 71:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/47/31481/abstract/19\">",
"      Ward RM, Sattler FR, Dalton AS Jr. Assessment of antifungal therapy in an 800-gram infant with candidal arthritis and osteomyelitis. Pediatrics 1983; 72:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/47/31481/abstract/20\">",
"      Swanson H, Hughes PA, Messer SA, et al. Candida albicans arthritis one year after successful treatment of fungemia in a healthy infant. J Pediatr 1996; 129:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/47/31481/abstract/21\">",
"      Harris MC, Pereira GR, Myers MD, et al. Candidal arthritis in infants previously treated for systemic candidiasis during the newborn period: report of three cases. Pediatr Emerg Care 2000; 16:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/47/31481/abstract/22\">",
"      Butler KM, Baker CJ. Candida: an increasingly important pathogen in the nursery. Pediatr Clin North Am 1988; 35:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/47/31481/abstract/23\">",
"      Murphy K, Bradley J, James HE. The treatment of Candida albicans shunt infections. Childs Nerv Syst 2000; 16:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/47/31481/abstract/24\">",
"      Ellis ME, Al-Abdely H, Sandridge A, et al. Fungal endocarditis: evidence in the world literature, 1965-1995. Clin Infect Dis 2001; 32:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/47/31481/abstract/25\">",
"      Mayayo E, Moralejo J, Camps J, Guarro J. Fungal endocarditis in premature infants: case report and review. Clin Infect Dis 1996; 22:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/47/31481/abstract/26\">",
"      Aspesberro F, Beghetti M, Oberh&auml;nsli I, Friedli B. Fungal endocarditis in critically ill children. Eur J Pediatr 1999; 158:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/47/31481/abstract/27\">",
"      Thaler M, Pastakia B, Shawker TH, et al. Hepatic candidiasis in cancer patients: the evolving picture of the syndrome. Ann Intern Med 1988; 108:88.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5972 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-629A639819-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_47_31481=[""].join("\n");
var outline_f30_47_31481=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H552172751\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1198561\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H364113269\">",
"      MUCOCUTANEOUS CANDIDIASIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Oropharyngeal candidiasis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H364112468\">",
"      - Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32199424\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H364112951\">",
"      Diaper dermatitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H522962008\">",
"      Intertrigo",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H364112958\">",
"      Vulvovaginitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H364112986\">",
"      Balanitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Esophagitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Chronic mucocutaneous candidiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1200993\">",
"      INVASIVE CANDIDIASIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1198823\">",
"      Candidemia and acute disseminated candidiasis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1201712\">",
"      Invasive focal infections",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Urinary tract infections",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Peritonitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Endophthalmitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Osteoarticular infections",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Meningitis/CNS infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1198646\">",
"      - Endocarditis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H522957355\">",
"      Hepatosplenic or chronic disseminated candidiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H552172751\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5972\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5972|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?26/63/27632\" title=\"diagnostic image 1\">",
"      Hepatosplenic candidiasis CT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5972|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/63/10228\" title=\"picture 1\">",
"      Thrush infant",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?32/40/33410\" title=\"picture 2\">",
"      Perleche",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/37/28242\" title=\"picture 3\">",
"      Hyphae candida albicans",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?12/53/13136\" title=\"picture 4A\">",
"      Candidal diaper dermatitis A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?4/53/4945\" title=\"picture 4B\">",
"      Candidal diaper dermatitis B",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/43/28338\" title=\"picture 5\">",
"      Candidal intertrigo neck folds",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/37/9809\" title=\"picture 6\">",
"      Candida albicans vaginitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?2/53/2911\" title=\"picture 7\">",
"      Oral candidiasis in a patient with CMCC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?28/24/29070\" title=\"picture 8\">",
"      Candidal onychomycosis in a patient with CMCC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/1/10258\" title=\"picture 9\">",
"      Chronic mucocutaneous candidiasis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/1/25630\" title=\"picture 10A\">",
"      Candida endophthalmitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/39/25214\" title=\"picture 10B\">",
"      Vitritis in endophthalmitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/63/34815\" title=\"picture 11A\">",
"      Disseminated candidiasis skin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/42/25248\" title=\"picture 11B\">",
"      Disseminated candidiasis nodule",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/46/40674\" title=\"picture 12\">",
"      Hepatic candidiasis histology",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/30/14826?source=related_link\">",
"      Bacterial arthritis: Clinical features and diagnosis in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/23/24953?source=related_link\">",
"      Balanoposthitis in children: Clinical manifestations, diagnosis, and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/55/33654?source=related_link\">",
"      Balanoposthitis in children: Epidemiology and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/19/37176?source=related_link\">",
"      Biology of Candida infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/49/15128?source=related_link\">",
"      Candida infections of the bladder and kidneys",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/1/15386?source=related_link\">",
"      Candida vulvovaginitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/59/30648?source=related_link\">",
"      Candidal intertrigo",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/0/40969?source=related_link\">",
"      Causes of primary adrenal insufficiency (Addison's disease)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/1/22553?source=related_link\">",
"      Chronic mucocutaneous candidiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/6/25703?source=related_link\">",
"      Clinical features and diagnosis of candidemia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/40/21129?source=related_link\">",
"      Clinical features and diagnosis of urinary tract infections in infants and children older than one month",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/39/20087?source=related_link\">",
"      Clinical features of hematogenous osteomyelitis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/62/31720?source=related_link\">",
"      Clinical manifestations and diagnosis of Candida infection in neonates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/15/17658?source=related_link\">",
"      Common problems of breastfeeding and weaning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/51/31543?source=related_link\">",
"      Dermatologic procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/30/24039?source=related_link\">",
"      Epidemiology and risk factors for Candida infection in neonates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/33/13849?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of fungal endophthalmitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/59/40889?source=related_link\">",
"      Epidemiology, presentation, and diagnosis of type 1 diabetes mellitus in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/32/33289?source=related_link\">",
"      Evaluation and diagnosis of hematogenous osteomyelitis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/38/4707?source=related_link\">",
"      Evaluation of the HIV-infected patient with odynophagia and dysphagia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/27/8631?source=related_link\">",
"      Fungal peritonitis in continuous peritoneal dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/53/10071?source=related_link\">",
"      Hepatosplenic candidiasis (chronic disseminated candidiasis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/15/27896?source=related_link\">",
"      Infective endocarditis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/58/43945?source=related_link\">",
"      Laboratory evaluation of the immune system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/60/7114?source=related_link\">",
"      Major side effects of inhaled glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/11/17594?source=related_link\">",
"      Microbiology and therapy of peritonitis in continuous peritoneal dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/3/3130?source=related_link\">",
"      Natural history and classification of pediatric HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/33/37401?source=related_link\">",
"      Overview of diaper dermatitis in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?42/49/43793?source=related_link\">",
"      Patient information: Diaper rash (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?43/41/44690?source=related_link\">",
"      Patient information: Diaper rash in infants and children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?26/54/27489?source=related_link\">",
"      Patient information: Thrush (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/51/40760?source=related_link\">",
"      Treatment of Candida infection in neonates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/16/3336?source=related_link\">",
"      Treatment of candidemia in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_47_31482="Autologous hematopoietic cell transplantation in multiple myeloma";
var content_f30_47_31482=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Autologous hematopoietic cell transplantation in multiple myeloma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?30/47/31482/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/47/31482/contributors\">",
"     S Vincent Rajkumar, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?30/47/31482/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/47/31482/contributors\">",
"     Robert S Negrin, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/47/31482/contributors\">",
"     Robert A Kyle, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?30/47/31482/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/47/31482/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?30/47/31482/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 15, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autologous hematopoietic cell transplantation (HCT), performed either at the time of initial diagnosis or at relapse, is considered the standard of care for younger patients (less than 70 years of age) with newly diagnosed multiple myeloma (",
"    <a class=\"graphic graphic_algorithm graphicRef73792 \" href=\"UTD.htm?11/52/12111\">",
"     algorithm 1",
"    </a>",
"    ). While neither chemotherapy nor autologous HCT produces a cure, event-free survival and overall survival are prolonged following autologous HCT when compared with treatment with conventional chemotherapy alone.",
"   </p>",
"   <p>",
"    As new chemotherapeutic agents (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    ) are incorporated into the initial treatment of multiple myeloma, survival with chemotherapy alone is improving. Whether the use of these newer agents, alone or in combination, will delay or eliminate the need for HCT in patients with multiple myeloma is not known at this time. In addition, survival with HCT is improving for certain populations with the incorporation of double (tandem) autologous HCT.",
"   </p>",
"   <p>",
"    In contrast, allogeneic HCT has the potential for cure, although at a cost of increased treatment-related mortality. The use of allogeneic HCT for multiple myeloma is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/28/36296?source=see_link\">",
"     \"Allogeneic hematopoietic cell transplantation in multiple myeloma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Practical issues regarding the use of autologous HCT in myeloma are presented here. Eligibility criteria for HCT, a comparison of HCT with other treatment strategies, and the initial chemotherapy choices for patients with myeloma are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/29/8666?source=see_link\">",
"     \"Determination of initial therapy in patients with multiple myeloma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/54/18282?source=see_link\">",
"     \"Initial chemotherapy for symptomatic multiple myeloma in patients who are candidates for transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The term \"hematopoietic cell transplantation\" (HCT) will be used throughout this review as a general term to cover transplantation of progenitor (stem) cells from any source (eg, bone marrow, peripheral blood, cord blood). Otherwise, the source of such cells will be specified (eg, autologous peripheral blood progenitor cell transplantation). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/49/38682?source=see_link\">",
"     \"Sources of hematopoietic stem cells\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INITIAL CHEMOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients who are candidates for HCT, induction chemotherapy is administered for approximately four months prior to stem cell collection in order to reduce the number of tumor cells in the bone marrow and peripheral blood, lessen symptoms, and mitigate end-organ damage. Specifically,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"     melphalan",
"    </a>",
"    -containing regimens should be avoided prior to the collection of stem cells, since their use has been associated with damage to the hematopoietic stem cell compartment as well as an increased risk of myelodysplasia following transplantation.",
"   </p>",
"   <p>",
"    Drugs that are not known to damage the hematopoietic stem cells (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    ) are preferred for initial therapy. Initial data suggest that these agents do not have an impact on the quality of stem cells collected, but may have variable impact on the ability to collect adequate hematopoietic stem cells. Specifically, prolonged initial therapy with a lenalidomide-based regimen may impair hematopoietic stem cell collection [",
"    <a class=\"abstract\" href=\"UTD.htm?30/47/31482/abstract/1\">",
"     1",
"    </a>",
"    ]. This effect appears to be minimized if hematopoietic stem cells are collected within the first four cycles of initial therapy and by using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/12/27844?source=see_link\">",
"     plerixafor",
"    </a>",
"    in patients who have problems mobilizing adequate stem cells [",
"    <a class=\"abstract\" href=\"UTD.htm?30/47/31482/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Retrospective studies and post-hoc analyses of prospective studies have evaluated the effect of response to induction therapy as a predictor of outcome following HCT with mixed results.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A post-hoc analysis of the IFM 2005-001 trial of induction chemotherapy followed by HCT evaluated the effect of response to induction therapy on the outcomes of 482 patients with previously untreated symptomatic multiple myeloma [",
"      <a class=\"abstract\" href=\"UTD.htm?30/47/31482/abstract/3\">",
"       3",
"      </a>",
"      ]. Patients who achieved less than a very good partial response (VGPR) after the first HCT could receive a second HCT. Patients who achieved a VGPR after induction chemotherapy had a significantly longer median progression-free survival when compared with patients who achieved a VGPR only after high dose therapy and HCT (41 versus 31 months, respectively). However, in this trial, the arm with the higher VGPR rate (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"       bortezomib",
"      </a>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      ) with induction did not have better overall survival.",
"     </li>",
"     <li>",
"      A single institution retrospective analysis included 472 patients with newly diagnosed multiple myeloma who underwent HCT within 12 months of their initial diagnosis [",
"      <a class=\"abstract\" href=\"UTD.htm?30/47/31482/abstract/4\">",
"       4",
"      </a>",
"      ]. Among patients who received initial chemotherapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      , adriamycin, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      (VAD), dexamethasone alone,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"       thalidomide",
"      </a>",
"      plus dexamethasone, or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"       lenalidomide",
"      </a>",
"      plus dexamethasone, there was no significant difference in response rates after HCT, post-transplantation complications, or treatment-related mortality. Longer follow-up is needed to evaluate median time to progression and overall survival after HCT.",
"     </li>",
"     <li>",
"      A single institution retrospective analysis of 286 patients who underwent HCT after induction therapy containing",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"       thalidomide",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"       lenalidomide",
"      </a>",
"      reported that, when compared with patients who achieved a partial remission (PR) with induction therapy, patients who failed to achieve a PR had a significantly shorter median overall survival (30.4 versus 73.5 percent) and progression-free survival (13.1 versus 22.1 months) [",
"      <a class=\"abstract\" href=\"UTD.htm?30/47/31482/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The above studies should be interpreted cautiously. They do not demonstrate that the type of initial therapy does not matter in terms of overall benefit since they only included patients who made it to transplant, and excluded patients who, due to differences in morbidity and mortality with each regimen, died during induction or failed to qualify for transplant as a result of induction-related morbidity. For example, the induction-related early mortality prior to transplant is approximately 10 percent in many studies evaluating",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    alone or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    plus dexamethasone [",
"    <a class=\"abstract\" href=\"UTD.htm?30/47/31482/abstract/6-8\">",
"     6-8",
"    </a>",
"    ], but less than 1 percent with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    plus low-dose dexamethasone [",
"    <a class=\"abstract\" href=\"UTD.htm?30/47/31482/abstract/9\">",
"     9",
"    </a>",
"    ]. Thus the choice of initial therapy is important and does affect overall outcome.",
"   </p>",
"   <p>",
"    In addition, these studies do not provide guidance regarding the optimal management of a patient who fails to achieve a PR with induction therapy. Such patients do benefit from HCT, although potential options that require evaluation in prospective trials include: modification or intensification of induction therapy or preparative regimen for the transplant (see below), tandem transplantation, and maintenance therapy after HCT.",
"   </p>",
"   <p>",
"    The specific regimen used as initial therapy is determined based upon patient characteristics, induction-related early mortality and morbidity, ease of administration, and side effect profiles. The choice of initial chemotherapy is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/54/18282?source=see_link\">",
"     \"Initial chemotherapy for symptomatic multiple myeloma in patients who are candidates for transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     COLLECTION OF STEM CELLS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hematopoietic progenitor (stem) cells should be collected",
"    <strong>",
"     before",
"    </strong>",
"    the patient is exposed to alkylating agents [",
"    <a class=\"abstract\" href=\"UTD.htm?30/47/31482/abstract/10\">",
"     10",
"    </a>",
"    ]. Hematopoietic stem cells can be harvested directly from the bone marrow or collected by apheresis from the peripheral blood after stimulation with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/13/23767?source=see_link\">",
"     granulocyte colony-stimulating factor",
"    </a>",
"    (G-CSF). Peripheral blood progenitor cells (PBPCs) are preferable to bone marrow cells for transplantation due to quicker engraftment and a potential for less contamination of the infused cells with tumor cells. The various sources of hematopoietic stem cells are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/49/38682?source=see_link&amp;anchor=H9#H9\">",
"     \"Sources of hematopoietic stem cells\", section on 'Hematopoietic stem cell mobilization'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/54/34664?source=see_link&amp;anchor=H5#H5\">",
"     \"Hematopoietic support after hematopoietic cell transplantation\", section on 'Autologous PBPC transplantation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    G-CSF alone and G-CSF plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    are the most common regimens used for stem cell mobilization [",
"    <a class=\"abstract\" href=\"UTD.htm?30/47/31482/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. The usual dose of G-CSF is 10",
"    <span class=\"nowrap\">",
"     micrograms/kg",
"    </span>",
"    per day subcutaneous. Cyclophosphamide is usually administered at a dose of 1.5 to 6",
"    <span class=\"nowrap\">",
"     grams/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    intravenous for two days. The choice between the two methods is mainly dependent on institutional preference and experience. There are no randomized trials comparing the two approaches.",
"   </p>",
"   <p>",
"    At Mayo Clinic, we prefer G-CSF alone (10",
"    <span class=\"nowrap\">",
"     micrograms/kg",
"    </span>",
"    once daily), and reserve G-CSF plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    for patients who fail to collect adequate stem cells with G-CSF alone, and for patients who have had an inadequate response to induction therapy. This is supported by the observation that patients with a high tumor burden demonstrate delayed platelet recovery when transfused with PBPCs collected following growth factor treatment alone [",
"    <a class=\"abstract\" href=\"UTD.htm?30/47/31482/abstract/13\">",
"     13",
"    </a>",
"    ]. Some institutions use G-CSF plus cyclophosphamide as their standard. G-CSF plus cyclophosphamide has the advantage of providing much higher PBPCs than G-CSF alone, but also carries the risk of longer time to start collection and the risk of neutropenia.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/12/27844?source=see_link\">",
"     Plerixafor",
"    </a>",
"    , a chemokine receptor type 4 inhibitor that acts to impair the binding of hematopoietic stem cells within the bone marrow microenvironment, is also available for use in combination with G-CSF in patients with MM [",
"    <a class=\"abstract\" href=\"UTD.htm?30/47/31482/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. Initial reports suggest this agent may improve stem cell collection. We currently reserve plerixafor primarily for patients who fail stem cell collection with either G-CSF or G-CSF plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?30/47/31482/abstract/1,16-18\">",
"     1,16-18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/49/38682?source=see_link&amp;anchor=H13#H13\">",
"     \"Sources of hematopoietic stem cells\", section on 'Plerixafor (AMD3100, Mozobil)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Following initiation of one of the mobilization regimens discussed above, patients are monitored by peripheral blood CD34 counts. We begin apheresis when the peripheral CD34+ counts reach 10 CD34",
"    <span class=\"nowrap\">",
"     cells/microliter.",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/49/38682?source=see_link\">",
"     \"Sources of hematopoietic stem cells\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Apheresis is performed with a goal of collecting at least 3 x 10",
"    <sup>",
"     6",
"    </sup>",
"    CD34+",
"    <span class=\"nowrap\">",
"     cells/kg",
"    </span>",
"    if only one transplant is being considered, or at least 6 x 10",
"    <sup>",
"     6",
"    </sup>",
"    CD34+",
"    <span class=\"nowrap\">",
"     cells/kg",
"    </span>",
"    if two transplants are being considered. A minimum of 2 x 10",
"    <sup>",
"     6",
"    </sup>",
"    CD34+",
"    <span class=\"nowrap\">",
"     cells/kg",
"    </span>",
"    is considered essential for one transplant. In general, we harvest enough PBPCs for two transplantations; a single transplantation is done with one-half of the collected cells and the other half are cryopreserved. A second (tandem) transplant (using the cryopreserved stem cells) is considered for patients not achieving complete or near complete response with the first transplant. For patients achieving complete or near complete response with the first transplant, the cryopreserved stem cells may be reserved for transplantation at relapse [",
"    <a class=\"abstract\" href=\"UTD.htm?30/47/31482/abstract/19,20\">",
"     19,20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PROCESSING AND STORAGE OF STEM CELLS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peripheral blood progenitor cells (PBPCs) are cryopreserved in 5 percent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/22/33123?source=see_link\">",
"     dimethylsulfoxide",
"    </a>",
"    to be thawed at the bedside at the time of infusion [",
"    <a class=\"abstract\" href=\"UTD.htm?30/47/31482/abstract/21\">",
"     21",
"    </a>",
"    ]. Infused peripheral blood stem cells or bone marrow are inevitably contaminated by myeloma cells or their precursors, and may contribute to relapse [",
"    <a class=\"abstract\" href=\"UTD.htm?30/47/31482/abstract/22\">",
"     22",
"    </a>",
"    ]. In a xenotransplant mouse model, injection of G-CSF mobilized cells from patients with minimal myeloma resulted in the development of myeloma (including lytic bone lesions) in the recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?30/47/31482/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This observation suggested that purging these cells prior to transplantation might be beneficial, although attempts at purging are technically difficult and clinically disappointing even after removal of 2 to 3 logs of tumor cells [",
"    <a class=\"abstract\" href=\"UTD.htm?30/47/31482/abstract/10,24,25\">",
"     10,24,25",
"    </a>",
"    ]. In addition, delayed engraftment may [",
"    <a class=\"abstract\" href=\"UTD.htm?30/47/31482/abstract/26\">",
"     26",
"    </a>",
"    ] or may not [",
"    <a class=\"abstract\" href=\"UTD.htm?30/47/31482/abstract/27\">",
"     27",
"    </a>",
"    ] occur with stem cell selection.",
"   </p>",
"   <p>",
"    Two main strategies of purging myeloma cells have been tried:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Positive selection: the desired hematopoietic stem cells are identified and isolated either by CD34+ cell selection or by isolation of",
"      <span class=\"nowrap\">",
"       CD34+/Thy1+",
"      </span>",
"      stem cells by high speed cell sorting.",
"     </li>",
"     <li>",
"      Negative selection: neoplastic cells are removed using a combination of monoclonal antibodies.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The following is a survey of reports regarding these purging strategies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A prospective phase III study followed 111 patients with newly-diagnosed multiple myeloma undergoing transplantation who were randomly assigned to infusion of either CD34+ selected PBPCs, or unselected autologous PBPC [",
"      <a class=\"abstract\" href=\"UTD.htm?30/47/31482/abstract/28\">",
"       28",
"      </a>",
"      ]. CD34 selection resulted in a median reduction in tumor load of 2.2 logs. There was no significant difference in five-year overall survival, event-free survival, or relapse rate between the two arms.",
"     </li>",
"     <li>",
"      In a similar study involving 190 previously-treated patients with stable or responsive disease, CD34+ selection resulted in a median tumor load reduction of 3.1 log, with 54 percent of the products having no detectable tumor [",
"      <a class=\"abstract\" href=\"UTD.htm?30/47/31482/abstract/27\">",
"       27",
"      </a>",
"      ]. At a median follow-up period of 37 months, there were no differences in median survival or disease-free survival between those receiving CD34+ selected or unselected PBPCs.",
"     </li>",
"     <li>",
"      Sixty newly diagnosed patients undergoing tandem autologous transplantation were randomly assigned to receive either unmanipulated PBPCs or PBPCs purged of tumor cells using a two-step negative selection process [",
"      <a class=\"abstract\" href=\"UTD.htm?30/47/31482/abstract/29\">",
"       29",
"      </a>",
"      ]. Despite a three to four log reduction of tumor cells in vitro, recipients of the purged PBPCs remained polymerase chain reaction positive for minimal residual disease in vivo following transplantation; estimated overall survival at three years was 83 percent in both treatment groups.",
"     </li>",
"     <li>",
"      Thirty-nine patients with MM undergoing double (tandem) HCT underwent purging of the second stem cell collection using mouse monoclonal antibodies, including those directed against CD20 and CD19 [",
"      <a class=\"abstract\" href=\"UTD.htm?30/47/31482/abstract/30\">",
"       30",
"      </a>",
"      ]. Despite this, monoclonal peripheral blood B cells, clonally related to the malignant plasma cells, were present in 48 percent of the apheresis products. For the six patients with a predominance of monoclonal myeloma or myeloma precursor B cells in the apheresis product, the rates of complete remission and early relapse were zero and 50 percent, respectively. For the 13 patients with an oligo-",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      polyclonal pattern, these rates were 38 and zero percent, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Given the lack of evidence of a clinical benefit we do not attempt to purge myeloma cells from PBPC collections outside of a clinical trial. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/49/38682?source=see_link&amp;anchor=H24#H24\">",
"     \"Sources of hematopoietic stem cells\", section on 'Tumor cell purging'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     TIMING OF HCT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Timing of first HCT",
"    </span>",
"    &nbsp;&mdash;&nbsp;After adequate numbers of hematopoietic stem cells have been collected and stored, patients have two main options for further treatment:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Proceed with transplantation after recovery from stem cell collection (early transplant).",
"     </li>",
"     <li>",
"      Continue induction therapy or other form of standard dose chemotherapy until obtaining a plateau stage (defined as a stable M-protein in the serum and urine and no evidence of progression of myeloma) followed by close observation with plans to transplant at the time of early relapse (delayed transplant).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These two general approaches (early versus delayed transplantation) have been compared in randomized trials of patients receiving alkylator-based induction therapy. Only retrospective analyses have compared these approaches in patients receiving induction therapy with immunomodulatory (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    ) based or proteosome (ie,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    ) based regimens.",
"   </p>",
"   <p>",
"    In one trial, 185 patients under the age of 57 were treated with three to four courses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    ; they were then randomly assigned to receive either high dose chemotherapy and autologous PBPC transplantation or to receive conventional chemotherapy with high dose chemotherapy and autotransplantation performed as rescue treatment for primary resistance or relapse [",
"    <a class=\"abstract\" href=\"UTD.htm?30/47/31482/abstract/31\">",
"     31",
"    </a>",
"    ]. The estimated median survival was similar in the two groups (65 versus 64 months) (",
"    <a class=\"graphic graphic_figure graphicRef80540 \" href=\"UTD.htm?19/60/20429\">",
"     figure 1",
"    </a>",
"    ). The main advantages of early autotransplantation were better quality of life, a shorter period of chemotherapy and a longer median event-free survival (39 versus 13 months).",
"   </p>",
"   <p>",
"    A retrospective analysis of 290 patients initially treated with immunomodulatory drugs and who underwent stem cell collection compared the outcomes among patients who underwent early HCT (median time to HCT 5.3 months) with those who underwent delayed HCT (median time to HCT 44.5 months) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/47/31482/abstract/32\">",
"     32",
"    </a>",
"    ]. Estimated overall survival at four years (73 percent in both groups) and time to progression after HCT (20 months versus 16 months) were similar in both groups. Quality of life data were not available.",
"   </p>",
"   <p>",
"    In general, we prefer that patients proceed with their first HCT after recovery from stem cell collection (early HCT). This preference is principally based upon a desire to minimize exposure to chemotherapy and improve quality of life. However, with the incorporation of new chemotherapeutic agents (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    ) into the initial treatment of multiple myeloma, response and survival with chemotherapy alone is improving, and delayed HCT is increasingly a reasonable alternative for many patients. The factors that influence the decision between early versus delayed HCT include patient preference, patient age (as age approaches 70, early transplantation is preferred), response and tolerability to the initial chemotherapy regimen, insurance approval (some insurers do not cover stem cell harvest and cryopreservation), and whether centers have the facilities and resources for long-term storage of stem cells. Whether the use of these newer agents, alone or in combination, will delay or eliminate the need for HCT in patients with multiple myeloma is not known at this time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Timing of second HCT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who fail to achieve a complete response (CR) or very good partial response (VGPR) with their first autologous HCT may benefit from a second HCT. In such patients, if a second HCT is contemplated, it is preferable to perform the procedure within 6 to 12 months of the first transplant. On the other hand, patients who achieve CR or VGPR with the first HCT do not appear to benefit from a tandem HCT approach. In such patients, the second transplant can be delayed until relapse [",
"    <a class=\"abstract\" href=\"UTD.htm?30/47/31482/abstract/33\">",
"     33",
"    </a>",
"    ]. The efficacy of tandem (double) transplantation is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/29/8666?source=see_link&amp;anchor=H14#H14\">",
"     \"Determination of initial therapy in patients with multiple myeloma\", section on 'Double HCT'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     PREPARATIVE CHEMOTHERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     General",
"    </span>",
"    &nbsp;&mdash;&nbsp;A preparative (conditioning) regimen, consisting of chemotherapy with or without radiation therapy, is given to eradicate malignant cells prior to rescue of the hematopoietic system with a PBPC infusion [",
"    <a class=\"abstract\" href=\"UTD.htm?30/47/31482/abstract/34\">",
"     34",
"    </a>",
"    ]. The standard conditioning regimen used for HCT in myeloma is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"     melphalan",
"    </a>",
"    at a dose of 200",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ,",
"    </span>",
"    with dose reductions based on age and renal function. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Patients with renal insufficiency'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H11\">",
"     'Older adults'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The use of this dose is primarily based upon two randomized trials that have compared",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"     melphalan",
"    </a>",
"    200",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    with a lower dose of melphalan in preparation for HCT.",
"   </p>",
"   <p>",
"    The first was a French cooperative study that compared the two most common preparative regimens at that time in 282 newly diagnosed symptomatic patients &lt;65 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?30/47/31482/abstract/35\">",
"     35",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"       Melphalan",
"      </a>",
"      140",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      plus 8 Gy total body irradiation versus",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"       Melphalan",
"      </a>",
"      200",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients randomly assigned to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"     melphalan",
"    </a>",
"    200",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    had significantly faster hematologic recovery, less transfusion requirements, shorter hospitalizations, and a lower incidence of severe mucositis (30 versus 50 percent). While the median duration of event-free survival was similar in both arms (21 months), survival at 45 months was significantly better in patients receiving melphalan 200",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    (66 versus 46 percent).",
"   </p>",
"   <p>",
"    The second was an Italian study comparing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"     melphalan",
"    </a>",
"    200",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    with melphalan 100",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    as preparative regimens for HCT in 298 newly diagnosed symptomatic patients &lt;65 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?30/47/31482/abstract/36\">",
"     36",
"    </a>",
"    ]. After a median follow-up of 44.6 months, patients randomly assigned to melphalan 200",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    demonstrated the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A significantly longer median progression-free survival (31.4 versus 26.2 months) and a trend towards improved projected overall survival at five years (62 versus 48 percent).",
"     </li>",
"     <li>",
"      A significantly higher percent of patients with at least one severe (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      nonhematologic event (45 versus 30 percent). Greater gastrointestinal toxicity (11 versus 1 percent), mucositis (17 versus 3 percent), need for intravenous broad-spectrum antibiotics (41 versus 29 percent), and need for platelet transfusions (56 versus 38 percent).",
"     </li>",
"     <li>",
"      Treatment-related mortality was 3 percent in both groups.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In two other randomized studies, the use of more intensive preparative regimens, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/37/35414?source=see_link\">",
"     thiotepa",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/10/10408?source=see_link\">",
"     busulfan",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?30/47/31482/abstract/37\">",
"     37",
"    </a>",
"    ] or high-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/43/40630?source=see_link\">",
"     idarubicin",
"    </a>",
"    , cyclophosphamide, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"     melphalan",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?30/47/31482/abstract/38\">",
"     38",
"    </a>",
"    ] did not result in better outcomes than melphalan at a dose of 200",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     .",
"    </span>",
"   </p>",
"   <p>",
"    Further studies are underway investigating the incorporation of newer agents. As an example, in a multicenter phase II study, adding",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"     melphalan",
"    </a>",
"    (200",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    did not increase toxicity and appeared to yield a higher rate of complete plus very good responses compared with melphalan alone [",
"    <a class=\"abstract\" href=\"UTD.htm?30/47/31482/abstract/39\">",
"     39",
"    </a>",
"    ]. These results require confirmation in a randomized trial.",
"   </p>",
"   <p>",
"    For most patients undergoing autologous HCT for multiple myeloma, we recommend a preparative regimen of high dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"     melphalan",
"    </a>",
"    rather than lower dose melphalan plus TBI or more intensive preparative regimens.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Patients with renal insufficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;The randomized trials that have shown benefit with HCT compared with chemotherapy have mainly studied patients with serum creatinine &lt;2.0",
"    <span class=\"nowrap\">",
"     mg/dL.",
"    </span>",
"    HCT in patients with renal failure must therefore be approached with caution. For patients with serum creatinine &gt;2.0",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    we suggest that the dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"     melphalan",
"    </a>",
"    used as the conditioning regimen be reduced to 140",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     .",
"    </span>",
"   </p>",
"   <p>",
"    Support",
"    for this dose adjustment comes from a retrospective review of 81 patients with multiple myeloma and renal failure (plasma creatinine &gt;2",
"    <span class=\"nowrap\">",
"     mg/dL)",
"    </span>",
"    who underwent autologous HCT [",
"    <a class=\"abstract\" href=\"UTD.htm?30/47/31482/abstract/40\">",
"     40",
"    </a>",
"    ]. Sixty patients received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"     melphalan",
"    </a>",
"    200",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     .",
"    </span>",
"    After excessive toxicity was noted in these patients, the subsequent 21 patients received melphalan 140",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     .",
"    </span>",
"    The patients who received melphalan 200",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    had significantly higher rates of severe pulmonary toxicity (57 versus 17 percent) and mucositis (93 versus 67 percent). Treatment-related mortality, event-free and overall survival were not significantly different between the two melphalan doses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Older adults",
"    </span>",
"    &nbsp;&mdash;&nbsp;In order to reduce toxicity in patients over 65 years of age, two sequential courses of an intermediate dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"     melphalan",
"    </a>",
"    (100",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    followed by hematopoietic stem cell rescue (MEL100) has been studied as an alternative to high dose melphalan 200",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     .",
"    </span>",
"    One prospective single arm study and two randomized trials have supported the tolerability of MEL 100 [",
"    <a class=\"abstract\" href=\"UTD.htm?30/47/31482/abstract/41-43\">",
"     41-43",
"    </a>",
"    ]. However, the results of the two randomized trials that used intermediate dose melphalan conditioning differed in efficacy when compared with standard dose melphalan based regimens.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A prospective, single arm study evaluated the use of up to three sequential courses of MEL100 followed by PBPC infusion in 71 patients, of whom 53 were &gt;60 years of age [",
"      <a class=\"abstract\" href=\"UTD.htm?30/47/31482/abstract/41\">",
"       41",
"      </a>",
"      ]. Rates of complete remission following the first, second, and third courses of MEL100 were 19, 34, and 47 percent, respectively. There were no treatment-related deaths.",
"     </li>",
"     <li>",
"      A multicenter trial of 194 previously untreated patients evaluated the use of two initial \"debulking\" courses of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      , adriamycin, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      (VAD) followed by randomly assigned treatment with either two consecutive (tandem) courses of autologous HCT employing MEL100 or conventional treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"       melphalan",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      (MP) [",
"      <a class=\"abstract\" href=\"UTD.htm?30/47/31482/abstract/42\">",
"       42",
"      </a>",
"      ]. At a median follow-up of 39 months, the administration of MEL100 produced the following significant results in the subgroup of 80 patients aged 65 to 70:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Higher rates of near complete plus partial remissions (47 versus 16 percent)",
"     </li>",
"     <li>",
"      Longer median event-free survival (28 versus 16 months) and overall survival (58 versus 37 months)",
"     </li>",
"     <li>",
"      Higher short-term toxicity (eg, mucositis, fever, need for red cell or platelet transfusions)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The French Intergroupe Francophone du Myelome (IFM) group reported on 447 previously untreated patients with myeloma age 65 to 75 years who were randomly assigned to treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"       melphalan",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"       thalidomide",
"      </a>",
"      (MPT) versus melphalan and prednisone alone (MP) versus tandem autologous HCT using MEL100 [",
"      <a class=\"abstract\" href=\"UTD.htm?30/47/31482/abstract/43\">",
"       43",
"      </a>",
"      ]. Treatment with MPT was associated with significantly longer median overall survival when compared with treatment with either MP or tandem autologous HCT. There was no difference in median overall survival between the MP and transplant arms. This study suggests that an intermediate dose of melphalan may not be the optimal conditioning regimen. Further details on the regimens and results of this trial are presented separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/1/28698?source=see_link&amp;anchor=H3#H3\">",
"       \"Initial chemotherapy for symptomatic multiple myeloma in patients who are NOT candidates for transplantation\", section on 'Melphalan, prednisone, and thalidomide'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    At present we recommend a single dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"     melphalan",
"    </a>",
"    (200",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    as the conditioning regimen rather than tandem melphalan 100",
"    <span class=\"nowrap\">",
"     mg/m2",
"    </span>",
"    in elderly patients (&gt;65 years of age) who are eligible for transplantation. However, for patients 70 years of age or older, we usually reduce the dose of melphalan to 140",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?30/47/31482/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     CARE DURING THE TRANSPLANTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autologous HCT has been performed in both the inpatient and outpatient settings. Approximately 24 hours after completion of the preparative chemotherapy, peripheral blood progenitor cells (PBPCs) are reinfused. A period of pancytopenia follows. Red blood cell and platelet transfusions are administered as necessary while hematopoietic colony-stimulating factors (ie, G-CSF) are used to speed neutrophil engraftment. Neutrophil engraftment usually occurs by day 12 and platelet counts are expected to recover to greater than 20,000 by day 16 [",
"    <a class=\"abstract\" href=\"UTD.htm?30/47/31482/abstract/45\">",
"     45",
"    </a>",
"    ]. Red blood cell transfusion requirements during autologous HCT are usually minimal. Approximately 30 to 40 percent of patients can undergo autologous transplantation entirely as an outpatient, with daily monitoring until engraftment [",
"    <a class=\"abstract\" href=\"UTD.htm?30/47/31482/abstract/46\">",
"     46",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/54/34664?source=see_link\">",
"     \"Hematopoietic support after hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients who undergo HCT are at risk for bacterial, viral, and fungal infections, the time course of which varies in the posttransplant period, according to the degree of immune deficiency and cytopenia induced by the transplantation procedure (",
"    <a class=\"graphic graphic_figure graphicRef64491 \" href=\"UTD.htm?4/7/4223\">",
"     figure 2",
"    </a>",
"    ). Approximately 40 percent of patients with multiple myeloma undergoing autologous HCT will experience febrile neutropenia [",
"    <a class=\"abstract\" href=\"UTD.htm?30/47/31482/abstract/47\">",
"     47",
"    </a>",
"    ]. As a result, prophylactic therapies to prevent infection including antiviral and antifungal drugs are recommended during the period of increased risk. In addition, all markers of potential infection must be investigated thoroughly. These issues are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/30/25066?source=see_link\">",
"     \"Overview of infections following hematopoietic cell transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/57/32666?source=see_link\">",
"     \"Prophylaxis of infections in hematopoietic cell transplant recipients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/59/3001?source=see_link\">",
"     \"Prophylaxis of infection during chemotherapy-induced neutropenia in high-risk adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/31/29178?source=see_link\">",
"     \"Prophylaxis of invasive fungal infections in adult hematopoietic cell transplant recipients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/52/40778?source=see_link\">",
"     \"Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     MAINTENANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since virtually all patients who received autologous HCT for multiple myeloma eventually develop relapsed disease, trials have investigated the use of chemotherapeutic and biologic agents in an attempt to eliminate residual malignant cells after HCT. The following sections review different maintenance options. Until further data in support of maintenance therapy are reported, we suggest observation after HCT with treatment at the time of progression rather than the use of maintenance therapy. Maintenance may be considered for patients with high risk disease or those who fail to obtain a very good partial response with HCT. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/29/8666?source=see_link&amp;anchor=H5#H5\">",
"     \"Determination of initial therapy in patients with multiple myeloma\", section on 'Risk stratification'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Lenalidomide",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two randomized trials have suggested that maintenance",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    prolongs progression-free survival (PFS) in patients who have undergone autologous HCT, but is also associated with substantial rates of severe neutropenia. Longer follow-up is needed to evaluate overall survival and long-term toxicities. Until further results are available, we reserve post-transplant lenalidomide maintenance primarily for patients on clinical trials or those who fail to obtain a very good partial response with HCT. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/29/8666?source=see_link&amp;anchor=H5#H5\">",
"     \"Determination of initial therapy in patients with multiple myeloma\", section on 'Risk stratification'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following are the two large randomized trials that have evaluated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    maintenance after HCT:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      IFM trial &mdash; A phase III trial in 614 younger patients with newly diagnosed MM who had stable disease after autologous HCT randomly assigned treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"       lenalidomide",
"      </a>",
"      consolidation followed by either lenalidomide 10 to 15",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      or placebo, each administered until relapse [",
"      <a class=\"abstract\" href=\"UTD.htm?30/47/31482/abstract/48\">",
"       48",
"      </a>",
"      ]. At a median follow-up of 45 months, patients assigned to lenalidomide had a longer median PFS (41 versus 23 months), but a similar rate of overall survival at four years (73 versus 75 percent). Lenalidomide treatment resulted in higher rates of severe neutropenia (51 versus 18 percent), febrile neutropenia (10 versus 2 cases), and thromboembolism (10 versus 3 percent). There was an increased incidence of second primary malignancies (3.1 versus 1.2 per 100 patient-years) among patients receiving lenalidomide.",
"     </li>",
"     <li>",
"      CALGB Trial &mdash; Another phase III trial in 460 patients with newly diagnosed MM who had stable disease after autologous HCT randomly assigned therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"       lenalidomide",
"      </a>",
"      10",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      or placebo administered until progression [",
"      <a class=\"abstract\" href=\"UTD.htm?30/47/31482/abstract/49\">",
"       49",
"      </a>",
"      ]. An interim analysis after a median follow-up of 18 months demonstrated an improvement in PFS and a trend towards improved overall survival. The study was unblinded and patients assigned to placebo were allowed to cross over to lenalidomide maintenance. At a median follow-up of 34 months, patients assigned to lenalidomide had a longer median time to progression (46 versus 27 months) and a suggestion of improved survival at three years (88 versus 80 percent; hazard ratio 0.62; 95% CI 0.40-0.95). In an exploratory subgroup analysis, there was no survival benefit seen in patients who were in complete response at randomization, those with elevated beta-2 microglobulin, or those who received",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"       thalidomide",
"      </a>",
"      during induction therapy. Lenalidomide treatment resulted in significantly higher rates of severe neutropenia (45 versus 15 percent) and second primary malignancies (18 versus 6 cases).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The benefits of improved PFS must be balanced against the increased rate of severe (grade",
"    <span class=\"nowrap\">",
"     3/4)",
"    </span>",
"    neutropenia, risk of second cancers and other toxicities [",
"    <a class=\"abstract\" href=\"UTD.htm?30/47/31482/abstract/50\">",
"     50",
"    </a>",
"    ], the cost, and the possibility that the PFS advantage may be neutralized by the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    at time of first relapse in the observation arm. Although data from one study (CALGB) suggest an overall survival benefit with lenalidomide maintenance, the confidence interval surrounding this benefit was wide, and such a benefit has not been seen in the IFM study, which has a longer follow-up. Further, neither trial had a planned crossover in which the placebo arm was treated with lenalidomide upon progression of disease. Since the overall survival benefit is seen in only one of the two trials and since there is a real concern about excess second cancers in all three phase III trials in which lenalidomide was given in the context of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"     melphalan",
"    </a>",
"    therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?30/47/31482/abstract/51\">",
"     51",
"    </a>",
"    ], the use of lenalidomide maintenance should be restricted primarily to clinical trials. If clinical circumstances dictate the need for post transplant lenalidomide to treat residual disease (such treatment is typically not considered maintenance) or high risk myeloma, then the risk of second cancers must be discussed with the patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Thalidomide",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several randomized trials have evaluated the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    maintenance after autologous HCT [",
"    <a class=\"abstract\" href=\"UTD.htm?30/47/31482/abstract/52-64\">",
"     52-64",
"    </a>",
"    ]. These have demonstrated that thalidomide maintenance prolongs progression-free survival and may improve overall survival, but is also associated with a significant increase in long-term toxicities, including peripheral neuropathy and thromboembolism. At this time it is not clear whether routine thalidomide maintenance offers adequate clinical benefit to overcome these toxicities.",
"   </p>",
"   <p>",
"    The use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    maintenance after HCT was analyzed in a 2012 meta-analysis of six randomized trials that included data from 2786 patients who had undergone HCT [",
"    <a class=\"abstract\" href=\"UTD.htm?30/47/31482/abstract/65\">",
"     65",
"    </a>",
"    ]. Thalidomide maintenance resulted in significantly longer progression-free survival (hazard ratio [HR] 0.65, 95% CI 0.59-0.72), which was seen in trials that used thalidomide during both induction and maintenance and in those that used thalidomide during maintenance alone. While there was a statistically significant increase in overall survival (HR 0.84; 95% CI 0.73-0.97) demonstrated, caution must be used in interpreting these results as there was significant heterogeneity among the results of individual trials. This heterogeneity may be due to differences in patient population and in therapies available at relapse.",
"   </p>",
"   <p>",
"    The following studies illustrate the heterogeneity of survival outcomes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Dutch HOVON-50 trial &mdash; In the HOVON-50 trial, 556 patients were randomly assigned to induction chemotherapy with either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      (VAD) or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"       thalidomide",
"      </a>",
"      , doxorubicin, and dexamethasone (TAD) [",
"      <a class=\"abstract\" href=\"UTD.htm?30/47/31482/abstract/54\">",
"       54",
"      </a>",
"      ]. Following autologous HCT, patients initially treated with VAD were placed on maintenance with interferon, while those treated with TAD were placed on thalidomide maintenance. Patients treated with the thalidomide regimen had a significantly longer progression-free survival (PFS, 34 versus 25 months). However, the difference in OS was not statistically significant (median 73 versus 60 months).",
"     </li>",
"     <li>",
"      Australian study &mdash; A prospective trial of 269 patients with newly diagnosed MM who had received up to 12 months of induction therapy followed by a single autologous HCT were randomly assigned maintenance therapy with either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"       prednisolone",
"      </a>",
"      alone or prednisolone plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"       thalidomide",
"      </a>",
"      for 12 months [",
"      <a class=\"abstract\" href=\"UTD.htm?30/47/31482/abstract/55\">",
"       55",
"      </a>",
"      ]. Patients assigned to maintenance with prednisolone plus thalidomide demonstrated significantly higher rates of PFS (42 versus 23 percent) and OS (86 versus 75 percent) at three years when compared with patients assigned to prednisolone therapy alone. The treatment in this trial is considered consolidation rather than maintenance, since the thalidomide was given for a fixed duration.",
"     </li>",
"     <li>",
"      The Blood and Marrow Transplant Clinical Trials Network (CTN) study &mdash; In the CTN trial, 436 patients with standard-risk MM who had undergone single or double autologous HCT were randomly assigned to one year of maintenance with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"       thalidomide",
"      </a>",
"      (200 mg daily) plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      (20 mg per day for four consecutive days, once a month) or to observation [",
"      <a class=\"abstract\" href=\"UTD.htm?30/47/31482/abstract/62\">",
"       62",
"      </a>",
"      ]. At a median follow-up of 40 months after first HCT, maintenance resulted in similar rates of PFS (49 versus 43 percent) and OS (80 versus 81 percent) at three years.",
"     </li>",
"     <li>",
"      The Medical Research Council (MRC) Myeloma IX trial &mdash; In the MRC Myeloma IX trial, 820 patients with newly diagnosed MM who had received induction therapy with or without subsequent autologous HCT were randomly assigned to receive maintenance",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"       thalidomide",
"      </a>",
"      or to be followed without maintenance, each until progression [",
"      <a class=\"abstract\" href=\"UTD.htm?30/47/31482/abstract/60\">",
"       60",
"      </a>",
"      ]. The maintenance thalidomide arm of this trial was stopped early after an analysis by an independent monitoring committee demonstrated a trend towards worse OS with thalidomide. Further analysis at a median follow-up from maintenance of 38 months demonstrated that thalidomide maintenance was associated with longer PFS (23 versus 15 months; HR 1.45, 95% CI 1.22-1.73), but no difference in median OS (HR 0.91, 95% CI 0.72-1.17). Thalidomide maintenance was associated with high rates of neurologic toxicity. &nbsp;",
"     </li>",
"     <li>",
"      Total Therapy II &mdash; A trial of tandem transplantation in 668 patients with newly-diagnosed myeloma randomly assigned patients to receive or not receive",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"       thalidomide",
"      </a>",
"      during the entire treatment period, although the drug was withheld during stem cell collection [",
"      <a class=\"abstract\" href=\"UTD.htm?30/47/31482/abstract/56,57\">",
"       56,57",
"      </a>",
"      ]. After a median follow-up of 72 months among survivors, patients who received thalidomide had higher rates of complete response (59 versus 42 percent, respectively) and estimated rates of five-year event-free survival (56 and 45 percent, respectively), but had a trend towards shorter median survival after relapse. Rates of five-year overall survival were similar (approximately 65 percent). After five years, the survival curves appear to separate, but this difference was not yet significant for the entire population studied [",
"      <a class=\"abstract\" href=\"UTD.htm?30/47/31482/abstract/58\">",
"       58",
"      </a>",
"      ]. This difference appeared to be significant when the analysis was restricted to patients with chromosomal abnormalities [",
"      <a class=\"abstract\" href=\"UTD.htm?30/47/31482/abstract/57\">",
"       57",
"      </a>",
"      ]. Thalidomide maintenance resulted in higher rates of severe peripheral neuropathy (27 versus 17 percent) and deep vein thrombosis (30 versus 17 percent). In addition, patients who received thalidomide maintenance demonstrated a trend towards an increased incidence of solid second primary malignancies (18 versus 11 cases) that did not reach statistical significance [",
"      <a class=\"abstract\" href=\"UTD.htm?30/47/31482/abstract/66\">",
"       66",
"      </a>",
"      ]. There was no increase in hematologic second primary malignancies.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Together, these trials suggest that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    maintenance prolongs the median progression-free survival by approximately 10 months, but is associated with significant toxicity. Drug-related adverse events, mainly peripheral neuropathy and thromboembolism, resulted in thalidomide discontinuation in a substantial number of patients (30 to 80 percent by two years).",
"   </p>",
"   <p>",
"    A significant proportion of patients now receive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    as initial therapy, and most studies of thalidomide maintenance did not use these drugs as initial therapy, making it harder to generalize their findings. Further, in most studies, a survival benefit is only seen in a subset of patients, such as those who fail to achieve a very good partial response with transplant or those with certain cytogenetic abnormalities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Combination chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maintenance combination chemotherapy has not been shown to improve event-free or overall survival after single or double HCT. As an example, one trial of 75 patients who had received a double (tandem) HCT for multiple myeloma with at least one poor prognostic feature (ie, cytogenetic abnormalities, extensive prior treatment, or elevated beta-2 microglobulin prior to HCT) administered four courses of CDEP chemotherapy (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    ) every three months, starting three to six months after the second transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?30/47/31482/abstract/67\">",
"     67",
"    </a>",
"    ]. There was no improvement in either event-free or overall survival when compared with 75 patients with similar adverse prognostic features who received tandem transplantation without subsequent chemotherapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Interferon",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two randomized trials have shown no survival benefit with interferon maintenance after autologous HCT [",
"    <a class=\"abstract\" href=\"UTD.htm?30/47/31482/abstract/68,69\">",
"     68,69",
"    </a>",
"    ]. As an example, a randomized study of 84 patients was conducted to evaluate the role of interferon maintenance following high dose chemotherapy and autologous marrow stem cell support [",
"    <a class=\"abstract\" href=\"UTD.htm?30/47/31482/abstract/68\">",
"     68",
"    </a>",
"    ]. Interferon delayed the onset of relapse so that the progression-free survival was prolonged (46 versus 27 months in controls). Overall survival was significantly improved in favor of interferon at a median follow-up of 52 months but ceased to be significant at a median follow-up of 77 months, as most patients ultimately succumbed to their disease. Results from a large Intergroup Trial confirmed no benefit with interferon as maintenance therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?30/47/31482/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Interferon alfa is not recommended as maintenance therapy due to inadequate proof of efficacy and the high frequency of undesirable side effects. This subject is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/1/28698?source=see_link&amp;anchor=H14#H14\">",
"     \"Initial chemotherapy for symptomatic multiple myeloma in patients who are NOT candidates for transplantation\", section on 'Maintenance therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Dendritic cell vaccination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical trials of dendritic cell-based idiotype vaccination as maintenance therapy after autologous peripheral blood stem cell transplantation (PBSCT) have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?30/47/31482/abstract/70,71\">",
"     70,71",
"    </a>",
"    ]. Although, the vaccination appears to be safe it has not shown any effect on survival. This approach and others using various immunotherapeutic modalities are experimental [",
"    <a class=\"abstract\" href=\"UTD.htm?30/47/31482/abstract/72-74\">",
"     72-74",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     MONITORING DISEASE AFTER THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients should be evaluated after transplantation to determine how their disease has responded to therapy. The preferred method is the measurement of monoclonal (M) protein in serum or urine. Free light chain (FLC) measurements are reserved for patients with unmeasurable levels of M protein in the serum and urine. Among patients without an M protein in serum or urine and normal FLC ratio, further evaluation includes bone marrow immunohistochemistry or immunofluorescence and plasma cell labeling index. We typically assess patients on day 100 following HCT and, if doing well, we reassess every three to four months thereafter.",
"   </p>",
"   <p>",
"    The International Myeloma Working Group has developed uniform response criteria, which are used to measure the effect of treatment for multiple myeloma. These criteria are described in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/50/31526?source=see_link\">",
"     \"Evaluating response to treatment of multiple myeloma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Investigators have also examined the use of multiparameter flow cytometry (MFC) as a measurement of minimal residual disease (MRD) and predictor of outcome in patients after autologous HCT. As an example, a prospective analysis of 295 patients with newly diagnosed MM evaluated the use of MFC of bone marrow samples obtained at day 100 following autologous HCT [",
"    <a class=\"abstract\" href=\"UTD.htm?30/47/31482/abstract/75\">",
"     75",
"    </a>",
"    ]. At a median follow-up of 57 months, patients who had no evidence of MRD had significantly longer median progression-free (71 versus 37 months, respectively) and overall survival (not reached versus 89 months, respectively) when compared with patients who had MRD. However, at this time, the importance of monitoring for MRD and the impact of MRD on the timing of further treatment is unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20487598\">",
"    <span class=\"h2\">",
"     Significance of response to chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The relationship between survival and the degree of response (complete versus partial) to initial therapy is controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?30/47/31482/abstract/76\">",
"     76",
"    </a>",
"    ]. While some studies have suggested a survival benefit from attaining a deeper response [",
"    <a class=\"abstract\" href=\"UTD.htm?30/47/31482/abstract/77,78\">",
"     77,78",
"    </a>",
"    ], it is unknown whether this just reflects underlying disease biology (ie, a prognostic marker) or specific treatment effect. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/1/28698?source=see_link&amp;anchor=H12#H12\">",
"     \"Initial chemotherapy for symptomatic multiple myeloma in patients who are NOT candidates for transplantation\", section on 'Significance of response to chemotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A survival benefit from attaining negative serum and urine immunofixation was demonstrated in a retrospective study of 344 patients with multiple myeloma who underwent autologous HCT between 1989 and 1998 with a median follow-up exceeding 10 years [",
"    <a class=\"abstract\" href=\"UTD.htm?30/47/31482/abstract/77\">",
"     77",
"    </a>",
"    ]. When compared with those who achieved a near complete response, very good partial response, or partial response, patients who achieved a CR had significantly higher rates of overall survival at 12 years (35 versus 22 percent).",
"   </p>",
"   <p>",
"    However, one must be careful when interpreting studies that show improved outcome in responders versus nonresponders (eg, CR versus no CR) since such comparisons have inherent methodologic flaws that cannot be overcome by increasing the sample size. In general, whether a treatment works or not, &ldquo;responders&rdquo; will typically appear to do better than &ldquo;nonresponders&rdquo; [",
"    <a class=\"abstract\" href=\"UTD.htm?30/47/31482/abstract/79,80\">",
"     79,80",
"    </a>",
"    ]. One way of overcoming the bias that exists when comparing responders with nonresponders is to perform landmark analysis at time points that ensure that almost all patients have had time to reach the response level being studied.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     TREATMENT OF RELAPSE AFTER HCT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognosis of patients who relapse after autologous HCT appears to differ depending upon the timing of the relapse [",
"    <a class=\"abstract\" href=\"UTD.htm?30/47/31482/abstract/81,82\">",
"     81,82",
"    </a>",
"    ]. As an example, a retrospective analysis of 494 patients who had relapsed after HCT found that those who relapse within the first 12 months have a shorter median overall survival (approximately 20 versus 83 months from HCT) when compared with those who relapse after 12 months [",
"    <a class=\"abstract\" href=\"UTD.htm?30/47/31482/abstract/81\">",
"     81",
"    </a>",
"    ]. Treatment options for relapsed multiple myeloma after an autologous HCT include a second autologous HCT, nonmyeloablative allogeneic HCT as part of a clinical trial, or treatment with salvage chemotherapy.",
"   </p>",
"   <p>",
"    In general, a second autologous HCT is not recommended for patients who relapse within 12 months of the first, since the progression free survival following the second HCT will most likely be even shorter than the benefit seen with the first transplant [",
"    <a class=\"abstract\" href=\"UTD.htm?30/47/31482/abstract/83\">",
"     83",
"    </a>",
"    ]. These patients are best treated with active agents that they have not received before or have had good responses to in the past as well as clinical trials investigating novel therapies.",
"   </p>",
"   <p>",
"    As mentioned above, we routinely harvest enough stem cells at initial chemotherapy for two transplantations; a single transplantation is done with one-half of the collected cells and the other half is cryopreserved. A second (tandem) transplant (using the cryopreserved stem cells) is considered for patients not achieving complete or near complete response with the first transplant. For patients achieving complete or near complete response with the first transplant, we suggest reserving the cryopreserved stem cells are for a second autologous HCT to be used at the time of relapse [",
"    <a class=\"abstract\" href=\"UTD.htm?30/47/31482/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Timing of second HCT'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    For patients who have already undergone a second HCT as part of a double (tandem) HCT or patients who were unable to collect enough progenitor (stem) cells for a second HCT, we discuss the possibility of allogeneic HCT or salvage chemotherapy. However, very few such patients are candidates for allogeneic HCT. These two options are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/15/37114?source=see_link\">",
"     \"Treatment of relapsed or refractory multiple myeloma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/28/36296?source=see_link&amp;anchor=H6#H6\">",
"     \"Allogeneic hematopoietic cell transplantation in multiple myeloma\", section on 'Autologous followed by nonmyeloablative allogeneic HCT in newly diagnosed myeloma'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?2/47/2802?source=see_link\">",
"       \"Patient information: Bone marrow transplant (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?12/16/12547?source=see_link\">",
"       \"Patient information: Multiple myeloma symptoms, diagnosis, and staging (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?30/40/31366?source=see_link\">",
"       \"Patient information: Multiple myeloma treatment (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?34/4/34886?source=see_link\">",
"       \"Patient information: Bone marrow transplantation (stem cell transplantation) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autologous hematopoietic cell transplantation (HCT) performed early in the disease course or at first relapse is considered the standard of care treatment for younger patients with newly diagnosed multiple myeloma due to improvements in event-free and overall survival when compared with conventional chemotherapy alone (",
"    <a class=\"graphic graphic_algorithm graphicRef73792 \" href=\"UTD.htm?11/52/12111\">",
"     algorithm 1",
"    </a>",
"    ). The principal characteristics that determine eligibility for HCT are age, performance status,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the presence and severity of certain comorbid conditions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/29/8666?source=see_link\">",
"     \"Determination of initial therapy in patients with multiple myeloma\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H1\">",
"     'Introduction'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In patients who are candidates for HCT, induction chemotherapy is administered for one to four months prior to stem cell collection in order to reduce the number of tumor cells in the bone marrow and peripheral blood, lessen symptoms, and mitigate end-organ damage.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among patients with standard risk multiple myeloma who are candidates for autologous HCT, we recommend the use of non-",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"       melphalan",
"      </a>",
"      containing regimens as induction chemotherapy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Recommendations for specific induction chemotherapy regimens are presented separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/54/18282?source=see_link\">",
"       \"Initial chemotherapy for symptomatic multiple myeloma in patients who are candidates for transplantation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Peripheral blood progenitor cells (PBPCs) are the preferred source of progenitor (stem) cells due to quicker engraftment and a potential for less contamination with tumor cells. We use apheresis to collect PBPCs with a goal of collecting 6 x 10",
"      <sup>",
"       6",
"      </sup>",
"      CD34+",
"      <span class=\"nowrap\">",
"       cells/kg,",
"      </span>",
"      which is considered sufficient for two transplants. We do not attempt to purge myeloma cells from PBPCs. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Collection of stem cells'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Processing and storage of stem cells'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that patients proceed with their first HCT after recovery from stem cell collection (early transplant) rather than the use of standard dose chemotherapy followed by close observation and HCT at the time of first relapse (delayed transplantation) (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). However, overall survival is similar between early versus delayed transplantation, and the decision between the two approaches is mainly guided by patient and physician preference. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Timing of HCT'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A second (tandem) autologous HCT outside of a clinical trial is recommended only for patients undergoing early transplantation who fail to achieve a complete or near complete response with their first transplant (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For most patients undergoing autologous HCT for multiple myeloma, we recommend a preparative regimen of high dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"       melphalan",
"      </a>",
"      (200",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       )",
"      </span>",
"      rather than lower dose melphalan plus total body irradiation or more intensive preparative regimens (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Preparative chemotherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with serum creatinine &gt;2.0",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      at the time of transplantation, we suggest that the dose of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"       melphalan",
"      </a>",
"      used as the conditioning regimen be reduced to 140",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Patients with renal insufficiency'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients over 65 years of age who are candidates for HCT, we suggest a single dose of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"       melphalan",
"      </a>",
"      (200",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       )",
"      </span>",
"      as the conditioning regimen rather than tandem intermediate dose melphalan 100",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). For patients 70 years of age or older, we usually reduce the dose of melphalan to 140",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       .",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Older adults'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients who undergo HCT are at risk for bacterial, viral, and fungal infections. A detailed discussion on the prophylaxis and treatment of infections in this patient population is presented separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/30/25066?source=see_link\">",
"       \"Overview of infections following hematopoietic cell transplantation\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/57/32666?source=see_link\">",
"       \"Prophylaxis of infections in hematopoietic cell transplant recipients\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/59/3001?source=see_link\">",
"       \"Prophylaxis of infection during chemotherapy-induced neutropenia in high-risk adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/31/29178?source=see_link\">",
"       \"Prophylaxis of invasive fungal infections in adult hematopoietic cell transplant recipients\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/52/40778?source=see_link\">",
"       \"Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The pros and cons of maintenance",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"       lenalidomide",
"      </a>",
"      should be discussed with patients. For patients who have achieved stable disease after autologous HCT, we suggest observation after HCT with treatment at the time of progression rather than the use of maintenance therapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Consolidation therapy with lenalidomide may be considered for patients who fail to obtain a very good partial response with HCT. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Maintenance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The International Myeloma Working Group has developed uniform response criteria, which are used to measure the effect of treatment for multiple myeloma. These criteria are described in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/50/31526?source=see_link\">",
"       \"Evaluating response to treatment of multiple myeloma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Treatment options for relapsed multiple myeloma after an autologous HCT include a second autologous HCT, allogeneic HCT as part of a clinical trial, or treatment with salvage chemotherapy regimens. For patients achieving complete or near complete response with the first transplant, we suggest reserving the cryopreserved stem cells for a second autologous HCT to be used at the time of relapse if &gt;12 months after the initial transplant (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). For eligible patients less than 65 with a suitable matched donor, we discuss the possibility of non-myeloablative allogeneic HCT or salvage chemotherapy. These two options are discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/15/37114?source=see_link\">",
"       \"Treatment of relapsed or refractory multiple myeloma\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/28/36296?source=see_link&amp;anchor=H6#H6\">",
"       \"Allogeneic hematopoietic cell transplantation in multiple myeloma\", section on 'Autologous followed by nonmyeloablative allogeneic HCT in newly diagnosed myeloma'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/47/31482/abstract/1\">",
"      Kumar S, Giralt S, Stadtmauer EA, et al. Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens. Blood 2009; 114:1729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/47/31482/abstract/2\">",
"      Cavallo F, Bringhen S, Milone G, et al. Stem cell mobilization in patients with newly diagnosed multiple myeloma after lenalidomide induction therapy. Leukemia 2011; 25:1627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/47/31482/abstract/3\">",
"      Moreau P, Attal M, P&eacute;gouri&eacute; B, et al. Achievement of VGPR to induction therapy is an important prognostic factor for longer PFS in the IFM 2005-01 trial. Blood 2011; 117:3041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/47/31482/abstract/4\">",
"      Kumar SK, Dingli D, Dispenzieri A, et al. Impact of pretransplant therapy in patients with newly diagnosed myeloma undergoing autologous SCT. Bone Marrow Transplant 2008; 41:1013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/47/31482/abstract/5\">",
"      Gertz MA, Kumar S, Lacy MQ, et al. Stem cell transplantation in multiple myeloma: impact of response failure with thalidomide or lenalidomide induction. Blood 2010; 115:2348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/47/31482/abstract/6\">",
"      Rajkumar SV, Rosi&ntilde;ol L, Hussein M, et al. Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma. J Clin Oncol 2008; 26:2171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/47/31482/abstract/7\">",
"      Facon T, Mary JY, P&eacute;gourie B, et al. Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy. Blood 2006; 107:1292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/47/31482/abstract/8\">",
"      Rajkumar SV, Blood E, Vesole D, et al. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2006; 24:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/47/31482/abstract/9\">",
"      Rajkumar SV, Jacobus S, Callander N, et al. Phase III trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the Eastern Cooperative Oncology Group (abstract). J Clin Oncol 2007; 25(18S):LBA8025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/47/31482/abstract/10\">",
"      Lemoli RM, Martinelli G, Zamagni E, et al. Engraftment, clinical, and molecular follow-up of patients with multiple myeloma who were reinfused with highly purified CD34+ cells to support single or tandem high-dose chemotherapy. Blood 2000; 95:2234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/47/31482/abstract/11\">",
"      Vesole DH, Tricot G, Jagannath S, et al. Autotransplants in multiple myeloma: what have we learned? Blood 1996; 88:838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/47/31482/abstract/12\">",
"      Hosing C, Qazilbash MH, Kebriaei P, et al. Fixed-dose single agent pegfilgrastim for peripheral blood progenitor cell mobilisation in patients with multiple myeloma. Br J Haematol 2006; 133:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/47/31482/abstract/13\">",
"      Desikan KR, Tricot G, Munshi NC, et al. Preceding chemotherapy, tumour load and age influence engraftment in multiple myeloma patients mobilized with granulocyte colony-stimulating factor alone. Br J Haematol 2001; 112:242.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.fda.gov/cder/foi/label/2008/022311lbl.pdf (Accessed on January 05, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/47/31482/abstract/15\">",
"      DiPersio JF, Stadtmauer EA, Nademanee A, et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood 2009; 113:5720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/47/31482/abstract/16\">",
"      Giralt S, Stadtmauer EA, Harousseau JL, et al. International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100). Leukemia 2009; 23:1904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/47/31482/abstract/17\">",
"      Tricot G, Cottler-Fox MH, Calandra G. Safety and efficacy assessment of plerixafor in patients with multiple myeloma proven or predicted to be poor mobilizers, including assessment of tumor cell mobilization. Bone Marrow Transplant 2010; 45:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/47/31482/abstract/18\">",
"      Worel N, Rosskopf K, Neumeister P, et al. Plerixafor and granulocyte-colony-stimulating factor (G-CSF) in patients with lymphoma and multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy for autologous hematopoietic stem cell mobilization: the Austrian experience on a named patient program. Transfusion 2011; 51:968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/47/31482/abstract/19\">",
"      Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med 2004; 351:1860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/47/31482/abstract/20\">",
"      Hari P, Pasquini MC, Vesole DH. New questions about transplantation in multiple myeloma. Oncology (Williston Park) 2006; 20:1230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/47/31482/abstract/21\">",
"      Berz D, McCormack EM, Winer ES, et al. Cryopreservation of hematopoietic stem cells. Am J Hematol 2007; 82:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/47/31482/abstract/22\">",
"      Zhou P, Zhang Y, Martinez C, et al. Melphalan-mobilized blood stem cell components contain minimal clonotypic myeloma cell contamination. Blood 2003; 102:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/47/31482/abstract/23\">",
"      Pilarski LM, Hipperson G, Seeberger K, et al. Myeloma progenitors in the blood of patients with aggressive or minimal disease: engraftment and self-renewal of primary human myeloma in the bone marrow of NOD SCID mice. Blood 2000; 95:1056.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/47/31482/abstract/24\">",
"      Galimberti S, Morabito F, Guerrini F, et al. Peripheral blood stem cell contamination evaluated by a highly sensitive molecular method fails to predict outcome of autotransplanted multiple myeloma patients. Br J Haematol 2003; 120:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/47/31482/abstract/25\">",
"      Gazitt Y, Reading CC, Hoffman R, et al. Purified CD34+ Lin- Thy+ stem cells do not contain clonal myeloma cells. Blood 1995; 86:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/47/31482/abstract/26\">",
"      Tricot G, Gazitt Y, Leemhuis T, et al. Collection, tumor contamination, and engraftment kinetics of highly purified hematopoietic progenitor cells to support high dose therapy in multiple myeloma. Blood 1998; 91:4489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/47/31482/abstract/27\">",
"      Stewart AK, Vescio R, Schiller G, et al. Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression-free survival after high-dose chemotherapy for multiple myeloma: results of a multicenter randomized controlled trial. J Clin Oncol 2001; 19:3771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/47/31482/abstract/28\">",
"      Bourhis JH, Bouko Y, Koscielny S, et al. Relapse risk after autologous transplantation in patients with newly diagnosed myeloma is not related with infused tumor cell load and the outcome is not improved by CD34+ cell selection: long term follow-up of an EBMT phase III randomized study. Haematologica 2007; 92:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/47/31482/abstract/29\">",
"      Barbui AM, Galli M, Dotti G, et al. Negative selection of peripheral blood stem cells to support a tandem autologous transplantation programme in multiple myeloma. Br J Haematol 2002; 116:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/47/31482/abstract/30\">",
"      Mitterer M, Oduncu F, Lanthaler AJ, et al. The relationship between monoclonal myeloma precursor B cells in the peripheral blood stem cell harvests and the clinical response of multiple myeloma patients. Br J Haematol 1999; 106:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/47/31482/abstract/31\">",
"      Fermand JP, Ravaud P, Chevret S, et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood 1998; 92:3131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/47/31482/abstract/32\">",
"      Kumar SK, Lacy MQ, Dispenzieri A, et al. Early versus delayed autologous transplantation after immunomodulatory agents-based induction therapy in patients with newly diagnosed multiple myeloma. Cancer 2012; 118:1585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/47/31482/abstract/33\">",
"      Elice F, Raimondi R, Tosetto A, et al. Prolonged overall survival with second on-demand autologous transplant in multiple myeloma. Am J Hematol 2006; 81:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/47/31482/abstract/34\">",
"      Kumar S, Dingli D, Dispenzieri A, et al. Impact of additional cytoreduction following autologous SCT in multiple myeloma. Bone Marrow Transplant 2008; 42:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/47/31482/abstract/35\">",
"      Moreau P, Facon T, Attal M, et al. Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du My&eacute;lome 9502 randomized trial. Blood 2002; 99:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/47/31482/abstract/36\">",
"      Palumbo A, Bringhen S, Bruno B, et al. Melphalan 200 mg/m(2) versus melphalan 100 mg/m(2) in newly diagnosed myeloma patients: a prospective, multicenter phase 3 study. Blood 2010; 115:1873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/47/31482/abstract/37\">",
"      Anagnostopoulos A, Aleman A, Ayers G, et al. Comparison of high-dose melphalan with a more intensive regimen of thiotepa, busulfan, and cyclophosphamide for patients with multiple myeloma. Cancer 2004; 100:2607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/47/31482/abstract/38\">",
"      Fenk R, Schneider P, Kropff M, et al. High-dose idarubicin, cyclophosphamide and melphalan as conditioning for autologous stem cell transplantation increases treatment-related mortality in patients with multiple myeloma: results of a randomised study. Br J Haematol 2005; 130:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/47/31482/abstract/39\">",
"      Roussel M, Moreau P, Huynh A, et al. Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM). Blood 2010; 115:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/47/31482/abstract/40\">",
"      Badros A, Barlogie B, Siegel E, et al. Results of autologous stem cell transplant in multiple myeloma patients with renal failure. Br J Haematol 2001; 114:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/47/31482/abstract/41\">",
"      Palumbo A, Triolo S, Argentino C, et al. Dose-intensive melphalan with stem cell support (MEL100) is superior to standard treatment in elderly myeloma patients. Blood 1999; 94:1248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/47/31482/abstract/42\">",
"      Palumbo A, Bringhen S, Petrucci MT, et al. Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial. Blood 2004; 104:3052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/47/31482/abstract/43\">",
"      Facon T, Mary JY, Hulin C, et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet 2007; 370:1209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/47/31482/abstract/44\">",
"      Kumar SK, Dingli D, Lacy MQ, et al. Autologous stem cell transplantation in patients of 70 years and older with multiple myeloma: Results from a matched pair analysis. Am J Hematol 2008; 83:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/47/31482/abstract/45\">",
"      Schmitz N, Linch DC, Dreger P, et al. Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet 1996; 347:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/47/31482/abstract/46\">",
"      Gertz MA, Ansell SM, Dingli D, et al. Autologous stem cell transplant in 716 patients with multiple myeloma: low treatment-related mortality, feasibility of outpatient transplant, and effect of a multidisciplinary quality initiative. Mayo Clin Proc 2008; 83:1131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/47/31482/abstract/47\">",
"      Jones JA, Qazilbash MH, Shih YC, et al. In-hospital complications of autologous hematopoietic stem cell transplantation for lymphoid malignancies: clinical and economic outcomes from the Nationwide Inpatient Sample. Cancer 2008; 112:1096.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/47/31482/abstract/48\">",
"      Attal M, Lauwers-Cances V, Marit G, et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med 2012; 366:1782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/47/31482/abstract/49\">",
"      McCarthy PL, Owzar K, Hofmeister CC, et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med 2012; 366:1770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/47/31482/abstract/50\">",
"      Kyle RA. Role of maintenance therapy after autologous stem cell transplant for multiple myeloma: lessons for cancer therapy. Mayo Clin Proc 2011; 86:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/47/31482/abstract/51\">",
"      Dimopoulos MA, Richardson PG, Brandenburg N, et al. A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide. Blood 2012; 119:2764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/47/31482/abstract/52\">",
"      Feyler S, Rawstron A, Jackson G, et al. Thalidomide maintenance following high-dose therapy in multiple myeloma: a UK myeloma forum phase 2 study. Br J Haematol 2007; 139:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/47/31482/abstract/53\">",
"      Attal M, Harousseau JL, Leyvraz S, et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 2006; 108:3289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/47/31482/abstract/54\">",
"      Lokhorst HM, van der Holt B, Zweegman S, et al. A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma. Blood 2010; 115:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/47/31482/abstract/55\">",
"      Spencer A, Prince HM, Roberts AW, et al. Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure. J Clin Oncol 2009; 27:1788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/47/31482/abstract/56\">",
"      Barlogie B, Tricot G, Anaissie E, et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 2006; 354:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/47/31482/abstract/57\">",
"      Barlogie B, Pineda-Roman M, van Rhee F, et al. Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities. Blood 2008; 112:3115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/47/31482/abstract/58\">",
"      Zangari M, van Rhee F, Anaissie E, et al. Eight-year median survival in multiple myeloma after total therapy 2: roles of thalidomide and consolidation chemotherapy in the context of total therapy 1. Br J Haematol 2008; 141:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/47/31482/abstract/59\">",
"      Barlogie B, Tricot G, Rasmussen E, et al. Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies. Blood 2006; 107:2633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/47/31482/abstract/60\">",
"      Morgan GJ, Gregory WM, Davies FE, et al. The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis. Blood 2012; 119:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/47/31482/abstract/61\">",
"      Barlogie B, Attal M, Crowley J, et al. Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciences. J Clin Oncol 2010; 28:1209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/47/31482/abstract/62\">",
"      Krishnan A, Pasquini MC, Logan B, et al. Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial. Lancet Oncol 2011; 12:1195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/47/31482/abstract/63\">",
"      Sonneveld P, Schmidt-Wolf IG, van der Holt B, et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial. J Clin Oncol 2012; 30:2946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/47/31482/abstract/64\">",
"      Stewart AK, Trudel S, Bahlis NJ, et al. A randomized phase 3 trial of thalidomide and prednisone as maintenance therapy after ASCT in patients with MM with a quality-of-life assessment: the National Cancer Institute of Canada Clinicals Trials Group Myeloma 10 Trial. Blood 2013; 121:1517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/47/31482/abstract/65\">",
"      Ludwig H, Durie BG, McCarthy P, et al. IMWG consensus on maintenance therapy in multiple myeloma. Blood 2012; 119:3003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/47/31482/abstract/66\">",
"      Usmani SZ, Sexton R, Hoering A, et al. Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance. Blood 2012; 120:1597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/47/31482/abstract/67\">",
"      Fassas AB, Spencer T, Desikan R, et al. Cytotoxic chemotherapy following tandem autotransplants in multiple myeloma patients. Br J Haematol 2002; 119:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/47/31482/abstract/68\">",
"      Cunningham D, Powles R, Malpas J, et al. A randomized trial of maintenance interferon following high-dose chemotherapy in multiple myeloma: long-term follow-up results. Br J Haematol 1998; 102:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/47/31482/abstract/69\">",
"      Barlogie B, Kyle RA, Anderson KC, et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol 2006; 24:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/47/31482/abstract/70\">",
"      Lacy MQ, Geyer S, Wettstein P, et al. Post autologous transplantation consolidation of multiple myeloma with idiotype-pulsed antigen presenting (dendritic) cells (APC8020) is associated with a trend to longer time to progression (TTP) [abstract]. Blood 2002; 100:433a.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/47/31482/abstract/71\">",
"      Yi Q, Desikan R, Barlogie B, Munshi N. Optimizing dendritic cell-based immunotherapy in multiple myeloma. Br J Haematol 2002; 117:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/47/31482/abstract/72\">",
"      Harrison SJ, Cook G. Immunotherapy in multiple myeloma--possibility or probability? Br J Haematol 2005; 130:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/47/31482/abstract/73\">",
"      Hansson L, Abdalla AO, Moshfegh A, et al. Long-term idiotype vaccination combined with interleukin-12 (IL-12), or IL-12 and granulocyte macrophage colony-stimulating factor, in early-stage multiple myeloma patients. Clin Cancer Res 2007; 13:1503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/47/31482/abstract/74\">",
"      Rhee Fv. Idiotype vaccination strategies in myeloma: how to overcome a dysfunctional immune system. Clin Cancer Res 2007; 13:1353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/47/31482/abstract/75\">",
"      Paiva B, Vidriales MB, Cerver&oacute; J, et al. Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood 2008; 112:4017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/47/31482/abstract/76\">",
"      Chanan-Khan AA, Giralt S. Importance of achieving a complete response in multiple myeloma, and the impact of novel agents. J Clin Oncol 2010; 28:2612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/47/31482/abstract/77\">",
"      Martinez-Lopez J, Blade J, Mateos MV, et al. Long-term prognostic significance of response in multiple myeloma after stem cell transplantation. Blood 2011; 118:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/47/31482/abstract/78\">",
"      Harousseau JL, Avet-Loiseau H, Attal M, et al. Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99-02 and 99-04 Trials. J Clin Oncol 2009; 27:5720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/47/31482/abstract/79\">",
"      Tannock I, Murphy K. Reflections on medical oncology: an appeal for better clinical trials and improved reporting of their results. J Clin Oncol 1983; 1:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/47/31482/abstract/80\">",
"      Rajkumar SV, Gahrton G, Bergsagel PL. Approach to the treatment of multiple myeloma: a clash of philosophies. Blood 2011; 118:3205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/47/31482/abstract/81\">",
"      Kumar S, Mahmood ST, Lacy MQ, et al. Impact of early relapse after auto-SCT for multiple myeloma. Bone Marrow Transplant 2008; 42:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/47/31482/abstract/82\">",
"      Vangsted AJ, Klausen TW, Andersen NF, et al. Improved survival of multiple myeloma patients with late relapse after high-dose treatment and stem cell support, a population-based study of 348 patients in Denmark in 1994-2004. Eur J Haematol 2010; 85:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/47/31482/abstract/83\">",
"      Shah N, Ahmed F, Bashir Q, et al. Durable remission with salvage second autotransplants in patients with multiple myeloma. Cancer 2012; 118:3549.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6656 Version 20.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-115.25.216.6-E8883028DF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_47_31482=[""].join("\n");
var outline_f30_47_31482=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INITIAL CHEMOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      COLLECTION OF STEM CELLS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PROCESSING AND STORAGE OF STEM CELLS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      TIMING OF HCT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Timing of first HCT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Timing of second HCT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PREPARATIVE CHEMOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      General",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Patients with renal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Older adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      CARE DURING THE TRANSPLANTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      MAINTENANCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Lenalidomide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Thalidomide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Combination chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Interferon",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Dendritic cell vaccination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      MONITORING DISEASE AFTER THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20487598\">",
"      Significance of response to chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      TREATMENT OF RELAPSE AFTER HCT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/6656\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/6656|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?11/52/12111\" title=\"algorithm 1\">",
"      Therapy approach MM I",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/6656|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/60/20429\" title=\"figure 1\">",
"      Early v late HCT in myeloma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/7/4223\" title=\"figure 2\">",
"      Infections after autologous HCT",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/28/36296?source=related_link\">",
"      Allogeneic hematopoietic cell transplantation in multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/29/8666?source=related_link\">",
"      Determination of initial therapy in patients with multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/50/31526?source=related_link\">",
"      Evaluating response to treatment of multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/54/34664?source=related_link\">",
"      Hematopoietic support after hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/1/28698?source=related_link\">",
"      Initial chemotherapy for symptomatic multiple myeloma in patients who are NOT candidates for transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/54/18282?source=related_link\">",
"      Initial chemotherapy for symptomatic multiple myeloma in patients who are candidates for transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/30/25066?source=related_link\">",
"      Overview of infections following hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?2/47/2802?source=related_link\">",
"      Patient information: Bone marrow transplant (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/4/34886?source=related_link\">",
"      Patient information: Bone marrow transplantation (stem cell transplantation) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?12/16/12547?source=related_link\">",
"      Patient information: Multiple myeloma symptoms, diagnosis, and staging (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/40/31366?source=related_link\">",
"      Patient information: Multiple myeloma treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/59/3001?source=related_link\">",
"      Prophylaxis of infection during chemotherapy-induced neutropenia in high-risk adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/57/32666?source=related_link\">",
"      Prophylaxis of infections in hematopoietic cell transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/31/29178?source=related_link\">",
"      Prophylaxis of invasive fungal infections in adult hematopoietic cell transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/49/38682?source=related_link\">",
"      Sources of hematopoietic stem cells",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/52/40778?source=related_link\">",
"      Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/15/37114?source=related_link\">",
"      Treatment of relapsed or refractory multiple myeloma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_47_31483="Complications of diagnostic laparoscopy";
var content_f30_47_31483=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F79748&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F79748&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Complications of diagnostic laparoscopy (from a total of 1794 laparoscopies)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"2\" rowspan=\"1\">",
"        Major",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Abdominal viscous perforation",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bleeding from biopsy site",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hemobilia",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Spleen laceration",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Total",
"       </td>",
"       <td>",
"        8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"2\" rowspan=\"1\">",
"        Minor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ascitic fluid leakage",
"       </td>",
"       <td>",
"        9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Abdominal wall hematoma",
"       </td>",
"       <td>",
"        6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vasovagal reaction",
"       </td>",
"       <td>",
"        5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prolonged abdominal pain",
"       </td>",
"       <td>",
"        4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Seizures",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Total",
"       </td>",
"       <td>",
"        31",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Vargas C, Jeffers LJ, Bernstein D, et al. Am J Gastroenterol 1995; 90:1258.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_47_31483=[""].join("\n");
var outline_f30_47_31483=null;
var title_f30_47_31484="Increased risk oral infection";
var content_f30_47_31484=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F56703&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F56703&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Conditions that are associated with increased risk of infection",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Condition",
"      </td>",
"      <td class=\"subtitle1\">",
"       Oral manifestation or complication",
"      </td>",
"      <td class=\"subtitle1\">",
"       Dental management",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Childhood cancers",
"      </td>",
"      <td>",
"       Decreased immune function, leading to gingival inflammation and alveolar bone loss",
"      </td>",
"      <td>",
"       Reduction of plaque and microorganisms through oral hygiene and use of chemotherapeutic agents, such as chlorhexidine",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Chemotherapeutic immunosuppression",
"      </td>",
"      <td>",
"       Oral ulceration; infection by opportunistic organisms",
"      </td>",
"      <td>",
"       Reduction of plaque and microorganisms through oral hygiene and use of chemotherapeutic agents, such as chlorhexidine",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Graft-versus-host disease",
"      </td>",
"      <td>",
"       Mucositis, xerostomia, oral pain",
"      </td>",
"      <td>",
"       Artificial saliva, chemotherapeutic agents to reduce plaque, pain control measures",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       HIV infection",
"      </td>",
"      <td>",
"       Severe acute and chronic gingival and periodontal inflammation, exceeding that expected for local irritants present",
"      </td>",
"      <td>",
"       Reduction of plaque and microorganisms through oral hygiene and use of chemotherapeutic agents, such as chlorhexidine",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Diabetes mellitus",
"      </td>",
"      <td>",
"       Increased gingival and periodontal inflammation and increased risk of odontogenic infections",
"      </td>",
"      <td>",
"       Reduction of plaque and microorganisms through oral hygiene and use of chemotherapeutic agents, such as chlorhoxidine",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Congenital heart disease",
"      </td>",
"      <td>",
"       Cyanotic friable oral tissues; ingress of microorganisms implicated in subacute bacterial endocarditis",
"      </td>",
"      <td>",
"       Adherence to American Heart Association guidelines for prevention of infective endocarditis [1]",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       In-dwelling catheters/central lines",
"      </td>",
"      <td>",
"       Risk of infection of device from oral bacteremia introduced by dental treatment",
"      </td>",
"      <td>",
"       Adherence to American Heart Association guidelines for prevention of infective endocarditis [1]",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Sickle cell anemia",
"      </td>",
"      <td>",
"       Nonspecific oral findings, but at increased risk for infection secondary to dental treatment in some cases",
"      </td>",
"      <td>",
"       Prophylaxis with appropriate antibiotic when needed for dental treatment",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     1. Wilson, W, Taubert, KA, Gewitz, M, et al. Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation 2007; 116:1736.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Casamassimo, PS. Pediatr Clin North Am 2000; 47:1149. Copyright 2000 W.B. Saunders Co.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_47_31484=[""].join("\n");
var outline_f30_47_31484=null;
var title_f30_47_31485="Rx entero PVE";
var content_f30_47_31485=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F71888&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F71888&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Suggested regimens for therapy of prosthetic valve endocarditis due to enterococci",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        American Heart Association",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        European Society of Cardiology",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Adult (for patients with normal renal function)",
"       </td>",
"       <td class=\"subtitle2\">",
"        Pediatric (not to exceed dose of normal adult)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         <strong>",
"          Strains susceptible to penicillin and vancomycin; high-level resistance to gentamicin and streptomycin must be determined:",
"         </strong>",
"        </p>",
"        <p>",
"         <strong>",
"          One of the following:",
"         </strong>",
"        </p>",
"        <p>",
"         Aqueous penicillin G 18-30 million units per 24 h IV either continuously or in 6 equally divided doses for 6 wks",
"        </p>",
"        <p>",
"         <strong>",
"          or",
"         </strong>",
"        </p>",
"        <p>",
"         Ampicillin 12 g per 24 h IV in 6 equally divided doses for 6 wks",
"        </p>",
"        <p>",
"         <strong>",
"          or",
"         </strong>",
"        </p>",
"        <p>",
"         Vancomycin* 30 mg/kg per 24 h IV in 2 equally divided doses for 6 wks; not to exceed 2 g per 24 h unless concentrations in serum are inappropriately low",
"        </p>",
"        <p>",
"         <strong>",
"          plus",
"         </strong>",
"        </p>",
"        <p>",
"         Gentamicin&bull;&Delta;&loz; 3 mg/kg per 24 h IV or IM in 3 equally divided doses for 6 wks",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         <strong>",
"          Strains susceptible to penicillin and vancomycin; high-level resistance to gentamicin and streptomycin must be determined:",
"         </strong>",
"        </p>",
"        <p>",
"         <strong>",
"          One of the following:",
"         </strong>",
"        </p>",
"        <p>",
"         Aqueous penicillin G 300,000 units/kg per 24 h IV in 4 or 6 equally divided doses for 6 wks",
"        </p>",
"        <p>",
"         <strong>",
"          or",
"         </strong>",
"        </p>",
"        <p>",
"         Ampicillin 300 mg/kg per 24 h IV in 4 or 6 equally divided doses for 6 wks",
"        </p>",
"        <p>",
"         <strong>",
"          or",
"         </strong>",
"        </p>",
"        <p>",
"         Vancomycin* 40 mg/kg per 24 h IV in 2 or 3 equally divided doses for 6 wks",
"        </p>",
"        <p>",
"         <strong>",
"          plus",
"         </strong>",
"        </p>",
"        <p>",
"         Gentamicin&bull;&Delta;&loz; 3 mg/kg per 24 h IV or IM in 3 equally divided doses for 6 wks",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         <strong>",
"          Strains susceptible to penicillin and vancomycin; high-level resistance to gentamicin and streptomycin must be determined:",
"         </strong>",
"        </p>",
"        <p>",
"         <strong>",
"          One of the following:",
"         </strong>",
"        </p>",
"        <p>",
"         Amoxicillin 200 mg/kg per 24 h IV in 4 or 6 equally divided doses for 6 wks",
"        </p>",
"        <p>",
"         <strong>",
"          or",
"         </strong>",
"        </p>",
"        <p>",
"         Ampicillin 12 g per 24 h (or 200 mg/kg per 24 h) IV in 4 or 6 equally divided doses for 6 wks",
"        </p>",
"        <p>",
"         <strong>",
"          or",
"         </strong>",
"        </p>",
"        <p>",
"         Vancomycin* 30 mg/kg per 24 h IV in 2 divided doses for 6 wks",
"        </p>",
"        <p>",
"         <strong>",
"          plus",
"         </strong>",
"        </p>",
"        <p>",
"         Gentamicin&bull;&Delta;&loz; 3 mg/kg per 24 h IV or IM in 2 or 3 equally divided doses for 6 wks",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     IV: intravenously; IM: intramuscularly; h: hours; wks: weeks.",
"     <br>",
"      * Given the increased risk of risk of nephrotoxicity with prolonged vancomycin plus aminoglycoside therapy, vancomycin therapy is recommended only for patients allergic to penicillins, or in the setting of infection due to enterococci resistant to penicillin and ampicillin (see text for discussion of alternative approach). In adults vancomycin is dosed based on actual body weight. Vancomycin dose adjusted for peak serum concentrations (1 h after infusion) of 30-45 &micro;g/mL and trough concentration of 15-20 &micro;g/mL. The dose may need to be increased beyond 30 mg/kg actual body weight and frequency may need to be increased to 3 equally divided doses.",
"      <br>",
"       &bull; Streptomycin can be used as long as high-level resistance not found and is indicated for isolates with high-level resistance to gentamicin but not streptomycin. Streptomycin dose adults: 15 mg/kg per 24 h IV or IM in 2 equally divided doses; pediatrics: 20-30 mg/kg per 24 h IV or IM in 2 equally divided doses. Streptomycin dose adjusted for peak serum concentrations (1 h after infusion) of 20- 35 &micro;g/mL and trough concentration of &lt;10 &micro;g/mL. If strain is gentamicin and streptomycin high-level resistant then &gt;6 weeks of a cell wall active agent will be needed. (See text).",
"       <br>",
"        &Delta; Monitor renal function and gentamicin serum concentrations at least once per week. In adults aminoglycosides are dosed based on ideal body weight. Gentamicin dosage adjusted for peak serum concentration 3-4 &micro;g/mL, trough &lt;1&micro;g/mL.",
"        <br>",
"         &loz; A combination of ampicillin with ceftriaxone has been suggested for gentamicin-resistant E. faecalis.",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     <p>",
"      1. Baddour, LM, Wilson, WR, Bayer, AS, et al. Infective endocarditis: Diagnosis, antimicrobial therapy, and management of complications: A statement for healthcare professionals from the committee on rheumatic fever, endocarditis, and Kawasaki disease, council on cardiovascular disease in the young, and the councils on clinical cardiology, stroke, and cardiovascular surgery and anesthesia, American Heart Association--executive summary: endorsed by the Infectious Diseases Society of America. Circulation 2005; 111:3167.",
"      <br>",
"       2. Habib G, Hoen B, Tornos P, et al. Guidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009): the Task Force on the Prevention, Diagnosis, and Treatment of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and the International Society of Chemotherapy (ISC) for Infection and Cancer. Eur Heart J 2009; 30:2369.",
"       <br>",
"        3. Liu, Catherine et al Clinical Practice guidelines by the Infectious Disease Society of America for the Treatment of Methicillin- Resistant Staphylococcus aureus Infections in Adults and Children. CID 2011; 52; 285-292.",
"       </br>",
"      </br>",
"     </p>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_47_31485=[""].join("\n");
var outline_f30_47_31485=null;
var title_f30_47_31486="Pressure controlled IRV";
var content_f30_47_31486=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F55132&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F55132&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pressure controlled inverse ratio ventilation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 383px; height: 221px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADdAX8DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiisr/hIdL/4Sr/hG/tX/ABOvsX9ofZ/Lb/Ub/L37sbfvcYzn2xQBq0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAU9Y1Ww0XT5b/V722sbKLG+e4kEaLk4GSeOTxRpeqWOqwyS6bdwXUcbmJ2icMFYAHacdDgg/iK4b47WFrqPgq3hu7pbRjqNssM8kIlhSV38tTKpI+T5zk5yvB7Vf+EmgjQfDlxHJrNrrF5dXRnubm1AEQcRxxhFAJwAkaDk5PXvQB21eVf83T/9yZ/7fV6rXlX/ADdP/wByZ/7fUAeq0UUUAFFFFABRRXAfHvxDqnhX4T67rOg3X2TUrbyPKm8tZNu6eNG+VgQflYjkd6AO/oryr/hTf/VR/iT/AODz/wCwo/4U3/1Uf4k/+Dz/AOwoA9Voryr/AIU3/wBVH+JP/g8/+wo/4U3/ANVH+JP/AIPP/sKAPVaK8q/4U3/1Uf4k/wDg8/8AsKP+FN/9VH+JP/g8/wDsKAPVaK8q/wCFN/8AVR/iT/4PP/sKP+FN/wDVR/iT/wCDz/7CgD1WivKJfg+kMZeX4lfEZEHVm13AH47Kwb3wh4VsSRffGzxdbEcfvvFcSfzWgD3WivnaXT/Asakn44+Mnwcfu/Egc/kqGtv4Aams3jbx/pll4o1fxHotn9gaxudSu2uH+eNzJgkDHzccAfdHXrQK62PbqKKKBhRRRQAUV4V4X0HVPiVqvjC+1fxt4t07+yvEF5pFrb6PfLaQrBEwKZVU+ZvnI3HJIAz0roP+FN/9VH+JP/g8/wDsKAPVaK8q/wCFN/8AVR/iT/4PP/sKsad8JPsWoW11/wALA+IVx5Eqy+TPrW+OTaQdrrs5U4wR6UAem0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBw/xkitZvBUqX91oFrB58ZMmuxeZbZzwCMj5vTmsT9ne5guPCespax6IsNvq80Cy6NbGC2nCxxfvFBJ3Zzjd7Y7ZOt8aJ9UtfCUFxo1n9uljvYTJaBEdp15ARVfgkuUyBzjdiqvwGfVv+EMnh1u4Fy9veNFDOqRqsi+XGX27PlKiYzKCOoUUAej15V/zdP8A9yZ/7fV6rXlX/N0//cmf+31AHqtFFFABRRRQAV5V+1H/AMkJ8Tf9uv8A6VRV6rXlX7Uf/JCfE3/br/6VRUAeq0UUUAFFZHibxJpHhfTGv9ev4bK1BwGkPLn+6qjlm9gCa8F8Z/HvU74yW/g6zGn2/QX16oeZvdYvur9WLf7opOSW5jWr06KvN2PobVdTsdIs3u9VvbaytU+9NcyrGg+rMQK8u8RfHrwrp+6PR473W5gSM20XlxA+8kmAR7qGr5p1S7u9Yvvtus3lzqN52mupDIV9lB4UeygCoaydXseTWzjpSj956xrfx68VXpZdKsNL0qIjqwa6lH0Y7F/NTXE6r468X6sW+3+KNWIPVbeUWq/TEQXj61ztFQ5yZ588fiJ7yt6aEd1Cl3J5l7uupP79wxlb82yaWOKOP/Vxov8AuqBT6Km5zSqSl8TuFepfso6isXxH8V6aWIa5sYbgDPB8ttv/ALVry2n/AA08Rf8ACJ/GbT9ZmkCWIljs7sngCOZSu4+ynDfhWlPc9DKWlWd+36o+9aKKK3PpQooooA8q+AX/ADUf/sc9S/8Aaden3t1b2NpNdXs8VvbQoZJJZWCoijkkk8ACvL/gIwVfiQzEBR4y1Ikk8D/V1hKk3xy8TzGV5Y/hppUxjVEcodYuF6kkc+Up9+eO5+UA0n+IvifxxdS2vwo0iA6ajFJPEOrBo7YkdfKQfM59/XqO9WYvhf4m1JfM8UfE7xNJOeSujsmnovsAoOfrXqdpbQWdrFbWkMcFvEoSOKNQqoo6AAcAVLQA2JPLjRNzNtAG5jkn3PvTqK8H+LPiTxLb/GK00HR9Uv7XTm0RLx4rSe0gIk+0OhcvcDBG3A2g54BA4NAHvFFeO6p8T/EFp4gvhFpelvolj4gh0OZmmkFw/m7MOoxtGN46nn261jj4h69rnjfwvLE0FrpEms31kNPtpmN1MsETj98CQvLKCF4xxz3oA96oryrxt8T9U0e30eK08M3thf6pdvbRjVgm1Qke/OIZG3Fvugbgc59OcjW/jBrGi6D4cvtQ0XT4rnWY5LcW73gX7NdJN5e+Rugg7luq8A8mgD2yivGtY+Kms6Xr2o2zWWky2um6rZ6ZKglcXFyZ1Qlol6ZUsTg5yB261Bo3xC1xrjTNM0axtru+1XWdWs0OpXsmyMW4LA7grEDAPygcdBjqAD2yivGH+K+rf8LCg0O2tdMu9Pm1KXSfOTzEMVwiEkFmPzYYYOEx6May/BXxN8V3PhLwul/Lotxq+uX13bx3tyxjihWEyk+cqBQGOwKgGMjk85oA97oryDwj8UNd8W6r4estI0fTYjf6U2pXLXVy6iNY7ryH8vah3g43KDjORk+t34dfEnUvFviqXQptKhtrnTIp/wC2GDMVgmWdo440J67lUvk9qAPUqKKKACiiigAooooA81/aBS3/AOEAM8+p/wBmzW93HJbS/Z2n3y4ZQoReScMxHoQD2pPgNpen6P4b1ax0m4822i1DaF8ox+Xi2gAyCTyy7ZCe5kNSfHuXSoPAsb67JPb2f2+2Q3dvP5UlrufaZV+Rt21WYlcfMMjirHwUXwwvhGYeDdYn1q1+1t9pvrgkyST7Ezuyq9E8sAAYAAFAHf15V/zdP/3Jn/t9XqteVf8AN0//AHJn/t9QB6rXmX7PGp3l98PDaateXF7qulahd2F3NcyNJKXWVm+ZmJJO11H0r02vG4Jh8OfjbeRXWIvDnjRllhmP3IdQUYZD6eZnOe5I9DQB7JRRRQAV5V+1H/yQnxN/26/+lUVeq15V+1H/AMkJ8Tf9uv8A6VRUAeq15d8WfizZ+DWfS9Kjj1DxEyA+SSfKtgejSkfmEHJ9gc0vxw+IzeDdMj07R2RvEN8pMW4bhbRZwZmHf0UHqfUA18rku8kks0kk00rmSWWRizyOTksxPJJPes5z5dEedjscsOuSPxfkW9a1TUtf1RtS16+lv79hjzZOAg/uoo4RfYfjk81UoorBu583OpKpLmm7sKKKKCAooooAKKKKACsQWyXmpa1by/dkSEZ9PlODW3WXYf8AIe1X/dh/9BNNdTei3FTa7f8AtyPq79nDx9/wlPhMaNqkv/FQaKq286seZogMJKPXIwCfUZP3hXr1fBGn3+p+H9dtNf8ADk4g1a0PAb7k6d43HdT/AJxwR9efCn4maP8AEPSfMs2Frq0CgXmnSt+8hbuR/eTPRh+ODxXRGXMj6bB4qOIhfr1O7oooqjrPlmLVb2TSvGPg3QpWi1jxV481KyWVesNsBEZ5PoE4PsT6V9KeG9FsvDug2OkaVEIbKziWKJB6DufUk5JPckmvnr4BaIb349/EvWJwWh0zUryKBW6LLNcPuYe+2LH0NfS2RkjIyOcUALRWL4i8T6X4f8pL+dnvJ/8AUWdvGZric/7Ea5Yj1OMDuRWL9k8T+JznUZn8NaS3/LrayB76Uf7cwysX0j3N6OKAOhbXtMGuJoy3kb6oyGQ20eXZFAzufGdgPYtjJ4GTWR4o0zwRf6vbL4qsvDdzqkkYjgGpRQPMybjhV3jcRktwO5NbGg6FpmgWf2XR7KK1hJ3PsGWkbuzsfmdj3ZiSfWvJvjV8MPEvjnVb2TTbrSRZzWUUEH2mR4ZIJEkLEkpGxkBycAsApJwO9AHdaReeE9b1LWrGPTrFbm11TZcLcW0a+fdoiuJF/vsAV+bqMe1WJbPwTZajDrctv4ct7+4mJjv2SBJZZeVO2TqW5I4OeorhNf8Ahfrt1B4ivNJvtPttcl8QJrekzs77Y8RpGyyELkZUPkAMOn4ZXiD4IXb22gwaVJYXVrZaL/ZNzaXc7wKzFy7zI6o5yzM2RgdByKAPYdcXQNTkj0XXRpV28/7xLC8Echkxn5hG3XvziuX0a+8AXmjT3I0/RNOsIZJ9FIvLeCBWVHPmQjPBjLZO3oeuK5G7+EesS60zpc6UbS5uNNupb2QyNeWhtURTHCSp3K2zhiykbjkGo9S+FXiaXRorGC60eSFtW1C9uIJJHTzIrhsx4lEZZSv8SgANnG7igDutG8HeDtJ8T3esxR6fLqd+8VxA0ywsbcbFiQW52hkUhQOCcnp6VsXNt4W0W4hmuYdEsJ7d5LmKSRYomjeU7XkUnBBcnBYfezg5rz74f/Ce40fX/D9/4jj0fUF0nQIdOj4MrRXUdw8olj3oMAKwAbhgc8d6qfFHwprfiP4oyR6VpNjc29z4Wmsjd6mj/Z4HecDKsqMDKFOQvBxnkUAelnRPCh8QNenTND/tzzFkM/kRfafM2na27G7dtzg9cZqpHpvga907U0jsvDNxYed51+qxQPF5oz88oxjd15bnrXG6L8IBbXniNtRms7hrvR7PS9O1Ex77q1aK1eCSUZHyM25T8rHOOcVzOnfBPV4fD+o2F3b6JJNNZQWYePUJ0WbypVdWIEQEZG0kcSc8HIoA9hhvvCNrHb6xDdaDDGsX2GC9SSFQIwQfJWT+7kA7QccDiq/hjRtB8PX3iDU7PUFmuNXvRdXc888Z2swAjjBUDCgH5Qcn5upzXk198G/FVxoOnxG90eTVraa6kiufOMRt1lCBVJEBW44T5i0aE8AEAVc1D4UeLj/adlaX+gTadqFxpt3LLIkkEoktljVwsaKUVT5eQB06cdQAe2/2nYZlH221zEHMg81fkCkBs88YJGfTNO06/s9Sthc6dd293bsSBLbyLIhI68g4ryG9+Dkl74W8a2rNpcGt63q899BfpFvb7O1wkywSttDbSU5UEgHnmuq+E3hC88JWuqi/hsoJb64WdktLqSdSwUKWJZEwTgcBe3JNAHe0UUUAFFFFAHjfx81HxLa6ho8OhDxatn9muJWfw5ZfaHNyDGIVmJ4EeC5I7+h7d18NfEl54n8LwXmp6Pq2k38W2C4i1K0Ns0kgRSzopJ/dksQDx0PHFdVRQAV5V/zdP/3Jn/t9XqteUTSCL9qF5GDFU8FFiFUscC97Ack+woA9Xrn/AB34T03xr4autF1iMmCbDJInDwyD7siHswP58g8E1V/4TzSP+fPxJ/4Tmo//ABitSbxBZxaLHqrQ6mbWQ4CJply045I5gEfmDp3X3oA8x8I+PNS8F6lb+D/iq4hnAEem6+xP2fUEHADsfuSAYzk89+xb2MEMAQQQeQRXC6/rvhXxNpsml65ouuX1lMQGin8N6htz2OTB8pH94EEetcDrOh+J/hXNGngHWtR1LSmBddD1HTLu/jjA/hjngjYx+ysQO5zQB7zXlX7Uf/JCfE3/AG6/+lUVZmi/G3UBb7vFXw48YaVt4aeGwkmhHuSyoQPwNct8cvix4S8YfC/WPDuiXd5Jr181sltYyWE6SSsLiNiBlMZwp78kYGaAPKvE2vz+K/Eeoa9dbg99JujQn/VQjiNPwXGfck96za6XTfAXivUIJpLfw5qqJCPmE9q8BPH8KuAW6dgaof8ACL+JP+hY8Rf+Cm4/+Irlabdz5GrSr1ZucovXyZk0V0sngLxZHpaag3hzVTA5wFW2dpeuOYgN46d1qivhbxKzBR4Y8Q5JxzpVwB/6BRyvsZ/Vq38j+5mRRXSar4E8WaXIiXPhzVnLjI+zWr3A/ExhgPoai0/wX4p1C6W3g8N60kjAkGexlgTgd3dQo/E0cr7B9WrfyP7mYFFbl54P8T2lzJBL4a11njOCYtOmlQ/RlUqfqCas6d4C8WahDPLB4c1VFhGWFxbPAx6/dVwC3TtmjlfYPq1b+R/czmqK1v8AhF/En/QseIv/AAU3H/xFX5PAXiyPS01BvDmqmBzgKts7S9ccxAbx07rRyvsH1at/I/uZzVZdh/yHtV/3Yf8A0E11a+FvErMFHhjxDknHOlXAH/oFZOoeGfEmheJtThvfDetO5EQzb2jyr93P3lyD94dDTUXqb0sNVcZrle3bzQlQiKa31CHUdMu7jT9UgOYru2cq6+xx1HtU/wBl1n/oWPEf/gtk/wAKVbPXHYLH4V8Su5OAq6bISfpxQoyWwU8NiqcuaEWmes+Dv2h9X0uJLbx1o7ajGvH9o6YAHI9XiJAz7gge1eraL8bvh5q6AxeJrS2fvHeq1uVPoS4A/Imvlb+xvFP/AEJHi7/wUy/4VFN4e8RT/wCu8BeKpP8Af0aQ/wBK1UpdUevSxWKStUpXPbvhr4x0Lwd4d+KPi+9uoprSbxVeLb+Q4Y3R4aNYyDht28kEcYyeleHaB8RvG+v/ABVPiO0l1UyXbi2uItNhMvlWpPMaLtYZUEkEg/N8xyc59w/Z78PWWi/DzU7rxp4Suo5k1uaS2iutDlnuI0aKHBSMRs4XIIyBjjrxXrlt410WNY4YLDxDGg+VVHhvUFUf+QMAVoemndXNLw74Y0vQPNewgLXk3+vvbhzLcTn/AG5WyzewzgdgK2qx9c8RWWiyxR3kGqSNIpZTZ6Xc3YA9zDGwB9jg1DpPivT9VvktLa31pJXBIa60a8to+Bnl5IlUfieaBm9RRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVzv/AAidr/wsT/hL/Pn+3f2V/ZPk8eX5fnebu6Z3Z464xXRUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUVz/j3xXY+CPCd94h1WK5msrPy/MS2VWkO+RUGAxA6sO44zQB0FFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUVz+jeK7HV/FniPw9bRXK3uhfZvtLyKojfz4y6bCCScAc5A56ZroKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK4D/AISHVP8Ahfv/AAjf2r/iS/8ACM/2h9n8tf8AX/avL37sbvu8Yzj2zXf15V/zdP8A9yZ/7fUAeq0UUUAFFFFABXlX7Uf/ACQnxN/26/8ApVFXqteVftR/8kJ8Tf8Abr/6VRUAdR8J/EUfir4c6Bq0bAvLaokwH8MqfJIP++lP4Yrra8Ujn/4VB8SLmO6/d+BPFFz5sUx+5p1+33lbsqP1z0GB0Ck17WDkZHSgAooooAKKKKACiiigAooooAKKKKACiiigAooooA8P+CtkmjfGz4v6fJInnz3dteomeSknmyk/h5y5+te4V8ueJBreifH3x/420BHul0A6cuoWKD5rizltR5pHuvlK34Z7YP0h4b13TvEuiWmr6Lcpc2F0m+ORT+YI7EHgjsRQBp0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFUNe1nT9A0qbUtZu4rOwhKiSeU4VNzBVye3zMB+NSaZqVjqtqt1pd7bXts33ZbaVZEP/AAJSRQBbryr/AJun/wC5M/8Ab6vVa8q/5un/AO5M/wDb6gD1WiiigAooooAK8q/aj/5IT4m/7df/AEqir1WvKv2o/wDkhPib/t1/9KoqAPQ/Eeiad4k0W70nWrVLqwuk2SxP39CD2IOCCOQRmvIdP1rW/gvNFpPi1rnV/AhYR2OtKu+WwBPEVwByVHADD8P7q+4VHcwQ3VvLBcxRzQSqUkjkUMrqeCCDwQfSgCLTb+01OxgvdOuYbqznUPFNC4dHX1BHBqzXj998MtZ8H3s2qfCPVEsFkbzJ9AviZLGc99neNj7ewyoGKtaL8ZbC2v00j4h6bc+D9aPAF781rN2zHOPlI9zgD1NAHq1FR288N1BHPbSxzQyDckkbBlYeoI4IqSgAooooAKKKKACiiigAooooAKKKKAPKvh4M/HX4ug/9Qj/0laqOs+CPEPgLWbrxB8K1iuLC5cy3/hmZ9kMrd3gPSN/bp9RhavfDv/ku3xc/7hH/AKStXqtAHAeB/iv4c8U3P9nvLLpGvodsulamvkTq3oA3Dfhz6gV39c34y8DeGvGdsIfEuj2t9tGElZdsqD0WRcMB7A1xK/CrXdDP/FD/ABD1zTYB9201FE1CFR/dUPjaPzNAHrVFeUrZfGmz+WDVvBGogcbry3uIiffEfGa9K0b+0P7Js/7aFoNT8pftP2QsYfMx82zd823OcZ5xQBcooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAOT+Kzzp8P8AV/sl1eWs7KiJLZ2IvZctIowsJ+/nOPYEnIxmuT/Z30O70Xw7qX2/w3Lok9zciQyTSHzLzj/WNEWbyj225rovi+st14MurGyvYILyZon+zyXotGuolkUywrLnKb0DLuHTPPBrK+BthcWOk6tmFLCwlug1ppY1QaibNfLUMDKCfvMC23Jx+JoA9Lryr/m6f/uTP/b6vOPGWpapH8TdYQX2op4oTxBp8ekWqTSBHsSvz7YwdrRnnecYz1xXb63Fqs37TiLod7Y2dyPB4LSXlo9yhT7acgKssZBzjnceh45yAD2WiubsrPxel5C19rmgTWoYGWOHRponZe4VjdMFPuVP0qfV7XxNLeFtG1fRrS02jEd1pUtw+e53rcRjHtt/OgDdorzLUfiRpng68mi8b+NPDtw4XatnpunSpcK+f4gJ5T7YKj61xkvxQ+ImqzSnwd4cuNRgJJilu/DstrEwzxiRrznjvtH0oA+gK8q/aj/5IT4m/wC3X/0qirP0zXPjhdWJW68J+FbS8J4kmu22KPdEdyf++u4rK8e+GfjJ438GX2haqvgSG1vPL8wWz3SzDZIrjBbK9VHrxnvQB71RWTqcGvSWVsul6lpltdqB58tzp8k6SHHOxFmQpzzyzcce9UbKz8XpeQtfa5oE1qGBljh0aaJ2XuFY3TBT7lT9KAOkqlrGlafrVhJZavZW19ZyfehuIxIh/A96z9XtfE0t4W0bV9GtLTaMR3WlS3D57netxGMe2386k0S38Qw3Eh1zVNJvICuESz02S2YNnqWaeQEYzxgfWgDz6b4MxaPcPd/DnxJq3hSdm3m2jf7TZsfeFz/XA7CkGu/Fnw18us+GdJ8VWi/8vOkXP2ebHq0cnDH2UV2ctl40MrmHX/DqxljtVtDmYgdgT9rGT74FaVtBry6PNHdalpkmqknyriPT5EhUcY3RGYs3fpIPw7gHAW3x08KQyrB4lg1rwzdE7fK1fT5I8n2ZQwx7nFdtovjPwzrm3+x/EGlXrN0SG7Rm/FQcj8qz7jSvGVzC0NzrnheaJhhkk8PzMp+oN5WB4t+D3h/XbOAQ6N4Xtr3H+kznSXCynHJURTxMvPPLNxx70AenUV4LY/AC6s7uFrHxjc6TaKwLxaQl1A+30RnupAp44JU/Q1rXHwo8ZQXZbRPi34ggtBjbHfwC8cY9XLqD/wB8/XNAHslFeSweAfiZBu2fF6U7uu/w9bv/ADc4rE+HCePV+JXxA0e58a22pS6d/Z+6bUdMd4z5kLP+6hjnjWH0bGdxAJweoB7rRWTbQa8ujzR3WpaZJqpJ8q4j0+RIVHGN0RmLN36SD8O+X9h8cf8AQw+G/wDwQz//ACZQB1VFZOpwa9JZWy6XqWmW12oHny3OnyTpIcc7EWZCnPPLNxx71RsrPxel5C19rmgTWoYGWOHRponZe4VjdMFPuVP0oA474d/8l2+Ln/cI/wDSVq9VrxXwxBrk3x2+K39g6jptlj+yvN+22D3W/wD0U7du2aPbjnOc5yOmOfUdEt/EMNxIdc1TSbyArhEs9NktmDZ6lmnkBGM8YH1oA2aK5eWy8aGVzDr/AIdWMsdqtoczEDsCftYyffArStoNeXR5o7rUtMk1Uk+VcR6fIkKjjG6IzFm79JB+HcA1qK5X7D44/wChh8N/+CGf/wCTK1NTg16Sytl0vUtMtrtQPPludPknSQ452IsyFOeeWbjj3oA1qK5uys/F6XkLX2uaBNahgZY4dGmidl7hWN0wU+5U/SukoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAPEv2kp7ezbQ7i50GDV1Ntfogk04XZSbyQYOxKr5m3PTIFdT8Fb3w5e+H5m8MaG2juvli8Q2JtQ82zkgEcjrzXolFABXlX/N0//cmf+31eq15V/wA3T/8Acmf+31AHceNfFWleDPDtzrWuz+VaQjACjLyufuog7sf/AK5wATXmtn4e8b/E5PtvjLULvwr4bmG6HQ9OfZdSJ2NxKRkZ7oB9QpFdv4z8FjxT4n8J6hd3SjT9EuZLySyaPcLiUqBE2c/LsOW6HPTiuwoA5fwj4A8K+EIlXw9odlZuBjzgm+Y/WRssfzrqKKKACiiigAooooAKKKKACiiigAooooAKKKKACvKvh3/yXb4uf9wj/wBJWr1WvKvh3/yXb4uf9wj/ANJWoA9VpCQoJJAA5JNY3jHxRpPg/QLjWNfultrOEd+WkbsiD+Jjjgf0BNeW2vh7xR8XNt/40kufD/g6T5rbQbaQpPdp1DXLjkA8fIP0IyQDodf+M3hmw1F9M0Rb/wATauvBtNEgNwVP+04+UD1wSR6VSXxP8WNW+fTPAuk6REfunVtT8xiPUrEMj6GvRPDvh/SPDenJY6Dp1rp9ov8AyzgjC5PqT1Y+5ya1KAPKPhDoXi6w8fePtW8bWunxXOqf2f5c2nMxtpvKidTsDneMAqDuxznHFer0UUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV5l9iu/wDhpf7d9mn+w/8ACI+R9o8s+X5n2zds3dN2OcdcV6bRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXkngi6gsvjV8Y7u7lSG2gj0qWWRzhURbRyWJ7AAE163Xyp41lutY+OnjfwJYPJE/ie80mO6mQ4KWcNqXnwfUgr9Rkd6APQfA2nT/FPxWvj3xDG6+HbGRk8O6dKDtbBwbt1P8RI+X0x7An2qoLCzt9PsbezsoUgtbeNYookGFRFGAo9gBU9ABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV4b4K0lbn9qz4h6q67jZWNpCuR0aWCHn64jYfia9yrh/Cfhe/0r4m+PdfumgNjrf2D7KEclx5MJR9wxxyeOTQB3FFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAf/Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Depiction of flow and airway pressure characteristics during a pressure limited breath provided by pressure-controlled inverse ratio ventilation (PC-IRV). End-expiratory alveolar pressure is positive at the end of the shortened expiratory period. Airflow has not ceased, and auto-PEEP has developed. A pressure limited breath without inverse ratio ventilation has similar pressure and flow characteristics except that flow has ceased at the end of expiration, and there is no auto-PEEP present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from Marcy, TW, Marini, JJ, Chest 1991; 100:494.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_47_31486=[""].join("\n");
var outline_f30_47_31486=null;
var title_f30_47_31487="Approach to lower GI bleeding";
var content_f30_47_31487=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F60651&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F60651&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 539px\">",
"   <div class=\"ttl\">",
"    Approach to patient with lower GI bleeding",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 519px; height: 573px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Zuccaro, G, Am J Gastroenterol 1998; 93:1202.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_47_31487=[""].join("\n");
var outline_f30_47_31487=null;
